Page last updated: 2024-12-10

coenzyme q10

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Occurs in Manufacturing Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

coenzyme Q10: Ubiquinone ring with a chain of 10 isoprene units; redox equilibrium with ubiqunol serving in mitochondrial inner membrane to transfer electrons; presence during reconstitution of acetylcholine receptor into phospholipid vesicles yields vesicles active in catalyzing carbamylcholine-sensitive Na+ flux; coenzyme Q10 depletion has been noted with use of statins [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

coenzyme Q10 : A ubiquinone having a side chain of 10 isoprenoid units. In the naturally occurring isomer, all isoprenyl double bonds are in the E- configuration. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5281915
CHEMBL ID454801
CHEBI ID46245
SCHEMBL ID11901691
SCHEMBL ID19858
MeSH IDM0083834

Synonyms (161)

Synonym
AC-4352
LS-15517
nsc-140665
smr000058651
MLS000028745
mitocor
kanekaq10
armolipid
bpm-31510
akvion
api-31510
ubidecarenonum [latin]
luvacor
coenzyme q(sub 10)
coq(sub 10)
2-(3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl)-5,6-dimethoxy-3-methyl-p-benzoquinone
ubiquinone q(sub 10)
2,5-cyclohexadiene-1,4-dione, 2-((2e,6e,10e,14e,18e,22e,26e,30e,34e)-3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl)-5,6-dimethoxy-3-methyl-
p-benzoquinone, 2-(3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl)-5,6-dimethoxy-3-methyl-
einecs 206-147-9
ubidecarenona [spanish]
nsc 140865
2,5-cyclohexadiene-1,4-dione, 2-(3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl)-5,6-dimethoxy-3-methyl-, (all-e)-
2,5-cyclohexadiene-1,4-dione, 2-((2e,6e,10e,14e,18e,22e,26e,30e,34e)-3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl)-5,6-dimethoxy-3-methyl
2-((all-e)-3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl)-5,6-dimethoxy-3-methyl-p-benzoquinone
coenzyme q-10
coq 10
ccris 9016
ubiquinone(10)
coenzyme-q10
LMPR02010001
neuquinon
terekol
ube-q
ubiquinone 50
heartcin
ubiquinone q10
neuquinone
coq10
justquinon
nsc140865
udekinon
emitolon
inokiten
303-98-0
ubidecarenone
coenzyme q10
ubiquinone-10 ,
coenzyme q10, >=98% (hplc)
CHEBI:46245 ,
all-trans-ubiquinone
Q10 ,
NCGC00159429-02
p-benzoquinone,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl)-5,6-dimethoxy-3-methyl-
2,4-dione, 2-(3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl)-5,6-dimethoxy-3-methyl-
q 10
2,4-dione, 2-(3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl)-5,6-dimethoxy-3-methyl-, (all-e)-
q 199
nsc-140865
ubidecarenone (jp17/inn)
adelir (tn)
D01065
co-enzyme q10
bio-quinone q10
2,3-dimethoxy-5-methyl-6-decaprenylbenzoquinone
C1971
unispheres q 10
ubidecarenone for system suitability
aqua q10
adelir
vitamin q
oristar ubq
api 31510
coenzyme q-199
CHEMBL454801
bpm31510
puresorb q 40
2-[(2e,6e,10e,14e,18e,22e,26e,30e,34e)-3,7,11,15,19,23,27,31,35,39-decamethyltetraconta-2,6,10,14,18,22,26,30,34,38-decaenyl]-5,6-dimethoxy-3-methylcyclohexa-2,5-diene-1,4-dione
2-(3,7,11,15,19,23,27,31,35,39-decamethyl-tetraconta-2,6,10,14,18,22,26,30,34,38-decaenyl)-5,6-dimethoxy-3-methyl-[1,4]benzoquinone
ubiquinone-q10
tox21_113394
cas-303-98-0
dtxcid4026054
tox21_111660
dtxsid6046054 ,
SCHEMBL11901691
AKOS015951232
unii-ej27x76m46
ubidecarenona
co q10
coenzyme q 10
ubidecarenone [inn:ban:jan:nf]
bp31510
co-enzyme q-10
ubidecarenonum
ej27x76m46 ,
2,5-cyclohexadiene-1,4-dione, 2-((2e,6e,10e,14e,18e,22e,26e,30e,34e)-3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaen-1-yl)-5,6-dimethoxy-3-methyl-
ubidecarenone [usp-rs]
ubiquinone 50 [mi]
ubidecarenone [jan]
ubidecarenone [mart.]
coenzyme q10 [vandf]
ubidecarenone [inn]
ubidecarenone [ep monograph]
ubidecarenone [dsc]
2-deca(3-methylbut-2-enylene)-5,6-dimethoxy-3-methyl-p-benzoquinone
ubiquinone [inci]
ubidecarenone for system suitability [usp-rs]
ubidecarenone [who-dd]
AKOS015897104
S2398
liquid-q
kaneka q10
(all-e)-2-(3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl)-5,6-dimethoxy-3-methyl-2,5-cyclohexadiene-1,4-dione
kudesan
q-gel
li-q-sorb
q-gel 100
(all-e)-2,3-dimethoxy-5-methyl-6-(3,7,11,15,19,23,27,31-octamethyl-2,6,10,14,18,22,26,30-dotriacontaoctaenyl)-2,5-cyclohexadiene-1,4-dione
SCHEMBL19858
C-7060
2-[(2e,6e,10e,14e,18e,22e,26e,30e,34e)-3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaen-1-yl]-5,6-dimethoxy-3-methyl-2,5-cyclohexadiene-1,4-dione
2-(3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl)-5,6-dimethoxy-3-methyl-p-benzoquinone, (all trans)-
2-[(2e,6e,10e,14e,18e,22e,26e,30e,34e)-3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl]-5,6-dimethoxy-3-methylbenzo-1,4-quinone #
q 10aa
2,5-cyclohexadiene-1,4-dione, 2-(3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl)-5,6-dimethoxy-3-methyl-, (all trans)-
2-((all-e)-3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl)-5,6-dimethoxy-3-methyl-2,5-cyclohexadiene-1,4-dione
2-((2e,6e,10e,14e,18e,22e,26e,30e,34e)-3,7,11,15,19,23,27,31,35,39-decamethyltetraconta-2,6,10,14,18,22,26,30,34,38-decaen-1-yl)-5,6-dimethoxy-3-methylcyclohexa-2,5-diene-1,4-dione
mfcd00042919
DB09270
EX-A973
ubidecarenone for system suitability, united states pharmacopeia (usp) reference standard
ubidecarenone, united states pharmacopeia (usp) reference standard
coenzyme q10, analytical standard
ubidecarenone for system suitability, european pharmacopoeia (ep) reference standard
ubidecarenone, european pharmacopoeia (ep) reference standard
coenzymeq10
aqua q 10l10
2-[(2e,6e,10e,14e,18e,22e,26e,30e,34e)-3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl]-5,6-dimethoxy-3-methyl- 2,5-cyclohexadiene-1,4-dione
unbiquinone
2-((2e,6e,10e,14e,18e,22e,26e,30e,34e)-3,7,11,15,19,23,27,31,35,39-decamethyltetraconta-2,6,10,14,18,22,26,30,34,38-decaenyl)-5,6-dimethoxy-3-methylcyclohexa-2,5-diene-1,4-dione
2-[(2e,6e,10e,14e,18e,22e,26e,30e,34e)-3,7,11,15,19,23,27,31,35,39-decamethyltetraconta-2,6,10,14,18,22,26,30,34,38-decaen-1-yl]-5,6-dimethoxy-3-methylcyclohexa-2,5-diene-1,4-dione
Q321285
coenzyme q10(coq10) ,
coenzymeq10,(s)
AS-13341
CS-0007796
HY-N0111
A936217
EN300-21680292
coq10; ubiquinone-10
ubidecarenone (ep monograph)
c01eb09
co-q10
vitamin q10
co q 10
ubidecarenonum (latin)
ubidecarenone for system suitability (usp-rs)
ubidecarenone (mart.)
coq10 200mg
ubidecarenone (usp-rs)

Research Excerpts

Overview

Coenzyme Q10 (ubiquinol) is an antioxidant that may play a significant role in the treatment of Attention Deficit Hyperactivity Disorder. It is an essential cofactor for energy production, with reduced levels being noted in HF.

ExcerptReferenceRelevance
"Coenzyme Q10 (CoQ10) is a member of the mitochondrial respiratory chain involved in cellular metabolism, including apoptosis."( Serum and tissue levels of coenzyme Q10 in pemphigus vulgaris.
Abdelkader, HA; Assaad, E; Rashed, LA; Saleh, MA, 2022
)
1.74
"Coenzyme Q10 (CoQ10) which acts as an electron transporter in the mitochondrial respiratory chain has many beneficial effects on liver diseases. "( CoQ10 Promotes Resolution of Necrosis and Liver Regeneration After Acetaminophen-Induced Liver Injury.
Chen, S; Chen, X; Fang, W; He, T; Tang, Y; Zhang, P, 2021
)
2.06
"Coenzyme Q10 (ubiquinol) is an antioxidant that may play a significant role in the treatment of Attention Deficit Hyperactivity Disorder."( Coenzyme Q10 in the Treatment of Attention Deficit Hyperactivity Disorder in Children: A Randomized Controlled Trial.
El Agami, O; Gamal, F; Salamah, A, 2022
)
2.89
"Coenzyme Q10 (CoQ10) is an essential cofactor for energy production, with reduced levels being noted in HF."( Coenzyme Q10 in the Treatment of Heart Failure with Preserved Ejection Fraction: A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial.
Alcalai, R; Amir, O; Asher, E; Ben Ivgi, F; Dadon, Z; Glikson, M; Gotsman, I; Hasin, T; Leibowitz, D; Samuel, TY; Weitzman, T, 2022
)
2.89
"Coenzyme Q10 (CoQ10) is an antioxidant, fat-soluble component present in the mitochondrial cells. "( Fortification methods of coenzyme Q10 in yogurt and its health functionality-a review.
Al-Bulushi, B; Chidambaram, SB; Derose, S; Essa, MM; Govindarajan, N; Qoronfleh, MW; Sarma, S, 2021
)
2.37
"Coenzyme Q10 is a vitamin-like substance made by the body that helps cells produce energy."( Coenzyme Q10 to manage chronic heart failure with a reduced ejection fraction: a systematic review and economic evaluation.
Beresford, L; Claxton, L; Cubbon, R; Dayer, M; Gottlieb, SS; Hartshorne-Evans, N; Kilroy, B; Llewellyn, A; Rothery, C; Sharif, S; Simmonds, M; Stewart, LA; Tierney, JF; Witte, KK; Wright, K, 2022
)
2.89
"Coenzyme Q10 (CoQ10) is a great candidate for the treatment of these diseases, acting precisely at the intersection between T2DM and CVD that is oxidative stress, due to its strong antioxidant activity and fundamental physiological role in mitochondrial bioenergetics."( Coenzyme Q10 for Diabetes and Cardiovascular Disease: Useful or Useless?
Pereira, MB; Renke, A; Renke, G, 2023
)
3.07
"Coenzyme Q10 (CoQ10) is an anti-inflammatory and anti-oxidative stress supplement that can improve inflammation and oxidative stress associated with AD."( Neuroprotective effects of coenzyme Q10-loaded exosomes obtained from adipose-derived stem cells in a rat model of Alzheimer's disease.
Amini, R; Hashemi, SM; Najafi, R; Saidijam, M; Sheykhhasan, M; Soleimani Asl, S, 2022
)
1.74
"Coenzyme Q10 (CoQ10) is an efficient antioxidant produced endogenously in a living organism. "( Preclinical and Clinical Role of Coenzyme Q10 Supplementation in Various Pathological States.
Khan, MI; Kumar, SR; Kumar, SS; Mahesh, P; Rajesh, K, 2022
)
2.45
"Coenzyme Q10 (Q10) is a powerful lipophilic antioxidant with poor solubility in aqueous media. "( A Co-Encapsulation of Coenzyme Q10 and Curcumin in Liposomes Coated with Chitosan (Q10-Cur-Lip-Chi) with Enhanced Solubility and Stability for Good Release Performance and Antioxidative Activity.
Chao, C; Li, Q; Lin, J; Xu, K; Xuan, Q; Ye, S; Yu, L; Zhao, S; Zhong, S, 2023
)
2.67
"Coenzyme Q10 is a lipid-soluble antioxidant that inhibits lipid peroxidation in biological membranes and supplies ATP cell synthesis, required as the organism's primary energy source."( The physiological insight of Coenzyme-Q10 administration in preventing the incidence of reperfusion arrhythmia among patients undergoing coronary artery bypass grafting surgery.
Andrianto, A; Dewi, IP; Putra, KNS; Soemantri, D; Wardhani, LFK, 2022
)
1.44
"Coenzyme Q10 (CoQ10) is a vital substance found throughout body. "( Nano-Liquid Chromatography with a New Monolithic Column for the Analysis of Coenzyme Q10 in Pistachio Samples.
Aydoğan, C; Beltekin, B; Demir, N; El Rassi, Z; Yurt, B, 2023
)
2.58
"Coenzyme Q10 (CoQ10) is an endogenously synthesized compound that is found in most living cells and plays an important role in cellular metabolism."( Can coenzyme Q10 alleviate the toxic effect of fenofibrate on skeletal muscle?
AbdElfattah, AA; Ayuob, NN; El-Bassouny, DR; Ellakkany, AS; Mansour, AA, 2023
)
2.19
"The coenzyme Q10 is a compound widely used in pharmaceutical and cosmetic formulations because it is a potent eliminator of free radicals, giving it antioxidant and anti-aging properties. "( Lipid nanoparticles containing coenzyme Q10 for topical applications: An overview of their characterization.
Mansur, CRE; Saez, V; Souza, IDL, 2023
)
1.75
"Coenzyme Q10 (CoQ10) is a lipid-soluble electron carrier in the mitochondrial electron transport chain."( Coenzyme Q10 Stimulate Reproductive Vatality.
Dong, X; Hu, C; Hu, Y; Nie, X; Shu, C; Xu, F, 2023
)
3.07
"Coenzyme Q10 is a fundamental endogenous factor involved in cell energy production that shows protective properties in oxidative stress, mainly in skeletal and heart muscle. "( A New Food-grade Coenzyme Q10 Formulation Improves Bioavailability: Single and Repeated Pharmacokinetic Studies in Healthy Volunteers.
Allegrini, P; De Combarieu, E; Frattini, E; Petrangolini, G; Riva, A; Ronchi, M, 2019
)
2.3
"Coenzyme Q10 (CoQ10) is a vitamin-like substance which functions as an electron carrier within the mitochondrial respiratory chain, as well as serving as an important intracellular antioxidant. "( Coenzyme Q10 Supplementation in Fibrosis and Aging.
Hargreaves, IP; Mantle, D, 2019
)
3.4
"Coenzyme Q10 (CoQ10) acts as an antioxidant and exerts neuroprotective effects."( Coenzyme Q10 supplementation reverses diabetes-related impairments in long-term potentiation induction in hippocampal dentate gyrus granular cells: An in vivo study.
Faraji, N; Karimi, SA; Komaki, A; Omidi, G; Shahidi, S, 2020
)
2.72
"The coenzyme Q10 (CoQ10) is a potent antioxidant with critical protection role against cell oxidative stress, caused by the mitochondrial dysfunction. "( Supplementation with exogenous coenzyme Q10 to media for in vitro maturation and embryo culture fails to promote the developmental competence of porcine embryos.
Cambra, JM; Cuello, C; Gil, MA; Lucas, X; Martinez, CA; Martinez, EA; Maside, C; Parrilla, I; Rodriguez-Martinez, H, 2019
)
1.36
"Coenzyme Q10 (CoQ10) is a lipophilic compound that has been used as an anti-aging supplement."( Enhancement of intestinal absorption of coenzyme Q10 using emulsions containing oleyl polyethylene acetic acids.
Maruyama, S; Miyashita, M; Nishimura, Y; Sato, Y; Sugawara, M; Takekuma, Y; Yamaki, Y; Yokoyama, S, 2020
)
1.55
"Coenzyme Q10 is an antioxidant that participates in adenosine triphosphate synthesis in mitochondria."( Coenzyme Q10 status, glucose parameters, and antioxidative capacity in college athletes.
Chang, PS; Chen, HW; Chiu, YW; Ho, CC; Lin, PT; Tsai, MC; Tseng, CY, 2020
)
2.72
"Coenzyme Q10 is an integral component of mitochondrial respiratory chain and the key component of mitochondrial ATP production."( Is mitochondrial bioenergetics and coenzyme Q10 the target of a virus causing COVID-19?
Gvozdjakova, A; Klauco, F; Kucharska, J; Sumbalova, Z, 2020
)
1.56
"Coenzyme Q10 (CoQ10) is a fat-soluble natural vitamin, which has a continuous oxidation-reduction cycle and is an effective antioxidant that can protect ovaries from oxidative damage."( Efficacy of coenzyme Q10 supplementation on glucose metabolism, lipid profiles, and biomarkers of inflammation in women with polycystic ovary syndrome: A protocol for a systematic review and meta-analysis.
Chen, H; Hu, X; Liu, M; Zhu, H; Zhu, Y, 2020
)
1.66
"Coenzyme Q10 is an example of a poorly water-soluble compound with low bioavailability, and significant inter-individual variation after oral administration; limiting its optimum efficacy, as a powerful antioxidant with significant promise in treating hearing disorders."( Microencapsulation of Coenzyme Q10 and bile acids using ionic gelation vibrational jet flow technology for oral delivery.
Al-Salami, H; Brown, D; Ionescu, CM; Jones, M; Kovacevic, B; Mooranian, A; Wagle, SR; Walker, D, 2020
)
1.59
"Coenzyme Q10 (CoQ10) is a ubiquitous cofactor in the body, operating in the inner mitochondrial membrane, where it plays a vital role in the generation of adenosine triphosphate (ATP) through the electron transport chain (ETC). "( Cellular Consequences of Coenzyme Q10 Deficiency in Neurodegeneration of the Retina and Brain.
Abdulhussein, D; Cordeiro, MF; Manzar, H; Yap, TE, 2020
)
2.3
"Coenzyme Q10 (CoQ10), is a promising antioxidant; however, low bioavailability owing to lipid-solubility is a limiting factor. "( Water-soluble coenzyme Q10 provides better protection than lipid-soluble coenzyme Q10 in a rat model of chronic tacrolimus nephropathy.
Bae, SK; Chung, BH; Chung, SJ; Cui, S; Kim, HL; Kim, JH; Ko, EJ; Lee, KE; Lim, SW; Luo, K; Quan, Y; Shin, YJ; Yang, CW, 2021
)
2.42
"Coenzyme Q10 is an essential component of the mitochondrial respiratory chain, where it transports electrons from complexes I and II to complex III."( Primary coenzyme Q10 nephropathy, a potentially treatable form of steroid-resistant nephrotic syndrome.
Airik, R; Tan, W, 2021
)
1.78
"Coenzyme Q10 (CoQ10) is a ubiquitous molecule in living organisms serving as a cofactor in energy production. "( Prospective study of plasma levels of coenzyme Q10 and lung cancer risk in a low-income population in the Southeastern United States.
Blot, WJ; Cai, Q; Franke, AA; Shidal, C; Shu, XO; Wu, J; Yoon, HS; Zheng, W, 2021
)
2.34
"Coenzyme Q10 (CoQ10) acts as an antioxidant that protects the cells by preventing lipid peroxidation. "( Cubosomes as a Potential Oral Drug Delivery System for Enhancing the Hepatoprotective Effect of Coenzyme Q10.
Darwish, AB; Mohsen, AM; Salama, A; Younis, MM, 2021
)
2.28
"Coenzyme Q10 (CoQ10) is a cofactor in the electron-transport chain of the mitochondria, but it is also a potent endogenous antioxidant."( Coenzyme Q10 deficiency in patients with hereditary hemochromatosis.
Daruich, JR; Di Carlo, MB; Martinefski, MR; Tripodi, VP; Yamasato, MF, 2021
)
2.79
"Coenzyme Q10 (CoQ10) is an essential component of the human body."( Efficacy of coenzyme Q10 in supportive therapy of the cardiovascular diseases and in the prevention of cardiotoxicity caused by chemotherapy.
Cieślewicz, A; Jabłecka, A; Miedziaszczyk, M, 2021
)
1.72
"Coenzyme Q10 (CoQ10) is a vital lipophilic molecule found in all respiratory eukaryotic cells, including spermatozoa."( Possible Protective Mechanisms of Coenzyme Q10 Action on Spermatozoa During Cryopreservation or Cooled-Stored Condition.
Appiah, MO; Asante-Badu, B; Liu, H; Lu, W; Wang, J; Zhao, J,
)
1.13
"Coenzyme Q10 (CoQ10) is an antioxidant molecule with anti-aging activity on human hair, and because of its pharmaceutical limitations such as large molecular weight, high lipophilicity and poor water solubility, its therapeutic effectiveness has been hampered. "( Coenzyme Q10 phospholipidic vesicular formulations for treatment of androgenic alopecia:
Abdel-Aziz, RTA; El-Zaafarany, GM; Montaser, MHA; Nasr, M, 2021
)
3.51
"Coenzyme Q10 (CoQ10) is a naturally occurring, lipid-soluble antioxidant and an essential electron carrier in the mitochondrial respiratory chain. "( Coenzyme Q10 improves the survival, mesenteric perfusion, organs and vessel functions in septic rats.
Bariskaner, H; Goktas, MT; Iskit, AB; Kilinc, I; Ozer, EK; Pehlivan, S; Ugurluoglu, C, 2017
)
3.34
"Coenzyme Q10 (CoQ10) is a mitochondrial-targeted antioxidant with known neuroprotective activity. "( Topical Coenzyme Q10 demonstrates mitochondrial-mediated neuroprotection in a rodent model of ocular hypertension.
Brenton, J; Butt, G; Cordeiro, MF; Davis, BM; Guo, L; Malaguarnera, G; Normando, EM; Pahlitzsch, M; Ravindran, N; Tian, K, 2017
)
2.33
"Coenzyme Q10 (CoQ10) is a lipid-soluble molecule found naturally in many eukaryotic cells and is essential for electron transport chain and energy generation in mitochondria. "( Design, optimization and characterization of coenzyme Q10- and D-panthenyl triacetate-loaded liposomes.
Çelik, B; Özdemir, S; Sağıroğlu, AA, 2017
)
2.16
"Coenzyme Q10 (CoQ10) is a powerful antioxidant substance synthesized in the body. "( Coenzyme Q10 Inhibits Th17 and STAT3 Signaling Pathways to Ameliorate Colitis in Mice.
Cho, ML; Jung, H; Jung, K; Kim, EK; Kim, JK; Lee, BI; Lee, HH; Lee, K; Lee, SH; Lee, SY; Park, SH; Shin, DY; Yang, EJ, 2017
)
3.34
"Coenzyme Q10 (CoQ10) is a fat‑soluble vitamin‑like substance used for the treatment of a variety of disorders, including osteoporosis. "( Coenzyme Q10 promotes osteoblast proliferation and differentiation and protects against ovariectomy-induced osteoporosis.
Chen, X; Cui, C; Li, X; Lin, Y; Wang, L; Yu, M; Zheng, D, 2018
)
3.37
"Coenzyme Q10 (CoQ10) is a vitamin-like oil-soluble molecule that has anti-oxidant and anti-ageing effects. "( Coenzyme Q10-Loaded Fish Oil-Based Bigel System: Probing the Delivery Across Porcine Skin and Possible Interaction with Fish Oil Fatty Acids.
Chan, LM; Heard, CM; Rehman, K; Wai, LK; Zulfakar, MH, 2018
)
3.37
"Coenzyme Q10 (CQ10), which is a fat-soluble quinone antioxidant, is involved in the pathophysiological processes of neurodegenerative diseases, cancer, diabetes, heart failure, and other diseases."( Coenzyme Q10 Regulates Antioxidative Stress and Autophagy in Acute Myocardial Ischemia-Reperfusion Injury.
Ge, J; Liang, S; Ping, Z, 2017
)
2.62
"Coenzyme Q10 (CoQ10) is an essential compound of the human body."( Coenzyme Q10 in Cardiovascular and Metabolic Diseases: Current State of the Problem.
Covantev, S; Goroshko, OA; Krasnykh, LM; Kukes, VG; Zozina, VI, 2018
)
2.64
"Coenzyme Q10 (CoQ10) is an endogenous antioxidant that could be effective in preventing oxidative stress."( Serum Coenzyme Q10 Is Associated with Clinical Neurological Outcomes in Acute Stroke Patients.
Hashemifard, S; Heydari, K; Hooshmandi, E; Madahi, M; Ramezani, M; Rezaei, O; Ryan, F; Sahraei, Z; Simani, L, 2018
)
1.68
"Coenzyme Q10 (CoQ10) is a mitochondrial respiratory cofactor and potent endogenous antioxidant. "( High-dose coenzyme Q10-loaded oleogels for oral therapeutic supplementation.
Lucangioli, S; Martinefski, MR; Masotta, NE; Rojas, AM; Tripodi, VP, 2019
)
2.36
"Coenzyme Q10 (CoQ10) is a well-known anti-adipogenic factor that possesses the capability to regulate non-alcoholic fatty liver disease (NAFLD). "( Coenzyme Q10 attenuates high-fat diet-induced non-alcoholic fatty liver disease through activation of the AMPK pathway.
Chen, K; Chen, X; Fang, W; Ling, W; Xue, H; Zhang, P, 2019
)
3.4
"Coenzyme Q10 (Q10) is a powerful antioxidant that buffers the potential adverse consequences of free radicals."( Investigation of protective effects of coenzyme Q10 on impaired synaptic plasticity in a male rat model of Alzheimer's disease.
Etaee, F; Faraji, N; Komaki, A; Komaki, H; Mirzaei, F; Raoufi, S; Shahidi, S, 2019
)
1.5
"Coenzyme Q10 (CoQ10) is an essential cofactor for mitochondrial electron transport, and its reduced form acts as a lipophilic antioxidant."( Coenzyme Q10 protects against burn-induced mitochondrial dysfunction and impaired insulin signaling in mouse skeletal muscle.
Ikeda, K; Inoue, S; Kaneki, M; Martyn, JAJ; Nakazawa, H; Shinozaki, S; Tompkins, RG; Yasuhara, S; Yorozu, T; Yu, YM, 2019
)
2.68
"Coenzyme Q10 (CoQ10) is an important cofactor in the mitochondrial respiratory chain and a potent endogenous antioxidant. "( Miniaturized imprinted solid phase extraction to the selective analysis of Coenzyme Q10 in urine.
Baez, F; Flor, S; García Becerra, C; Lucangioli, S; Tripodi, V, 2019
)
2.19
"Coenzyme Q10 (CoQ10) is a fat-soluble vitamin-like quinone that exerts antioxidative functions and is also an important factor in mitochondrial metabolism. "( Efficacy of coenzyme Q10 in patients with chronic kidney disease: protocol for a systematic review.
Gao, J; Han, E; Liu, J; Wang, Y; Xu, Y, 2019
)
2.34
"Coenzyme Q10 (CoQ10) acts as an antioxidant in the skin and is frequently contained in anti-aging products. "( Ultra-small NLC for improved dermal delivery of coenyzme Q10.
Baisaeng, N; Hoppel, M; Keck, CM; Löw, M; Schwarz, JC; Valenta, C, 2013
)
1.83
"Coenzyme Q10 (CoQ10) is an essential part of the mitochondrial respiratory chain. "( Mitochondrial coenzyme Q10 determination by isotope-dilution liquid chromatography-tandem mass spectrometry.
Itkonen, O; Suomalainen, A; Turpeinen, U, 2013
)
2.19
"Coenzyme Q10 (CoQ10) is an essential cofactor in the mitochondrial electron transport pathway, and is also the only known endogenously synthesized lipid-soluble antioxidant. "( Endogenous plasma coenzyme Q10 concentration does not correlate with plasma total antioxidant capacity level in healthy untrained horses.
Bohar Topolovec, M; Jazbec Križman, P; Kruljc, P; Nemec Svete, A; Prošek, M; Smidovnik, A, 2013
)
2.17
"Coenzyme Q10 (CoQ10) is an antioxidant, a membrane stabilizer, and a vital cofactor in the mitochondrial electron transport chain, enabling the generation of adenosine triphosphate. "( Coenzyme Q10 depletion in medical and neuropsychiatric disorders: potential repercussions and therapeutic implications.
Anderson, G; Berk, M; Maes, M; Morris, G, 2013
)
3.28
"Coenzyme Q10 (CoQ10) is a component of the electron transport chain as well as an important antioxidant in mitochondrial and lipid membranes."( An alternative medical approach for the neuroprotective therapy to slow the progression of Parkinson's disease.
Muroyama, A, 2013
)
1.11
"Coenzyme Q10 (CoQ10) is a mobile electron carrier in the mitochondrial respiratory chain (MRC) with antioxidant and potential neuroprotective activities."( Chronic treatment with coenzyme Q10 reverses restraint stress-induced anhedonia and enhances brain mitochondrial respiratory chain and creatine kinase activities in rats.
Aboul-Fotouh, S, 2013
)
1.42
"Coenzyme Q10 (CoQ10) is an essential cofactor involved in the mitochondrial electron transport chain and has been suggested as a potential therapeutic agent in AD."( Effect of DHA and coenzymeQ10 against Aβ- and zinc-induced mitochondrial dysfunction in human neuronal cells.
Barrow, CJ; McGee, S; Sadli, N; Suphioglu, C, 2013
)
1.11
"Coenzyme Q10 is an endogenous lipid-soluble antioxidant."( Effects of coenzyme Q10 supplementation (300 mg/day) on antioxidation and anti-inflammation in coronary artery disease patients during statins therapy: a randomized, placebo-controlled trial.
Lee, BJ; Lin, PT; Tseng, YF; Yen, CH, 2013
)
1.5
"Coenzyme Q10 (CoQ10) is an essential component in the electron-transport systems of mitochondria and bacteria and is often used as a supplementary treatment for some diseases. "( Emulsification using highly hydrophilic surfactants improves the absorption of orally administered coenzyme Q10.
Iseki, K; Mutoh, H; Sato, Y; Sugawara, M; Suzuki, M; Takekuma, Y, 2013
)
2.05
"Coenzyme Q10 is a natural antioxidant and scavenger of free radicals. "( Serum paraoxonase 1 status and its association with atherogenic indexes in gentamicin-induced nephrotoxicity in rats treated with coenzyme Q10.
Ahmadvand, H; Bagheri, S; Cheraghi, RA; Dehghani, A; Ghasemi Dehnoo, M, 2014
)
2.05
"Coenzyme Q10 is a potent antioxidant in both mitochondria and lipid membranes. "( The effects of coenzyme Q10 on seizures in mice: the involvement of nitric oxide.
Moezi, L; Mousavi, Z; Sattarinezhad, E; Shafaroodi, H; Sheikhnouri, K, 2014
)
2.2
"Coenzyme Q10 (CoQ10) is an essential component of the respiratory chain which produces ATP. "( Enhanced production techniques, properties and uses of coenzyme Q10.
de Dieu Ndikubwimana, J; Lee, BH, 2014
)
2.09
"Coenzyme Q10 (CoQ10) is a lipid-soluble antioxidant that could have beneficial effects in patients undergoing cardiac surgery with cardiopulmonary bypass. "( Prophylactic treatment with coenzyme Q10 in patients undergoing cardiac surgery: could an antioxidant reduce complications? A systematic review and meta-analysis.
de Frutos, F; Gea, A; Hernandez-Estefania, R; Rabago, G, 2015
)
2.15
"Coenzyme Q10 (CoQ10) is an antioxidant that is naturally synthesised by the body and can also be taken as a dietary supplement."( Co-enzyme Q10 supplementation for the primary prevention of cardiovascular disease.
Flowers, N; Hartley, L; Rees, K; Stranges, S; Todkill, D, 2014
)
1.12
"Coenzyme Q10 (CoQ10) is an antioxidant and anti-inflammatory compound, possessing both anti-arthritic and hepatoprotective potential."( Combination of coenzyme Q10 with methotrexate suppresses Freund's complete adjuvant-induced synovial inflammation with reduced hepatotoxicity in rats: Effect on oxidative stress and inflammation.
Tawfik, MK, 2015
)
1.49
"Coenzyme Q10 redox state is a key regulator of Arabidopsis basal resistance against bacterial pathogens."( Hypersensitive response-like lesions 1 codes for AtPPT1 and regulates accumulation of ROS and defense against bacterial pathogen Pseudomonas syringae in Arabidopsis thaliana.
Chan, SH; Dutta, A; Pauli, NT; Raina, R, 2015
)
1.86
"Coenzyme Q10 deficiency is a clinically and genetically heterogeneous disorder, with manifestations that may range from fatal neonatal multisystem failure, to adult-onset encephalopathy. "( Primary coenzyme Q10 deficiency presenting as fatal neonatal multiorgan failure.
Angelini, C; Burlina, A; Casarin, A; Cenacchi, G; Chiandetti, L; Clementi, M; Desbats, MA; Doimo, M; Limongelli, I; Lunardi, G; Navas, P; Rodriguez Hernandez, MA; Salviati, L; Spinazzi, M; Trevisson, E; Vetro, A; Zuffardi, O, 2015
)
2.29
"Coenzyme Q10 is a ubiquitous component of cellular membranes and belongs to the class of benzoquinones that mainly differ with regards to the length and composition of their hydrophobic tail. "( Border between natural product and drug: comparison of the related benzoquinones idebenone and coenzyme Q10.
Gueven, N; Smith, J; Woolley, K, 2015
)
2.08
"Coenzyme Q10 (CoQ10) is an essential part of the mitochondrial respiratory chain. "( Mitochondrial coenzyme Q10 determination via isotope dilution liquid chromatography tandem mass spectrometry.
Itkonen, O; Turpeinen, U, 2015
)
2.22
"Coenzyme Q10 (CoQ10) is an important cofactor in the mitochondrial respiratory chain and a potent endogenous antioxidant. "( A novel non-invasive sampling method using buccal mucosa cells for determination of coenzyme Q10.
Lucangioli, S; Martinefski, M; Samassa, P; Tripodi, V, 2015
)
2.08
"Coenzyme Q10 is a naturally-occurring coenzyme with antioxidant effects that is involved in electron transport in mitochondria and is thought to play a role in energy transfer in skeletal muscle."( Coenzyme Q10 and statin-related myopathy.
, 2015
)
2.58
"Coenzyme Q10 (CoQ10) is a lipid-soluble antioxidant synthesized in human body. "( Coenzyme Q10 suppresses Th17 cells and osteoclast differentiation and ameliorates experimental autoimmune arthritis mice.
Byun, JK; Cho, ML; Jeong, JH; Jhun, J; Jung, YO; Kim, EK; Lee, J; Lee, SH; Park, SH; Shin, D, 2015
)
3.3
"Coenzyme Q10 is an endogenous antioxidant as well as a popular dietary supplement. "( Rapid and sensitive analysis of reduced and oxidized coenzyme Q10 in human plasma by ultra performance liquid chromatography-tandem mass spectrometry and application to studies in healthy human subjects.
Claessens, AJ; Himmelfarb, J; Phillips, BR; Risler, LJ; Shen, DD; Yeung, CK, 2016
)
2.13
"Coenzyme Q10 (CoQ10) is a lipophilic antioxidant that improves human immunity, delays senility and enhances the vitality of the human body and has wide applications in pharmaceutical and cosmetic industries. "( [Production of coenzyme Q10 by metabolically engineered Escherichia coli].
Dai, G; Li, Q; Miao, L; Sun, T; Xiao, D; Zhang, X, 2015
)
2.21
"Coenzyme Q10 (CoQ10) is a natural compound that has recently been considered as an anti-inflammatory factor."( Functions of Coenzyme Q10 Supplementation on Liver Enzymes, Markers of Systemic Inflammation, and Adipokines in Patients Affected by Nonalcoholic Fatty Liver Disease: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial.
Alavinejad, P; Engali, KA; Farsi, F; Mohammadshahi, M; Rezazadeh, A; Zarei, M,
)
1.22
"Coenzyme Q10 (CoQ10) is an important antioxidant used in medicine, dietary supplements, and cosmetic applications. "( Batch production of coenzyme Q10 by recombinant Escherichia coli containing the decaprenyl diphosphate synthase gene from Sphingomonas baekryungensis.
Altamirano, C; Berríos, J; Díaz-Barrera, A; Martínez, I; Méndez, C, 2015
)
2.18
"Coenzyme Q10 is an antioxidant molecule playing an important role in mitochondria. "( Effect of coenzyme Q10 on organ damage in sepsis.
Abitagaoglu, S; Akinci, M; Akinci, SB; Aypar, U; Muftuoglu, S; Saricaoglu, F; Zeybek, ND, 2015
)
2.26
"Coenzyme Q10 (CoQ10) is a component of electron transport chain and acts as an antioxidant. "( Neuroprotection of Coenzyme Q10 in Neurodegenerative Diseases.
Chang, RC; Liu, J; Luo, X; Xu, H; Yang, X; Yu, J; Zhang, Y, 2016
)
2.21
"Coenzyme Q10 (CoQ10) is an endogenous lipid-soluble benzoquinone compound that functions as a diffusible electron carrier in the electron transport chain. "( Coenzyme Q10 Supplementation and Exercise in Healthy Humans: A Systematic Review.
Diaz-Castro, J; Guisado, R; Kajarabille, N; Ochoa, JJ; Pulido-Moran, M; Sarmiento, A, 2016
)
3.32
"Coenzyme Q10 (CoQ10) is an antioxidant that enhances the activity of complex I and II in the Electron Transport Chain. "( Coenzyme Q10 for Patients with Parkinson's Disease: A Systematic Review and Meta-Analysis.
El Ashal, G; El Ghonimy, S; Elfouly, Y; Fouda, S; Hani, Y; Hegazy, Y; Menshawy, A; Negida, A; Rashad, Y, 2016
)
3.32
"Coenzyme Q10 is a potent molecule but its high molecular weight and low aqueous solubility hamper its use as a therapeutic agent. "( Novel Carriers for Coenzyme Q10 Delivery.
Kumar, A; Kumar, S; Mahant, S; Nanda, S; Rao, R, 2016
)
2.21
"Coenzyme Q10 (CoQ10) is a member of the mitochondrial respiratory chain with a prominent role as a potent gene regulator."( Supplementation with coenzyme Q10 reduces plasma lipoprotein(a) concentrations but not other lipid indices: A systematic review and meta-analysis.
Pirro, M; Sahebkar, A; Simental-Mendía, LE; Stefanutti, C, 2016
)
1.47
"Coenzyme Q10 (CoQ10) is a natural constituent of foods and is also often used in both functional foods and supplements. "( The effect of dietary intake of coenzyme Q10 on skin parameters and condition: Results of a randomised, placebo-controlled, double-blind study.
Mervic, L; Pogačnik, T; Pravst, I; Žmitek, J; Žmitek, K, 2017
)
2.18
"Coenzyme Q10 (CoQ10) is a lipid-soluble benzoquinone with antioxidant features that make it important in the treatment of ischemia reperfusion injury. "( The effect of coenzyme Q10 on venous ischemia reperfusion injury.
Aydın, H; Elbey, H; Özalp, B; Tekkesin, MS; Uzun, H, 2016
)
2.24
"Coenzyme Q10 (CoQ10) is a supplement and has shown preliminary benefits in migraine prophylaxis."( Effectiveness of coenzyme Q10 in prophylactic treatment of migraine headache: an open-label, add-on, controlled trial.
Akbari Oryani, M; Mali, S; Olfati, N; Salehi, M; Shoeibi, A; Soltani Sabi, M, 2017
)
1.52
"Coenzyme Q10 is an endogenous lipid-soluble antioxidant."( Effects of coenzyme Q10 supplementation on antioxidant capacity and inflammation in hepatocellular carcinoma patients after surgery: a randomized, placebo-controlled trial.
Cheng, SB; Huang, YC; Huang, YT; Lin, PT; Liu, HT, 2016
)
1.55
"Coenzyme Q10 (CoQ10) is an important anti-oxidant compound with anti-inflammatory and neuro-protective properties."( Targeting Oxidative Stress, Cytokines and Serotonin Interactions Via Indoleamine 2, 3 Dioxygenase by Coenzyme Q10: Role in Suppressing Depressive Like Behavior in Rats.
Abuelezz, SA; Hendawy, N; Magdy, Y, 2017
)
1.39
"Coenzyme Q10 (CoQ10) is a naturally occurring compound that plays a fundamental role in cellular bioenergetics and is an effective antioxidant. "( Relative bioavailability of two forms of a novel water-soluble coenzyme Q10.
Fir, M; Pravst, I; Prosek, M; Smidovnik, A; Walczak, J; Zmitek, J; Zmitek, K, 2008
)
2.03
"Coenzyme Q10 (CoQ10) is a vitamin-like substance which plays a crucial role in the respiratory chain ranging from bacteria to humans and in the radical scavenging in human body. "( Enhanced production of coenzyme Q10 by overexpressing HMG-CoA reductase and induction with arachidonic acid in Schizosaccharomyces pombe.
Cheng, B; Li, WJ; Sun, XX; Yuan, QP, 2010
)
2.11
"Coenzyme Q10 (CoQ10) is a naturally occurring component present in living cells. "( Safety assessment of coenzyme Q10 (CoQ10).
Fujii, K; Fukutomi, N; Funahashi, I; Hidaka, T; Hosoe, K, 2008
)
2.11
"Coenzyme Q10 (CoQ(10)) is an essential electron carrier in the mitochondrial respiratory chain and a strong antioxidant. "( Coenzyme Q10 distribution in blood is altered in patients with fibromyalgia.
Bonal, P; Campa, F; Cordero, MD; deMiguel, M; Jiménez-Jiménez, LM; Moreno-Fernández, AM; Navas, P; Ruiz-Losada, A; Salviati, L; Sánchez Alcázar, JA; Sánchez-Domínguez, B, 2009
)
3.24
"Coenzyme Q10 (CoQ10) is a biosynthesized quinone with 10 isoprene side chains in humans. "( Effect of coenzyme Q10 on cutaneous healing in skin-incised mice.
Cho, BJ; Choi, BS; Kim, CJ; Kim, HR; Kim, TD; Park, TW; Sim, SS; Song, HS, 2009
)
2.2
"Coenzyme Q10 (ubiquinone) is a mitochondrial coenzyme which is essential for the production of ATP. "( Role of coenzyme Q10 (CoQ10) in cardiac disease, hypertension and Meniere-like syndrome.
Devi, P; Kaur, H; Kumar, A; Mohan, V, 2009
)
2.23
"Coenzyme Q10 (CoQ10) is a strong antioxidant that has anti-inflammatory effects."( Lower plasma Coenzyme Q10 in depression: a marker for treatment resistance and chronic fatigue in depression and a risk factor to cardiovascular disorder in that illness.
Bosmans, E; Kubera, M; Maes, M; Mihaylova, I; Uytterhoeven, M; Vrydags, N, 2009
)
1.44
"Coenzyme Q10 (CoQ10) is a popular food supplement. "( Development of coenzyme Q10-enriched rice using sugary and shrunken mutants.
Kadowaki, K; Kawamukai, M; Nakamura, Y; Ohtani, T; Satoh, H; Takahashi, S, 2010
)
2.16
"Coenzyme Q10 (CoQ(10)) is an effective natural antioxidant with a fundamental role in cellular bioenergetics and numerous known health benefits. "( Coenzyme Q10 contents in foods and fortification strategies.
Pravst, I; Zmitek, J; Zmitek, K, 2010
)
3.25
"Coenzyme Q10 (CoQ10) is an endogenous cellular antioxidant that is used as a nutritional supplement and for medicinal purposes. "( Preparation and characterization of liposomal coenzyme Q10 for in vivo topical application.
Lee, WC; Tsai, TH, 2010
)
2.06
"Coenzyme Q10 (CoQ10) is a component of the mitochondrial electron transport chain and is considered an important cellular antioxidant. "( Plasma coenzyme Q10 levels and postmenopausal breast cancer risk: the multiethnic cohort study.
Caberto, CP; Chai, W; Cooney, RV; Franke, AA; Goodman, MT; Henderson, BE; Kolonel, LN; Le Marchand, L; Shvetsov, YB; Wilkens, LR, 2010
)
2.26
"Coenzyme Q10 is an essential cofactor in the mitochondrial electron transport pathway, and is endowed for its potent antioxidant capacity; characters that endorse its implication in several clinical practices and as a food supplement. "( Coenzyme Q10: a novel gastroprotective effect via modulation of vascular permeability, prostaglandin E₂, nitric oxide and redox status in indomethacin-induced gastric ulcer model.
El-Abhar, HS, 2010
)
3.25
"Coenzyme Q10 (CoQ10) is a major antioxidant principle found in human body which plays a vital role in maintaining several biochemical pathways of body. "( Bioavailability enhancement of coenzyme Q10: an extensive review of patents.
Beg, S; Javed, S; Kohli, K, 2010
)
2.09
"Coenzyme Q10 (CoQ) is a powerful antioxidant that reduces oxidative stress. "( Mediterranean diet supplemented with coenzyme Q10 induces postprandial changes in p53 in response to oxidative DNA damage in elderly subjects.
Camargo, A; Castaño, JP; Cruz-Teno, C; Delgado-Casado, N; Delgado-Lista, J; Fuentes, F; Gutierrez-Mariscal, FM; Lopez-Miranda, J; Perez-Jimenez, F; Perez-Martinez, P; Rodriguez-Cantalejo, F; Santos-Gonzalez, M; Villalba-Montoro, JM; Yubero-Serrano, EM, 2012
)
2.09
"Coenzyme Q10 (CoQ10) is a widely used supplement in heart diseases treatment or antioxidative dietary. "( Coenzyme Q10 production by Sphingomonas sp. ZUTE03 with novel precursors isolated from tobacco waste in a two-phase conversion system.
Chen, J; Fang, J; Li, X; Qiu, L; Wang, W; Wu, S; Zhong, L; Zhong, W, 2011
)
3.25
"Coenzyme Q10 (CoQ10) is a potent antioxidant that may improve function in dystrophin-deficient muscle."( CINRG pilot trial of coenzyme Q10 in steroid-treated Duchenne muscular dystrophy.
Connolly, AM; Escolar, DM; Florence, J; Gorni, K; Henricson, E; Hu, F; Martin, GR; Mayhew, J; Nie, L; Pasquali, L; Pestronk, A; Rocha, CT; Spurney, CF, 2011
)
1.41
"Coenzyme Q10 is a small electron carrier of the respiratory chain with antioxidant properties, widely used for the treatment of mitochondrial disorders. "( Targeting mitochondrial dysfunction and neurodegeneration by means of coenzyme Q10 and its analogues.
Ienco, EC; LoGerfo, A; Mancuso, M; Orsucci, D; Siciliano, G, 2011
)
2.05
"Coenzyme Q10 (CoQ10) is a key cofactor in the mitochondrial respiratory chain, but whether CoQ10 is depleted in septic shock remains unknown."( Coenzyme Q10 levels are low and may be associated with the inflammatory cascade in septic shock.
Akuthota, P; Buettner, C; Cocchi, MN; Donnino, MW; Kim, D; Naini, AB; Salciccioli, JD, 2011
)
2.53
"Coenzyme Q10 is a key component of the electron transport chain which plays an essential role in ATP production and also has antioxidant effects. "( Behavioral improvement after chronic administration of coenzyme Q10 in P301S transgenic mice.
Beal, MF; Dumont, M; Elipenahli, C; Gerges, M; Jainuddin, S; Stack, C; Starkov, A; Yang, L, 2012
)
2.07
"Coenzyme Q10 (CoQ10) is a lipid-soluble antioxidant that may protect against mitochondrial reactive oxygen species and thus prevent doxorubicin-induced cardiotoxicity."( Lack of effect of coenzyme q10 on doxorubicin cytotoxicity in breast cancer cell cultures.
Greenlee, H; Lau, YI; Maurer, M; Naini, A; Shaw, J, 2012
)
1.43
"Coenzyme Q10 (CoQ10) is a common antioxidant supplement with known cardioprotective effects and potential anticancer benefits."( A randomized, double-blind, placebo-controlled study of oral coenzyme Q10 to relieve self-reported treatment-related fatigue in newly diagnosed patients with breast cancer.
Case, D; Garino, LA; Giguere, J; Lesser, GJ; Lively, MO; Naughton, MJ; Shaw, EG; Stark, N; Vitolins, MZ; Williford, S, 2013
)
2.07
"Coenzyme Q10 (CoQ10) is an essential factor of the mitochondrial respiratory chain and has effective antioxidant properties. "( Coenzyme Q10 decreases basic fibroblast growth factor (bFGF)-induced angiogenesis by blocking ERK activation.
Choi, JS; Jeong, JW; Kim, YJ; Park, SY; Yi, EY, 2011
)
3.25
"Coenzyme Q10 is a natural antioxidant and scavenging free radicals. "( Amelioration of altered antioxidant enzymes activity and glomerulosclerosis by coenzyme Q10 in alloxan-induced diabetic rats.
Ahmadvand, H; Khosrowbeygi, A; Tavafi, M,
)
1.8
"Coenzyme Q10(CoQ10) is a known anti-adipogenic factor. "( Coenzyme Q10 increases the fatty acid oxidation through AMPK-mediated PPARα induction in 3T3-L1 preadipocytes.
Kang, HJ; Kim, HS; Kim, JH; Kim, N; Kim, SJ; Lee, JO; Lee, SK; Lee, YW; Moon, JW; Park, SH; Sha, J; You, GY, 2012
)
3.26
"Coenzyme Q10 (CoQ10) is an essential electron carrier in the mitochondrial respiratory chain and a strong antioxidant."( Oral coenzyme Q10 supplementation improves clinical symptoms and recovers pathologic alterations in blood mononuclear cells in a fibromyalgia patient.
Bullón, P; Carrión, AM; Cordero, MD; Cotán, D; de Miguel, M; del-Pozo-Martín, Y; Sánchez-Alcazar, JA,
)
1.37
"Coenzyme Q10 (CoQ10) is an essential cofactor in the mitochondrial electron transport pathway and has a powerful antioxidant capacity."( Coenzyme Q10 displays antidepressant-like activity with reduction of hippocampal oxidative/nitrosative DNA damage in chronically stressed rats.
Aboul-Fotouh, S, 2013
)
2.55
"Coenzyme Q10 (CoQ10) serves as an electron carrier within the mitochondrial respiratory chain (MRC), where it is integrally involved in oxidative phosphorylation and consequently ATP production. "( Blood mononuclear cell coenzyme Q10 concentration and mitochondrial respiratory chain succinate cytochrome-c reductase activity in phenylketonuric patients.
Briddon, A; Hargreaves, IP; Heales, SJ; Land, JM; Lee, PJ, 2002
)
2.07
"Coenzyme Q10 (CoQ10) is an essential component of the mitochondrial respiratory chain and an important scavenger of reactive oxygen species. "( Coenzyme Q10 levels in Prader-Willi syndrome: comparison with obese and non-obese subjects.
Bittel, D; Butler, MG; Dasouki, M; DiMauro, S; Hunter, S; Naini, A, 2003
)
3.2
"Coenzyme Q10 (CoQ) is an endogenously synthesised compound that acts as an electron carrier in the mitochondrial electron transport chain. "( Can coenzyme Q10 improve vascular function and blood pressure? Potential for effective therapeutic reduction in vascular oxidative stress.
Hodgson, JM; Watts, GF, 2003
)
2.32
"Coenzyme Q10 is an antioxidant that may have a therapeutic role in cervical cancer."( Coenzyme Q10 and lipid-related gene induction in HeLa cells.
Goldberg, GL; Gorelick, C; Khabele, D; Lopez-Jones, M; Romney, SL, 2004
)
3.21
"Coenzyme Q10 (CoQ) is an endogenous enzyme cofactor, which may provide protective benefits as an antioxidant. "( Age-related changes in plasma coenzyme Q10 concentrations and redox state in apparently healthy children and adults.
DeGrauw, T; Horn, PS; Miles, L; Miles, MV; Morrison, JA; Pesce, AJ; Tang, PH, 2004
)
2.05
"Coenzyme Q10 is a component of the mitochondrial respiratory chain and a potent anti-oxidant."( Role of mitochondria in neuronal cell death induced by oxidative stress; neuroprotection by Coenzyme Q10.
Borowy-Borowski, H; Hung, M; McCarthy, S; Pandey, S; Sikorska, M; Somayajulu, M, 2005
)
1.27
"Coenzyme Q10 is an essential cofactor in the electron transport chain and serves as an important antioxidant in both mitochondria and lipid membranes. "( Coenzyme Q10 affects expression of genes involved in cell signalling, metabolism and transport in human CaCo-2 cells.
Althammer, M; Döring, F; Groneberg, DA; Kindermann, B; Klapper, M; Littarru, GP; Vormann, J, 2005
)
3.21
"Coenzyme Q10 is a vitamin-like nutrient that has a fundamental role in mitochondrial function, especially as it relates to the production of energy (ATP) and also as an antioxidant."( Potential role of ubiquinone (coenzyme Q10) in pediatric cardiomyopathy.
Bhagavan, HN; Chopra, RK, 2005
)
1.34
"Coenzyme Q10 (ubiquinone) is a naturally occurring compound widely distributed in animal organisms and in humans. "( [Coenzyme Q10: its biosynthesis and biological significance in animal organisms and in humans].
Siemieniuk, E; Skrzydlewska, E, 2005
)
2.68
"Coenzyme Q10 (CoQ10) is an essential biological cofactor which increases brain mitochondrial concentration and exerts neuroprotective effects. "( Coenzyme Q10 protects SHSY5Y neuronal cells from beta amyloid toxicity and oxygen-glucose deprivation by inhibiting the opening of the mitochondrial permeability transition pore.
Cao, CM; Li, G; Yang, ES; Zou, LY, 2005
)
3.21
"Coenzyme Q10 (CoQ10) is an endogenous cofactor in the mitochondrial energy production. "( The impact of coenzyme Q10 on systolic function in patients with chronic heart failure.
Coleman, CI; Kluger, J; Patel, AA; Sander, S; White, CM, 2006
)
2.14
"Coenzyme Q10 (CoQ10) is an effective lipophilic antioxidant and protects against lipid peroxidation by scavenging radicals. "( Decreased coenzyme Q10 concentration in plasma of children with cystic fibrosis.
Houwen, RH; Lecluse, AL; Oudshoorn, JH; Vaes, WH; van den Berg, R; van der Laag, J, 2006
)
2.18
"Coenzyme Q10 (CoQ10) is a powerful antioxidant that buffers the potential adverse consequences of free radicals produced during oxidative phosphorylation in the inner mitochondrial membrane. "( Coenzyme Q10: a review of its promise as a neuroprotectant.
Doraiswamy, PM; Johnson, S; Steffens, DC; Young, AJ, 2007
)
3.23
"Coenzyme Q10 (CoQ10) is a compound with mitochondrial bioenergetic functions."( Suppression of azoxymethane-induced colonic premalignant lesion formation by coenzyme Q10 in rats.
Kitano, M; Sakano, K; Sugimura, T; Takahashi, M; Wakabayashi, K,
)
1.08
"Coenzyme Q10 (CoQ10) is an endogenous cofactor required for mitochondrial energy production and touted to treat heart failure and prevent statin-induced myopathy. "( Electrocardiographic and hemodynamic effects of coenzyme Q10 in healthy individuals: a double-blind, randomized controlled trial.
Cios, D; Kluger, J; Lipeika, J; Sander, S; Shah, SA; White, CM, 2007
)
2.04
"Coenzyme Q10 (CoQ10) is an antioxidant with well-established pharmacological activities against several chronic diseases; however, it is marketed only as a nutritional supplement without any claims of its therapeutic activity and one of the reasons for this could be the poor oral bioavailability rendering difficulties in administering this molecule to achieve therapeutic concentrations. "( Development of potent oral nanoparticulate formulation of coenzyme Q10 for treatment of hypertension: can the simple nutritional supplements be used as first line therapeutic agents for prophylaxis/therapy?
Ankola, DD; Bhardwaj, V; Kumar, MN; Ramarao, P; Viswanad, B, 2007
)
2.03
"Coenzyme Q10 (CoQ10) is a lipid-soluble antioxidant and essential component of the mitochondrial electron transfer system in the body, and is in wide use as a functional food material and cosmetic raw material. "( Comparison of uptake between PureSorb-Q40 and regular hydrophobic coenzyme Q10 in rats and humans after single oral intake.
Kettawan, A; Miyawaki, H; Nukui, K; Okamoto, T; Sato, K; Yamagishi, T, 2007
)
2.02
"Coenzyme Q10 (CoQ10) is a promising agent for neuroprotection in neurodegenerative diseases. "( Therapeutic effects of coenzyme Q10 (CoQ10) and reduced CoQ10 in the MPTP model of Parkinsonism.
Beal, MF; Calingasan, NY; Cleren, C; Lorenzo, B; Schomer, A; Sireci, A; Wille, EJ; Yang, L, 2008
)
2.1
"Coenzyme Q10 (CoQ10) is a pro-vitamin like substance that appears to be efficient for treatment of neurodegenerative disorders and ischemic heart disease."( Coenzyme Q10 protect against ischemia/reperfusion induced biochemical and functional changes in rabbit urinary bladder.
Huang, CH; Hydery, T; Juan, YS; Kogan, B; Leggett, RE; Levin, RM; Lin, WY; Mannikarottu, A; Schuler, C, 2008
)
2.51
"Coenzyme Q10 is an important component of mitochondrial electron transport chain and antioxidant. "( Effects of coenzyme Q10 on the heart ultrastructure and nitric oxide synthase during hyperthyroidism.
Balci, H; Caner, M; Demirci, C; Ergin, B; Kapucu, A; Oztay, F; Ustunova, S, 2007
)
2.17
"Coenzyme Q10 (CoQ10) is a natural mitochondrial respiratory chain constituent with antioxidant properties. "( Studies of hypoxemic/reoxygenation injury: without aortic clamping. VII. Counteraction of oxidant damage by exogenous antioxidants: coenzyme Q10.
Buckberg, GD; Ihnken, K; Morita, K; Young, HH, 1995
)
1.94
"Coenzyme Q10 is an endogenous substance which has a well established role as electron carrier in the mitochondrial synthesis of adenosine triphosphate (ATP). "( [Coenzyme Q10 (ubiquinone) in the treatment of heart failure. Are any positive effects documented?].
Spigset, O, 1994
)
2.64
"Coenzyme Q10 (CoQ10) is a natural and essential cofactor in the heart. "( Myocardial preservation by therapy with coenzyme Q10 during heart surgery.
Folkers, K; Judy, WV; Stogsdill, WW, 1993
)
2
"Coenzyme Q10 (CoQ10) is a naturally occurring vitamin-like substance that may have a beneficial role in ischemia-reperfusion injury. "( Effects of short-term supplementation with coenzyme Q10 on myocardial protection during cardiac operations.
Bennett, G; Hadjinikolas, L; Hooper, J; Hue, D; Jenkins, M; Kemp, M; Taggart, DP, 1996
)
2
"Coenzyme Q10 is an essential cofactor of the electron transport chain and is an antioxidant. "( Coenzyme Q10 in the central nervous system and its potential usefulness in the treatment of neurodegenerative diseases.
Beal, MF; Matthews, RT, 1997
)
3.18
"Coenzyme Q10 (CoQ10) is a critical adjuvant therapy for patients with congestive heart failure (CHF), even when traditional medical therapy is successful. "( Refractory congestive heart failure successfully managed with high dose coenzyme Q10 administration.
Sinatra, ST, 1997
)
1.97
"Coenzyme Q10 is an essential cofactor of the electron transport chain as well as a potent free radical scavenger in lipid and mitochondrial membranes. "( Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects.
Baik, M; Beal, MF; Browne, S; Matthews, RT; Yang, L, 1998
)
3.19
"Coenzyme Q10 (CoQ10) is an essential cofactor of the electron transport chain as well as an important antioxidant. "( Coenzyme Q10 administration and its potential for treatment of neurodegenerative diseases.
Beal, MF, 1999
)
3.19
"Coenzyme Q10 (CoQ10) is an important mitochondrial electron transfer component and has been postulated to function as a powerful antioxidant protecting LDL from oxidative damage. "( Plasma coenzyme Q10 concentrations are not decreased in male patients with coronary atherosclerosis.
Grobbee, DE; Kardinaal, AF; Princen, HM; van de Vijver, LP; van Poppel, G; Weber, C, 1999
)
2.2
"Coenzyme Q10 is an endogenous lipid soluble antioxidant. "( Effects of coenzyme Q10 treatment on antioxidant pathways in normal and streptozotocin-induced diabetic rats.
Rauscher, FM; Sanders, RA; Watkins, JB, 2001
)
2.14
"Coenzyme Q10 (CoQ10) is a component of the antioxidant machinery that protects cell membranes from oxidative damage and decreases apoptosis in leukemic cells cultured in serum-depleted media. "( Coenzyme Q protects cells against serum withdrawal-induced apoptosis by inhibition of ceramide release and caspase-3 activation.
Barroso, MP; Fernández-Ayala, DJ; Gómez-Díaz, C; López-Lluch, G; Martín, SF; Navas, P; Rodríguez-Aguilera, JC; Villalba, JM, 2000
)
1.75
"Coenzyme Q10 (CoQ10) is an antioxidant and plays an important role in the synthesis of adenosine triphosphate. "( The effect of pravastatin and atorvastatin on coenzyme Q10.
Anthony, M; Bleske, BE; Casselberry, N; Datwani, M; Secontine, SG; Shea, MJ; Uhley, VE; Willis, RA, 2001
)
2.01
"Coenzyme Q10 (CoQ10) is an essential cofactor of the electron transport gene as well as an important antioxidant, which is particularly effective within mitochondria. "( Coenzyme Q10 as a possible treatment for neurodegenerative diseases.
Beal, MF, 2002
)
3.2
"Coenzyme Q10 (CoQ10) is an essential component of the mitochondrial membrane and plays an important role in the maintenance of normal cardiac function. "( Effect of coenzyme Q10 on hemodynamic response to ocular timolol.
Inada, M; Iwasaka, T; Kurihara, S; Miki, H; Onoyama, H; Sugiura, T; Takahashi, N; Uyama, M, 1989
)
2.12
"Coenzyme Q10 (CoQ10) is a redox component in the respiratory chain. "( Research on coenzyme Q10 in clinical medicine and in immunomodulation.
Folkers, K; Wolaniuk, A, 1985
)
2.09
"Coenzyme Q10 (CoQ10) is a co-factor of the mitochondrial electron-transfer system. "( 11C-coenzyme Q10: a new myocardial imaging tracer for positron emission tomography.
Ido, T; Ishiwata, K; Kawashima, K; Miura, Y; Monma, M; Takahashi, T; Yanai, K, 1985
)
2.27

Effects

Coenzyme Q10 (CoQ10) has a number of vital functions in all cells, both mitochondrial and extramitochondrial. It has a potential role in the prevention and treatment of heart failure through improved cellular bioenergetics.

Coenzyme Q10 has an important role as an add-on drug treatment for attention deficit hyperactivity disorder by improving symptoms, particularly hyperactivity, and in minimizing atomoxetine adverse effects. It has shown many beneficial effects on abrogating ROS production and ameliorating liver injury.

ExcerptReferenceRelevance
"Coenzyme Q10 has an important role as an add-on drug treatment for attention deficit hyperactivity disorder by improving symptoms, particularly hyperactivity, and in minimizing atomoxetine adverse effects."( Coenzyme Q10 in the Treatment of Attention Deficit Hyperactivity Disorder in Children: A Randomized Controlled Trial.
El Agami, O; Gamal, F; Salamah, A, 2022
)
3.61
"Coenzyme Q10 (CoQ10) has a number of vital functions in all cells, both mitochondrial and extramitochondrial. "( Disorders of Human Coenzyme Q10 Metabolism: An Overview.
Hargreaves, I; Heaton, RA; Mantle, D, 2020
)
2.33
"Coenzyme Q10 (CoQ10) has a potential role in the prevention and treatment of heart failure through improved cellular bioenergetics. "( Low circulating coenzyme Q10 during acute phase is associated with inflammation, malnutrition, and in-hospital mortality in patients admitted to the coronary care unit.
Aikawa, T; Daida, H; Hayashi, H; Hiki, M; Kasai, T; Kato, T; Miyauchi, K; Miyazaki, T; Murata, A; Ouchi, S; Shimada, K; Shimizu, M; Suda, S; Sugita, Y; Takagi, A; Takahashi, S; Yatsu, S, 2017
)
2.24
"Coenzyme Q10 (CoQ10) has a pathophysiologic role in many disease states. "( Role of coenzyme Q10 in chronic heart failure, angina, and hypertension.
Giles, JT; Kennedy, DT; Mitchell, TM; Tran, MT, 2001
)
2.19
"Coenzyme Q10 has an important role as an add-on drug treatment for attention deficit hyperactivity disorder by improving symptoms, particularly hyperactivity, and in minimizing atomoxetine adverse effects."( Coenzyme Q10 in the Treatment of Attention Deficit Hyperactivity Disorder in Children: A Randomized Controlled Trial.
El Agami, O; Gamal, F; Salamah, A, 2022
)
3.61
"Coenzyme Q10 (CoQ10) has effectively treated and prevented various cardiac diseases and toxicities."( Coenzyme Q10 protects against doxorubicin-induced cardiomyopathy via antioxidant and anti-apoptotic pathway.
Arafat, EA; El-Desoky, MM; Mostafa, N; Shabaan, DA, 2023
)
3.07
"Coenzyme Q10 (CoQ10) has shown many beneficial effects on abrogating ROS production and ameliorating liver injury."( CoQ10 alleviates hepatic ischemia reperfusion injury via inhibiting NLRP3 activity and promoting Tregs infiltration.
Chen, C; Duan, J; Gan, X; Gao, J; Gu, A; Zhang, S, 2023
)
1.63
"Coenzyme Q10 (CoQ10) has become a popular nutritional supplement due to its wide range of beneficial biological effects. "( Efficacy and Optimal Dose of Coenzyme Q10 Supplementation on Inflammation-Related Biomarkers: A GRADE-Assessed Systematic Review and Updated Meta-Analysis of Randomized Controlled Trials.
Dai, S; Fan, Z; Hou, S; Ji, Q; Liang, Y; Liu, M; Liu, Z; Tian, Z; Yang, Y; Zhao, D, 2023
)
2.64
"Coenzyme Q10 (CoQ10) has positive impacts on the reproductive system due to its antioxidant properties, protecting the cells from free-radical oxidative damage and apoptosis."( Upregulation of FSHR and PCNA by administration of coenzyme Q10 on cyclophosphamide-induced premature ovarian failure in a mouse model.
Agabalazadeh, A; Bahrami, AM; Banimohammad, M; Delashoub, M; Delkhosh, A; Kalarestaghi, H; Mohaqiq, M; Niazi, V; Shokoohi, M; Shoorei, H; Tehrani, AA, 2019
)
1.49
"Coenzyme Q10 has several disadvantages to be formulated in topical dosage forms, such as low water solubility and large molecular weight."( Coenzyme Q10 nanostructured lipid carriers as an inducer of the skin fibroblast cell and its irritability test in a mice model.
Erawati, T; Shoviantari, F; Soeratri, W, 2019
)
2.68
"Coenzyme Q10 has shown promise in treating male infertility; however, there are inconsistencies across the published data. "( Coenzyme Q10 effect on semen parameters: Profound or meagre?
Alahmar, AT; Gupta, G; Rajender, S; Vishvkarma, R, 2020
)
3.44
"Coenzyme Q10 (CoQ10) has antioxidant effects and is commercially available and marketed extensively. "( The therapeutic efficacy of water-soluble coenzyme Q10 in an experimental model of tacrolimus-induced diabetes mellitus.
Bae, SK; Chung, BH; Chung, SJ; Cui, S; Kim, JH; Ko, EJ; Lim, SW; Luo, K; Quan, Y; Shin, YJ; Yang, CW, 2020
)
2.27
"Coenzyme Q10 (CoQ10) has been reported to reduce sevoflurane anesthesia‑induced cognitive deficiency in 6‑day‑old mice."( Coenzyme Q10 alleviates sevoflurane‑induced neuroinflammation by regulating the levels of apolipoprotein E and phosphorylated tau protein in mouse hippocampal neurons.
Lian, N; Wang, Y; Xie, K; Yang, M; Yu, Y, 2020
)
2.72
"Coenzyme Q10 (CoQ10) has a number of vital functions in all cells, both mitochondrial and extramitochondrial. "( Disorders of Human Coenzyme Q10 Metabolism: An Overview.
Hargreaves, I; Heaton, RA; Mantle, D, 2020
)
2.33
"Coenzyme Q10 (CoQ10) has been widely used in topical and cosmeceutical products due to its cutaneous antioxidant and energizer effects. "( Investigation of ex vivo Skin Penetration of Coenzyme Q10 from Microemulsions and Hydrophilic Cream.
Bosse, K; Mrestani, Y; Neubert, RHH; Tessema, EN; Wohlrab, J, 2020
)
2.26
"Coenzyme Q10 (CoQ10) has been known as ubiquinone or ubidecarenone, which is a kind of lipid-soluble and vitamin-like antioxidant. "( Diabetes, Age, and Duration of Supplementation Subgroup Analysis for the Effect of Coenzyme Q10 on Oxidative Stress: A Systematic Review and Meta-Analysis.
Hajiluian, G; Heshmati, J; Jafari Karegar, S; Sepidarkish, M; Shidfar, F; Shokri, A, 2021
)
2.29
"Coenzyme Q10 (CoQ10) has antioxidant and anti-inflammatory activity. "( Coenzyme Q10 protects skeletal muscle from ischemia-reperfusion through the NF-kappa B pathway.
Anbari, K; Boroujeni, MB; Gharravi, AM; Gholami, M; Khayat, ZK; Niapour, A, 2017
)
3.34
"Coenzyme Q10 (CoQ10) has shown anti-inflammatory effects in some diseases."( Coenzyme Q10 Prevents the Interleukin-1 Beta Induced Inflammatory Response via Inhibition of MAPK Signaling Pathways in Rat Articular Chondrocytes.
Chen, W; Guo, Y; He, M; He, P; Huang, S; Li, X; Liu, M; Liu, Q; Xu, D, 2017
)
2.62
"Coenzyme Q10 (CoQ10) has been used as the additional supplement for pain therapy."( Effect of coenzyme Q10 on mitochondrial respiratory proteins in trigeminal neuralgia.
Apaijai, N; Chattipakorn, N; Chattipakorn, SC; Jaiwongkam, T; Kerdphoo, S; Khuankaew, C; Pongsiriwet, S; Sawaddiruk, P; Tassaneeyakul, W, 2018
)
1.6
"Coenzyme Q10 (CoQ10) has widely been used for the treatment of mitochondrial disorders and neurodegenerative diseases."( Ubisol-Q10 Prevents Glutamate-Induced Cell Death by Blocking Mitochondrial Fragmentation and Permeability Transition Pore Opening.
Huang, X; Kumari, S; Li, H; Li, PA; Mehta, SL; Milledge, GZ, 2016
)
1.16
"Coenzyme Q10 (CoQ10) has a potential role in the prevention and treatment of heart failure through improved cellular bioenergetics. "( Low circulating coenzyme Q10 during acute phase is associated with inflammation, malnutrition, and in-hospital mortality in patients admitted to the coronary care unit.
Aikawa, T; Daida, H; Hayashi, H; Hiki, M; Kasai, T; Kato, T; Miyauchi, K; Miyazaki, T; Murata, A; Ouchi, S; Shimada, K; Shimizu, M; Suda, S; Sugita, Y; Takagi, A; Takahashi, S; Yatsu, S, 2017
)
2.24
"Coenzyme Q10 (CoQ10) has been extensively studied as adjunctive therapy for ischemic heart disease, and its cardioprotective ability is well-established. "( Coenzyme Q9 provides cardioprotection after converting into coenzyme Q10.
Bagchi, D; Bak, I; Das, DK; Das, S; Juhasz, B; Krishnaraju, AV; Lekli, I; Mukherjee, S; Sengupta, K; Tosaki, A; Trimurtulu, G, 2008
)
2.03
"Coenzyme Q10 (CoQ10) has been reported as a powerful antioxidant in plasma."( The advantages of a novel CoQ10 delivery system in skin photo-protection.
Duan, M; Li, Y; Liu, G; Yan, Z; Yue, Y; Zhou, H, 2010
)
1.08
"Coenzyme Q10 and vitamin D have been used to prevent and treat statin myopathy; however, clinical trial evidence demonstrating their efficacy is limited."( Evidence-based management of statin myopathy.
Harper, CR; Jacobson, TA, 2010
)
1.08
"Coenzyme Q10 consumption has been accompanied with a tendency to increasing or an increase of vitamin content, while taurine consumption lead to the reverse effect."( [Effect of coenzyme Q10 and taurine on the availability of vitamins in the rat experiment].
Beketova, NA; Isaeva, VA; Karagodina, ZV; Kodentsova, VM; Kosheleva, OV; Kulakova, SN; Pereverzeva, OG; Sharanova, NÉ; Soto, SKh; Vasil'ev, AV; Vrzhesinskaia, OA, 2010
)
1.47
"Coenzyme Q10 (CoQ10) has been found to be effective in cardiovascular diseases and neurodegenerative diseases. "( Characterization and pharmacokinetics of coenzyme Q10 nanoparticles prepared by a rapid expansion of supercritical solution process.
Jiang, S; Li, Q; Meng, X; Sang, M; Zhao, X; Zu, Y, 2012
)
2.09
"Coenzyme Q10 has emerged as a valuable molecule for pharmaceutical and cosmetic applications. "( The production of coenzyme Q10 in microorganisms.
Cluis, CP; Martin, VJ; Pinel, D, 2012
)
2.16
"Coenzyme Q10 has been recognized as an important antioxidant factor besides its main role in bioenergetic metabolism. "( CoQ10 plasmatic levels in breast-fed infants compared to formula-fed infants.
Compagnoni, G; Giuffrè, B; Lista, G; Marini, A; Mosca, F, 2004
)
1.77
"Coenzyme Q10 (CoQ10) has been suggested to be effective in the prevention of migraine, and levels can be quantified with standardized reference ranges."( Coenzyme Q10 deficiency and response to supplementation in pediatric and adolescent migraine.
Burdine, D; Ellinor, PL; Hershey, AD; Kabbouche, MA; Lecates, SL; Manning, P; Powers, SW; Segers, A; Vockell, AL, 2007
)
3.23
"Coenzyme Q10 depletion has been speculated to play a potential role in statin-related adverse events, and withdrawal of statin is the choice in patients developing myotoxicity or liver toxicity."( Effect of atorvastatin withdrawal on circulating coenzyme Q10 concentration in patients with hypercholesterolemia.
Chen, SH; Chu, CS; Kou, HS; Lai, WT; Lee, CJ; Lee, KT; Sheu, SH; Voon, WC, 2006
)
1.31
"Coenzyme Q10 (CoQ) has been promoted as an effective agent for reducing the deleterious effects of septic shock by acting as an oxygen free radical scavenger and thus stabilizing mitochondrial membranes and by inhibiting the arachidonic acid metabolic pathway and the formation of various prostaglandins. "( Effects of coenzyme Q10 on the mediator cascade of sepsis.
Coran, AG; Drongowski, RA; Gastman, B; Lelli, JL; Remick, DG, 1993
)
2.12
"Coenzyme Q10 has been found to enhance recovery of function after reperfusion in numerous experimental acute ischemia-reperfusion models. "( The effect of coenzyme Q10 on infarct size in a rabbit model of ischemia/reperfusion.
Birnbaum, Y; Hale, SL; Kloner, RA, 1996
)
2.1
"Coenzyme Q10 or ubiquinone has been shown to have both anti-cancer and immune system enhancing properties when tested in animals. "( CoQ10: could it have a role in cancer management?
Hertz, N; Hodges, S; Lister, R; Lockwood, K, 1999
)
1.75
"Coenzyme Q10 (CoQ) has long been utilized as a cardioprotective agent in various heart diseases. "( Dual involvement of coenzyme Q10 in redox signaling and inhibition of death signaling in the rat heart mitochondria.
Das, DK; Hattori, R; Imamura, H; Nakao, Y; Osako, M; Otani, H; Yamamura, T, 2001
)
2.08
"Coenzyme Q10 (CoQ10) has a pathophysiologic role in many disease states. "( Role of coenzyme Q10 in chronic heart failure, angina, and hypertension.
Giles, JT; Kennedy, DT; Mitchell, TM; Tran, MT, 2001
)
2.19
"Coenzyme Q10 has been found to be a promising anti-oxidant agent in sodium nitrite-induced lipid peroxidation."( Effects of oral coenzyme Q10 supplementation on sodium nitrite-induced lipid peroxidation in rats.
Frankiewicz-Jóźko, A; Grudziński, IP, 2001
)
1.38
"Coenzyme Q10 (CoQ10) has the potential to improve the efficiency of energy production in mitochondria by bypassing defective components in the respiratory chain as well as reducing the effects of oxidative stress."( The effects of ageing on the response to cardiac surgery: protective strategies for the ageing myocardium.
Linnane, A; Lyon, W; Marasco, S; Nagley, P; Ou, R; Pepe, S; Rosenfeldt, FL; Rowland, M, 2002
)
1.04
"Coenzyme Q10 (CoQ10) has already been favorably evaluated in the clinical treatment of heart disease. "( Pharmacokinetics of coenzyme Q10 in recovery of acute sensorineural hearing loss due to hypoxia.
Sato, K, 1988
)
2.04

Actions

Coenzyme Q10 (CoQ10) plays a potential role in the prevention and treatment of cardiovascular disease through improved cellular bioenergetics. It is also a potent antioxidant and influencing inflammatory mediators.

ExcerptReferenceRelevance
"Coenzyme Q10 (CoQ10) plays an essential electron carrier role in the mitochondrial electron transfer chain (ETC) as well as being a potent antioxidant and influencing inflammatory mediators. "( COVID-19 and the Assessment of Coenzyme Q10.
Hargreaves, IP; Heaton, RA; Turton, N, 2022
)
2.45
"Coenzyme Q10 (CoQ10) plays a potential role in the prevention and treatment of cardiovascular disease through improved cellular bioenergetics. "( Low coenzyme Q10 levels in patients with acute cardiovascular disease are associated with long-term mortality.
Aikawa, T; Daida, H; Hiki, M; Miyazaki, T; Ouchi, S; Shimada, K; Shimizu, M; Shiozawa, T; Sugita, Y; Takagi, A; Takahashi, S, 2021
)
2.62
"Coenzyme Q10 (Q10) plays an important role in the cellular antioxidant system by protecting the cells from free-radical oxidative damage and apoptosis. "( Protective Effects of Coenzyme Q10 on Developmental Competence of Porcine Early Embryos.
Cui, XS; Liang, S; Niu, YJ; Shin, KT, 2017
)
2.21
"Coenzyme Q10 (CoQ10) plays a critical role in mitochondrial oxidative phosphorylation by serving as an electron carrier in the respiratory electron transport chain. "( Therapeutic Potential of Co-enzyme Q10 in Retinal Diseases.
Marcheggiani, F; Reilly, J; Shu, X; Tiano, L; Tohari, AM; Zhang, X; Zhou, X, 2017
)
1.9
"Coenzyme Q10 (CoQ10) plays an important role in the human respiratory chain and is widely used as medicine and dietary supplement. "( Mutagenesis of Rhodobacter sphaeroides using atmospheric and room temperature plasma treatment for efficient production of coenzyme Q10.
Gao, G; Gong, X; Han, YJ; Li, S; Sun, X; Zhang, C; Zhang, LL; Zou, RS, 2019
)
2.16
"Coenzyme Q10 (CoQ10) plays a key role in the exchange of electrons in lysosomal membrane, which contributes to protons' translocation into the lumen and to the acidification of intra-lysosomal medium, which is essential for the proteolytic function of hydrolases responsible -when deficient- of a wide range of inherited lysosomal diseases such as Sanfilippo syndromes. "( Treatment effect of coenzyme Q(10) and an antioxidant cocktail in fibroblasts of patients with Sanfilippo disease.
Arias, A; Coll, MJ; Garcia-Villoria, J; Gort, L; Matalonga, L; Ribes, A, 2014
)
1.85
"Coenzyme Q10 (CoQ10) plays an indispensable role in ATP generation through oxidative phosphorylation and helps in scavenging superoxides generated during electron transfer reactions. "( Modeling of process parameters for enhanced production of coenzyme Q10 from Rhodotorula glutinis.
Balakumaran, PA; Meenakshisundaram, S, 2015
)
2.1
"Coenzyme Q10 induced an increase of Complex I-linked respiration."( Effect of Simvastatin, Coenzyme Q10, Resveratrol, Acetylcysteine and Acetylcarnitine on Mitochondrial Respiration.
Fišar, Z; Hroudová, J; Kopřivová, A; Macečková, D; Singh, N, 2016
)
1.47
"Coenzyme Q10 (CoQ10) plays an important role in bioenergetic processes and has antioxidant activity. "( Impact of oral ubiquinol on blood oxidative stress and exercise performance.
Bloomer, RJ; Canale, RE; Farney, TM; McCarthy, CG, 2012
)
1.82
"Coenzyme Q10 (CoQ10) plays a pivotal role in oxidative phosphorylation (OXPHOS), as it distributes electrons among the various dehydrogenases and the cytochrome segments of the respiratory chain. "( Prenyldiphosphate synthase, subunit 1 (PDSS1) and OH-benzoate polyprenyltransferase (COQ2) mutations in ubiquinone deficiency and oxidative phosphorylation disorders.
Bacq, D; Chretien, D; Dallner, G; de Lonlay, P; Delahodde, A; Giurgea, I; Mollet, J; Munnich, A; Rötig, A; Schlemmer, D, 2007
)
1.78
"Coenzyme Q10 (CoQ10) plays a pivotal role in oxidative phosphorylation (OXPHOS) as it distributes electrons between the various dehydrogenases and the cytochrome segments of the respiratory chain. "( Infantile and pediatric quinone deficiency diseases.
Mollet, J; Munnich, A; Rio, M; Rötig, A, 2007
)
1.78
"Coenzyme Q10 plays a central role in cellular bioenergy generation and its regulation. "( Coenzyme Q(10)--its role as a prooxidant in the formation of superoxide anion/hydrogen peroxide and the regulation of the metabolome.
Kios, M; Linnane, AW; Vitetta, L, 2007
)
1.78
"Coenzyme Q10 (CoQ10) plays an essential physiologic role in oxidative phosphorylation and its plasma and tissue concentration has been evaluated in various pathologic conditions, both endocrine and non endocrine; among the latter particularly in cardiac failure. "( [Circulating levels of CoQ10 in hypo- and hyperthyroidism].
Ferrari, D; Pandolfi, C; Pellegrini, L; Stanic, I, 1994
)
1.73
"Coenzyme Q10 (CoQ10) plays an important role in oxidative mithocondrial phosphorylation and prevents lipid peroxidation in biological membranes. "( Effect of ubidecarenone oral treatment on aerobic power in middle-aged trained subjects.
Bargossi, AM; Bonetti, A; Carmosino, G; Fiorella, PL; Solito, F, 2000
)
1.75
"Coenzyme Q10 (CoQ10) plays an important role in oxidative mithocondrial phosphorylation and prevents lipid peroxidation in biological membranes. "( Effect of ubidecarenone oral treatment on aerobic power in middle-aged trained subjects.
Bargossi, AM; Bonetti, A; Carmosino, G; Fiorella, PL; Solito, F, 2000
)
1.75

Treatment

Treatment with coenzyme Q10 (50 and 100 mg/kg) for 10 weeks showed significant and dose dependently increased in level of nociceptive threshold, endogenous antioxidant, and Na,K-ATPase enzyme. The treatment demonstrated its potential independent role in positive modification of oxidative stress, antiatherogenic fraction of lipid profile, atherogenic ratio, platelet aggregation.

ExcerptReferenceRelevance
"Coenzyme Q10 treatment is effective for reducing proteinuria and seems to be renoprotective."( Long-term follow-up results of patients with ADCK4 mutations who have been diagnosed in the asymptomatic period: effects of early initiation of CoQ10 supplementation.
Arıcı, M; Atayar, E; Atmaca, M; Bayazıt, AK; Candan, C; Gülhan, B; Özaltın, F; Topaloğlu, R, 2019
)
1.24
"Coenzyme Q10 treatment decreased the blood pressure in rat model with preeclampsia by regulating the circulating levels of sFlt-1 and PlGF. "( Implication of nuclear factor-erythroid 2-like 2/heme oxygenase 1 pathway in the protective effects of coenzyme Q10 against preeclampsia-like in a rat model.
Chen, P; Li, H; Li, L; Lu, Y; Wang, X; Zhao, H; Zhou, Q, 2020
)
2.22
"Coenzyme Q10 treatment of sperm from various species improves sperm quality during cryopreservation and cooled-stored condition."( Possible Protective Mechanisms of Coenzyme Q10 Action on Spermatozoa During Cryopreservation or Cooled-Stored Condition.
Appiah, MO; Asante-Badu, B; Liu, H; Lu, W; Wang, J; Zhao, J,
)
1.13
"Coenzyme Q10 treatment was started immediately."( Response to Early Coenzyme Q10 Supplementation Is not Sustained in CoQ10 Deficiency Caused by CoQ2 Mutation.
Alikaşifoğlu, A; Düzova, A; Eminoğlu, FT; Eroglu, FK; Göçmen, R; Gönç, N; Güçer, Ş; Nalçacıoğlu, H; Orhan, D; Ozaltin, F; Özçakar, ZB; Topaloğlu, R; Yalnızoğlu, D, 2018
)
1.54
"Coenzyme Q10 treatment was administered. "( Long-term outcomes of a patient with late-onset multiple acyl-CoA dehydrogenase deficiency caused by novel mutations in ETFDH: A case report.
Han, YZ; Wang, J; Wu, JC; Yang, RM; Yu, XE, 2018
)
1.92
"(Coenzyme Q10 as adjunctive treatment of chronic heart failure: a randomised, double-blind, multicentre trial with focus on SYMptoms, BIomarker status [Brain-Natriuretic Peptide (BNP)], and long-term Outcome [hospitalisations/mortality]; ISRCTN94506234)."( The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial.
Alehagen, U; Dolliner, P; Filipiak, KJ; Kumar, A; Littarru, GP; Mortensen, SA; Pella, D; Rosenfeldt, F; Steurer, G, 2014
)
1.38
"Coenzyme Q10 treatment (10 mg/kg/day, i.p.) was applied for 6 consecutive days, starting 1 day before cisplatin administration."( Coenzyme Q10 treatment ameliorates acute cisplatin nephrotoxicity in mice.
Al-Sultan, AI; Fouad, AA; Refaie, SM; Yacoubi, MT,
)
2.3
"Coenzyme Q10 treatment (10mg/kg/day, i.p.) was applied for five consecutive days, starting three days before arsenite administration."( Coenzyme Q10 counteracts testicular injury induced by sodium arsenite in rats.
Al-Sultan, AI; Fouad, AA; Yacoubi, MT, 2011
)
2.53
"Coenzyme Q10 treatment was given as two i.p."( Hepatoprotective effect of coenzyme Q10 in rats with acetaminophen toxicity.
Fouad, AA; Jresat, I, 2012
)
1.4
"Coenzyme Q10 treatment (0.4mg/kg/day, i.p.) was applied for four weeks following trichloroacetic acid administration."( Therapeutic effect of coenzyme Q10 against experimentally-induced hepatocellular carcinoma in rats.
Al-Mulhim, AS; Fouad, AA; Jresat, I, 2013
)
1.43
"Coenzyme Q10, used in treatment of heart failure, and carnitine and its derivatives may have beneficial effects on arrhythmias, although clinical studies have been limited."( Vitamins, supplements, herbal medicines, and arrhythmias.
Chung, MK,
)
0.85
"In coenzyme Q10-treated animals, however, there were no changes in the levels of endogenous total coenzyme Q9, alpha-tocopherol, or total glutathione as well as in the level of the enhanced total coenzyme Q10 during the reperfusion period."( Changes in the levels of endogenous coenzyme Q homologs, alpha-tocopherol, and glutathione in rat liver after hepatic ischemia and reperfusion, and the effect of pretreatment with coenzyme Q10.
Dohi, K; Kawasaki, T; Marubayashi, S; Yamada, K, 1984
)
0.97
"Coenzyme Q10 pretreatment maintained the adenosine triphosphate level at 18.9 even after 24 hours of preservation."( Protection by coenzyme Q10 of canine myocardial reperfusion injury after preservation.
Kawasaki, T; Matsushima, T; Matsuura, Y; Sueda, T, 1992
)
1.37
"In coenzyme Q10 treated endotoxin shock rats, superoxide production was significantly decreased, and lipid peroxide production in the liver was also inhibited."( [Superoxide production of polymorphonuclear leukocytes in endotoxin shock and antioxidative effect of coenzyme Q10].
Suzuki, H, 1991
)
1.01
"Coenzyme Q10-treated and control rats were exercised by 90 min of downhill treadmill running."( Protective effect of coenzyme Q10 on exercise-induced muscular injury.
Hanaki, Y; Ozawa, T; Shimomura, Y; Sugiyama, S; Suzuki, M, 1991
)
1.32
"Coenzyme Q10 pretreatment inhibited disturbances in peak airway pressure, total compliance of lung plus chest wall, lung clearance index, plasma histamine, base excess, and lactate; however, it had little effect on the circulation."( Effect of coenzyme Q10 on endotoxin shock in dogs.
Inada, Y; Yasumoto, K, 1986
)
1.39
"Coenzyme Q10 (CoQ10) treatment, orally administered as 100 mg daily dose, was initiated in a series of patients with advanced heart failure in an open, controlled design. "( Long-term coenzyme Q10 therapy: a major advance in the management of resistant myocardial failure.
Baandrup, U; Folkers, K; Mortensen, SA; Vadhanavikit, S, 1985
)
2.11
"Pretreatment with coenzyme Q10 (10 mg/kg/day, oral) and L-Carnitine (350 mg/kg/day, oral) were conducted for 5 consecutive weeks."( CoQ10 and L-carnitine attenuate the effect of high LDL and oxidized LDL on spermatogenesis in male rats.
Garjani, A; Ghanbarzadeh, S; Khorrami, A; Ziaee, M, 2014
)
0.73
"Pretreatment with coenzyme Q10 (CoQ10) was performed to explore the preventive effect of CoQ10 on hypoglycemia-related acute neuropathic pain."( Acute Hypoglycemia Induces Painful Neuropathy and the Treatment of Coenzyme Q10.
Candiotti, KA; Mei, S; Rodriguez, Y; Yang, J; Zhang, YP, 2016
)
0.99
"Co-treatment with coenzyme Q10 induced reduction in muscle necrosis as well as in CK and myoglobin levels."( Elucidation of the mechanism of atorvastatin-induced myopathy in a rat model.
Abdallah, D; El-Ganainy, SO; El-Khatib, AS; El-Mallah, A; Khattab, MM; Mohy El-Din, MM, 2016
)
0.76
"Treatment with coenzyme Q10 or sitagliptin and their co-administration ameliorated STZ-nicotinamide-induced renal damage which was reflected by decreased oxidative stress, TNF-α, TGF-β, MPO activity, nitrite content along with histopathological changes."( Effect of concomitant administration of coenzyme Q10 with sitagliptin on experimentally induced diabetic nephropathy in rats.
Balaraman, R; Maheshwari, R; Sen, AK; Seth, A; Shukla, D, 2017
)
1.06
"Treatment with coenzyme Q10 plus alpha-lipoic acid significantly restored contractile responses to all forms of stimulation."( The beneficial effect of coenzyme Q10 and lipoic acid on obstructive bladder dysfunction in the rabbit.
Chuang, SM; Huang, CH; Hydery, T; Juan, YS; Kogan, B; Levin, RM; Li, S; Mannikarottu, A; Schuler, C, 2008
)
0.99
"Treatment with coenzyme Q10 in subjects with systolic BP (SBP) > 140 mmHg or diastolic BP (DBP) > 90 mmHg resulted in mean decreases in SBP of 11 mmHg (95% CI 8, 14) and DBP of 7 mmHg (95% CI 5, 8)."( Blood pressure lowering efficacy of coenzyme Q10 for primary hypertension.
Bellusci, A; Ho, MJ; Wright, JM, 2009
)
0.97
"Treatment with Coenzyme Q10 (50 and 100 mg/kg) for 10 weeks showed significant and dose dependently increased in level of nociceptive threshold, endogenous antioxidant, and Na,K-ATPase enzyme."( Elucidation of molecular mechanism involved in neuroprotective effect of Coenzyme Q10 in alcohol-induced neuropathic pain.
Bodhankar, SL; Ghosh, P; Ghule, AE; Kandhare, AD, 2013
)
0.96
"The treatment with coenzyme Q10 demonstrated its potential independent role in positive modification of oxidative stress, antiatherogenic fraction of lipid profile, atherogenic ratio, platelet aggregability."( Prevention of coronary atherosclerosis by the use of combination therapy with antioxidant coenzyme Q10 and statins.
Bachutashvili, Z; Chapidze, G; Dolidze, N; Kapanadze, S; Latsabidze, N, 2005
)
0.87
"Pretreatment with coenzyme Q10, the electron transporter in the mitochondrial respiratory chain, remarkably reduced apoptosis as well as the mitochondrial depolarization induced by rotenone, but other free radical scavengers such as N-acetylcysteine, glutathione, and vitamin C did not."( Mitochondrial membrane depolarization and the selective death of dopaminergic neurons by rotenone: protective effect of coenzyme Q10.
Geum, D; Kim, K; Lee, KH; Moon, Y; Park, JH, 2005
)
0.86
"Treatment with coenzyme Q10 strongly inhibited these changes in HUVEC under high glucose condition."( Coenzyme Q10 prevents high glucose-induced oxidative stress in human umbilical vein endothelial cells.
Kimura, I; Kobayashi, S; Okamoto, T; Sasaoka, T; Sekizaki, N; Suzuki, T; Tsuneki, H; Wada, T, 2007
)
2.12
"In untreated group, coenzyme Q10 and vitamin E plasma levels decreased while lactic acid and creatine kinase plasma levels increased during reperfusion."( Protective role in vivo of coenzyme Q10 during reperfusion of ischemic limbs.
Destito, C; Iacocagni, A; Littarru, GP; Marin, AW; Oradei, A; Romagnoli, A, 1994
)
0.9
"Pretreatment with coenzyme Q10 given intraperitoneally improved aortic flow, cardiac output, stroke volume, coronary flow, and heart rate."( Improvement of cardiac function impaired by repeated ischemic arrests in isolated rat hearts.
Ali, K; Fukaya, Y; Furukawa, Y; Morimoto, M, 1993
)
0.61
"Treatment with coenzyme Q10, an essential cofactor of the electron transport chain, resulted in significant decreases in cortical lactate concentrations in 18 patients, which reversed following withdrawal of therapy."( Energy metabolism defects in Huntington's disease and effects of coenzyme Q10.
Beal, MF; Jenkins, BG; Koroshetz, WJ; Rosen, BR, 1997
)
0.87
"Treatment with coenzyme Q10 attenuated the elevation of blood pressure, the membranous phospholipid degradation, and the enhanced phospholipase A2 activity."( Effect of coenzyme Q10 on structural alterations in the renal membrane of stroke-prone spontaneously hypertensive rats.
Kawaguchi, H; Minami, M; Okamoto, H; Saito, H; Togashi, H; Yasuda, H, 1991
)
1.02

Toxicity

This study aimed to investigate the ability of Coenzyme Q10 (Coq10) to avoid these adverse effects. In this study, the efficacy of three antioxidants (melatonin, CoQ10, vinpocetine) on alleviation of toxic effects of CP was evaluated.

ExcerptReferenceRelevance
"This experiment was designed to evaluate whether or not liposomal encapsulated-doxorubicin and combination therapy of free doxorubicin with coenzyme Q10, an antioxidant, mitigate the delayed adverse effects on cardiac muscle mitochondria."( Approaches that mitigate doxorubicin-induced delayed adverse effects on mitochondrial function in rat hearts; liposome-encapsulated doxorubicin or combination therapy with antioxidant.
Hayakawa, M; Ozawa, T; Sugiyama, S; Yamada, K, 1995
)
0.49
" The results show a low incidence of side effects: 38 adverse effects were reported in 36 patients (1."( Italian multicenter study on the safety and efficacy of coenzyme Q10 as adjunctive therapy in heart failure. CoQ10 Drug Surveillance Investigators.
Baggio, E; Carmosino, G; Gandini, R; Passeri, M; Plancher, AC, 1994
)
0.53
"5 years) show a low incidence of side effects: 10 adverse reactions were reported in 8 (0."( Italian multicenter study on the safety and efficacy of coenzyme Q10 as adjunctive therapy in heart failure (interim analysis). The CoQ10 Drug Surveillance Investigators.
Baggio, E; Carmosino, G; Gandini, R; Passeri, M; Plancher, AC, 1993
)
0.53
" No serious adverse events were observed in any group."( Safety assessment of coenzyme Q10 (Kaneka Q10) in healthy subjects: a double-blind, randomized, placebo-controlled trial.
Fujii, K; Fukutomi, N; Harashima, S; Ikematsu, H; Nakamura, K, 2006
)
0.65
" The two compounds displayed similar toxicological profiles, and it was concluded that neither CoQ10 nor its (2Z)-isomer produce toxic effects in rats in single or repeated doses."( Comparative oral toxicity of coenzyme Q10 and its (2Z)-isomer in rats: single and four-week repeated dose toxicity studies.
Hatakeyama, S; Kawase, S; Yoshimura, I, 2006
)
0.63
" Combined treatment with CoQ10 and green tea was more effective in mitigating adverse effect of GM nephrotoxicity."( Modification of biochemical parameters of gentamicin nephrotoxicity by coenzyme Q10 and green tea in rats.
Balaraman, R; Farswan, M; Rathod, S; Upaganlawar, A, 2006
)
0.57
"Fifty consecutive new cardiology clinic patients who were on statin drug therapy (for an average of 28 months) on their initial visit were evaluated for possible adverse statin effects (myalgia, fatigue, dyspnea, memory loss, and peripheral neuropathy)."( Treatment of statin adverse effects with supplemental Coenzyme Q10 and statin drug discontinuation.
Langsjoen, AM; Langsjoen, JO; Langsjoen, PH; Lucas, LA, 2005
)
0.58
" However, for each individual patient, care providers should weigh the cardioprotective effect of dexrazoxane against the possible risk of adverse effects including a lower response rate."( Prevention of anthracycline-induced cardiotoxicity in children: the evidence.
Caron, HN; Kremer, LC; van Dalen, EC, 2007
)
0.34
" These results confirm that P40 is an extremely safe material and it can produce better absorption of CoQ10."( Safety assessment of PureSorb-Q40 in healthy subjects and serum coenzyme Q10 level in excessive dosing.
Matsuoka, Y; Miyawaki, H; Nuku, K; Sato, K; Yamagishi, T, 2007
)
0.58
"Metastatic cancers are associated with cellular oxidative stress, and during cancer chemotherapy excess drug-induced oxidative stress can limit therapeutic effectiveness and cause a number of side effects, including fatigue, nausea, vomiting, diarrhea and more serious adverse effects, such as cardiomyopathy, peripheral neuropathy, hepatotoxicity and pulmonary fibrosis."( Reversing mitochondrial dysfunction, fatigue and the adverse effects of chemotherapy of metastatic disease by molecular replacement therapy.
Conklin, KA; Nicolson, GL, 2008
)
0.35
" No adverse changes in mortality and clinical signs occurred."( Toxicity of coenzyme Q(10): a report of 90-day repeated dose toxicity study in rats.
Jingru, M; Min, J; Mingkai, L; Shuyu, C; Xiaoxing, L; Xue, M; Yumei, W; Zhipeng, W, 2007
)
0.34
" This was followed by the second study, where females were given with doses of 75, 150, 200, or 300 mg/kg/day in order to determine a no observed adverse effect level (NOAEL)."( Subchronic oral toxicity of ubiquinol in rats and dogs.
Fujii, K; Hosoe, K; Kishida, H; Kitahara, M; Kitano, M; Kubo, H; Oda, S; Watanabe, D,
)
0.13
" No significant changes in body weight, food intake, behavior, mortality, hematology, blood biochemistry, vital organ weight, sperm abnormality, mutagenicity and micronucleus formation were observed and no clinical signs or adverse effects were detected by administration of CoQ10."( Acute, subacute toxicity and genotoxic effect of Bio-Quinone Q10 in mice and rats.
Dam, J; Fu, X; Ji, R, 2009
)
0.35
" The published reports concerning safety studies indicate that CoQ10 has low toxicity and does not induce serious adverse effects in humans."( Safety assessment of coenzyme Q10 (CoQ10).
Fujii, K; Fukutomi, N; Funahashi, I; Hidaka, T; Hosoe, K, 2008
)
0.66
" In the rat study, no adverse effects were observed with P40 at doses up to 2,000 mg/kg in both sexes."( Blood CoQ10 levels and safety profile after single-dose or chronic administration of PureSorb-Q40: animal and human studies.
Belardinelli, R; Kettawan, A; Littarru, GP; Miyawaki, H; Nukui, K; Okamoto, T; Sato, K; Tiano, L; Yamagishi, T, 2008
)
0.35
" Amitriptyline toxic systemic effects include cardiovascular, autonomous nervous, and central nervous systems."( Coenzyme Q10 and alpha-tocopherol protect against amitriptyline toxicity.
Cordero, MD; de Miguel, M; Garrido-Maraver, J; Gomez-Skarmeta, JL; Moreno-Fernández, AM; Navas, P; Oropesa-Avila, M; Rodríguez-Hernández, A; Sánchez-Alcázar, JA, 2009
)
1.8
" Monthly evaluations included review of adverse events and CoQ(10) blood levels."( Safety and tolerability of high-dosage coenzyme Q10 in Huntington's disease and healthy subjects.
Beal, MF; Browne, SE; Como, P; Cudkowicz, ME; Daigneault, S; de Blieck, EA; Ferrante, K; Ferrante, RJ; Frank, S; Goldstein, M; Hunt, V; Hyson, HC; Jennings, D; Kelsey, T; Kieburtz, K; McDermott, M; Metakis, LJ; Newhall, K; Ravina, B; Shoulson, I; Walker, F; Watts, A; Weber, J; Zimmerman, C, 2010
)
0.63
" Anthracycline--and nonanthracycline-induced cardiac toxicity--clinically significant and frequent adverse event of conservative treatment of cancer."( [Cardiotoxicity of conservative treatment of solid tumors].
Askol'skiĭ, AV; Kasap, NV; Klimanov, MIu; Lial'kin, SA; Maĭdanevich, NN; Sivak, LA,
)
0.13
" In conclusion, the nanoparticles containing antioxidant actives were safe for topical use and presented anti-aging activity in vivo and are suitable to be used as cosmetic ingredient."( Safety and efficacy of antioxidants-loaded nanoparticles for an anti-aging application.
Bruschi, M; Carvalho, AR; Felippi, CC; Oliveira, D; Raffin, RP; Ströher, A; Van Etten, EA, 2012
)
0.38
"Cyclosporine, a potent immunosuppressant, has nephrotoxic adverse effects that may be mediated by oxidative stress."( Effect of reduced form of coenzyme Q10 on cyclosporine nephrotoxicity.
Homma, Y; Ishikawa, A; Sato, T, 2013
)
0.69
"Statins are potent cholesterol-lowering drugs that can have serious adverse effects on the muscles and liver."( Efficiency of hepatocyte pretreatment with coenzyme Q10 against statin toxicity.
Abdoli, N; Azarmi, Y; Eghbal, MA, 2014
)
0.67
"The anticancer drug; doxorubicin (DOX), causes testicular toxicity as an adverse effect."( Protective mechanisms of coenzyme-Q10 may involve up-regulation of testicular P-glycoprotein in doxorubicin-induced toxicity.
El-Sheikh, AA; Mahmoud, MM; Morsy, MA; Rifaai, RA, 2014
)
0.4
" However, the primary adverse effect limiting their use is myopathy."( Red yeast rice and coenzyme Q10 as safe alternatives to surmount atorvastatin-induced myopathy in hyperlipidemic rats.
Abdelbaset, M; Agha, AM; Mahmoud, SS; Negm, SA; Safar, MM, 2014
)
0.73
" These results revealed that CoQ10 can serve as a useful adjuvant and promote the safe use of MTX in the management of arthritis, not only by potentiating the antiarthritic effect of MTX, but also by alleviating MTX-induced hepatocellular injury."( Combination of coenzyme Q10 with methotrexate suppresses Freund's complete adjuvant-induced synovial inflammation with reduced hepatotoxicity in rats: Effect on oxidative stress and inflammation.
Tawfik, MK, 2015
)
0.77
" Secondary endpoints were change in global fatigue score (GFS; the average of all BFI items), anxiety and depression assessed by the Hospital Anxiety and Depression Scale (HADS), quality of life assessed by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) and EORTC Breast Cancer-Specific QLQ (EORTC QLQ-BR23), and adverse events."( Efficacy and safety of an amino acid jelly containing coenzyme Q10 and L-carnitine in controlling fatigue in breast cancer patients receiving chemotherapy: a multi-institutional, randomized, exploratory trial (JORTC-CAM01).
Ariyoshi, K; Doi, T; Inoue, K; Ishiki, H; Iwase, S; Kawaguchi, T; Kitamura, K; Miyaji, T; Miyara, K; Odagiri, H; Sagara, Y; Tsutsumi, C; Yamaguchi, T; Yotsumoto, D, 2016
)
0.68
" No severe adverse events were observed."( Efficacy and safety of an amino acid jelly containing coenzyme Q10 and L-carnitine in controlling fatigue in breast cancer patients receiving chemotherapy: a multi-institutional, randomized, exploratory trial (JORTC-CAM01).
Ariyoshi, K; Doi, T; Inoue, K; Ishiki, H; Iwase, S; Kawaguchi, T; Kitamura, K; Miyaji, T; Miyara, K; Odagiri, H; Sagara, Y; Tsutsumi, C; Yamaguchi, T; Yotsumoto, D, 2016
)
0.68
" In this study, the efficacy of three antioxidants (melatonin, coenzyme Q10 (CoQ10), and vinpocetine) on alleviation of toxic effects of CP was evaluated."( A mechanistic approach for modulation of chlorpyrifos-induced toxicity in human lymphocytes by melatonin, coenzyme Q10, and vinpocetine.
Abdollahi, M; Baeeri, M; Ghayomi, F; Navaei-Nigjeh, M; Rezvanfar, MA, 2016
)
0.89
"CoQ10 supplementation at doses as high as 1800 mg per day was safe in all subjects and well-tolerated in most."( Coenzyme Q10 dose-escalation study in hemodialysis patients: safety, tolerability, and effect on oxidative stress.
Ahmad, S; Billings, FT; Claessens, AJ; Himmelfarb, J; Ikizler, TA; Linke, L; Roshanravan, B; Shao, B; Shen, DD; Sundell, MB; Yeung, CK, 2015
)
1.86
"Conifer-tree polyprenols in combination with CoQ10 may be generally safe in patients with SIM, but caution should be exercised in patients with glomerular filtration rate <60mL/min and routine monitoring of the liver enzymes and CK is advocated in all patients."( Pilot study of safety and efficacy of polyprenols in combination with coenzyme Q10 in patients with statin-induced myopathy.
Erglis, A; Kletnieks, U; Latkovskis, G; Saripo, V; Sokolova, E; Upite, D; Vanaga, I, 2016
)
0.67
" The current meta-analysis provided evidence that CoQ10 was safe and well tolerated in participants with PD and no superior to placebo in terms of motor symptoms."( The efficacy and safety of coenzyme Q10 in Parkinson's disease: a meta-analysis of randomized controlled trials.
Jin, YM; Sun, MX; Wang, WW; Xie, CL; Zhang, WL; Zhu, ZG, 2017
)
0.75
" More than 100 microcystin analogues have been detected, among which microcystin-LR is the most abundant and toxic variant."( Amelioratory effect of coenzyme Q10 on potential human carcinogen Microcystin-LR induced toxicity in mice.
Bhide, M; Koiri, RK; Lone, Y, 2017
)
0.77
"To investigate the toxic mechanism of hexavalent chromium Cr(VI) and search for an antidote for Cr(VI)-induced cytotoxicity, a study of mitochondrial dysfunction induced by Cr(VI) and cell survival by recovering mitochondrial function was performed."( CoQ10 Deficiency May Indicate Mitochondrial Dysfunction in Cr(VI) Toxicity.
da Silveira E Sá, RC; Liu, K; Xiao, F; Yi, X; Zhang, Y; Zhong, C; Zhong, X, 2017
)
0.46
" The antioxidants in question markedly ameliorated serum interleukin-1β and tumor necrosis factor-α, and brain NO, lipid peroxide, glutathione, and superoxide dismutase levels as well as protein expression of brain-derived neurotrophic factor (BDNF) and P-cyclic-AMP response element-binding protein (CREB) that were altered by a toxic dose of PRA, as well as histopathological alterations, including improvement of the cerebellum architecture."( Neuroprotective efficacy of nano-CoQ against propionic acid toxicity in rats: Role of BDNF and CREB protein expressions.
Alanazi, K; Alesikri, M; Alhusaini, A; Almarshad, S; Almasoud, R; Alrumayyan, B; Hasan, IH, 2020
)
0.56
" Animals received a single toxic dose of CP (7."( Epigallocatechin gallate and coenzyme Q10 attenuate cisplatin-induced hepatotoxicity in rats via targeting mitochondrial stress and apoptosis.
Aljaser, FS; Alrashed, M; Alsharidah, AS; AlSubki, RA; Banu, N; Fatima, S; Suhail, N; Wasi, S, 2021
)
0.91
" Only one RCT reported adverse events, and they found that patients had no adverse effects or symptoms following supplementation."( Efficacy and Safety of Coenzyme Q10 Supplementation in the Treatment of Polycystic Ovary Syndrome: a Systematic Review and Meta-analysis.
Chen, Z; He, Q; Hu, H; Liu, Y; Xiu, H; Zhang, T; Zhang, Z, 2023
)
1.22
" DF toxic effects could be the consequences of mitochondrial dysfunction and free radical effects."( Hepatoprotective Effect of Coenzyme Q10 in Rats with Diclofenac Toxicity.
Abed Al-Kareem, Z; Ali Zghair, M; Aziz, ND, 2022
)
1.02
" This study aimed to investigate the ability of Coenzyme Q10 (Coq10) to avoid these adverse effects."( Coq10 for preventing cardiotoxicity in breast cancer patients treated with trastuzumab.
Al-Hammadi, N; AlSabri, E; Hadi, NR; Kudhair, AH; Qassam, H, 2023
)
1.17

Pharmacokinetics

ExcerptReferenceRelevance
"5 h after administration, and the terminal elimination half-life was 33."( Pharmacokinetic study of deuterium-labelled coenzyme Q10 in man.
Hasegawa, J; Morishita, N; Motegi, K; Seki, T; Tomono, Y, 1986
)
0.53
" In this study, we examined the effects of coenzyme Q10 (CoQ10), one of the most popular dietary supplements, on the pharmacokinetic parameters of theophylline in rats."( The effect of coenzyme Q10 on the pharmacokinetic parameters of theophylline.
Baskaran, R; Choi, HG; Jeong, TC; Kim, JH; Nagayya-Sriraman, S; Shanmugam, S; Yong, CS; Yoo, BK, 2008
)
0.97
" The pharmacokinetic study of each dosage form, in comparison to a CoQ(10) crystal suspension, was also carried out in rats after a single oral dose."( Physicochemical and pharmacokinetic characterization of water-soluble Coenzyme Q(10) formulations.
Hatanaka, J; Kimura, Y; Lai-Fu, Z; Onoue, S; Yamada, S, 2008
)
0.35
"4 mL) and adequate sensitivity was successfully applied to pharmacokinetic studies of CoQ(10) in dogs and an investigation of the effect of CoQ(10) formulation on CoQ(10) baseline levels."( Validated HPLC method for the quantitative determination of CoQ(10) in dog plasma and its application to a pharmacokinetic study.
Lin, L; Liu, C; Pan, C; Wang, L; Xu, H; Xu, P; Yuan, B, 2011
)
0.37
" The estimated elimination half-life (t(1/2)) was 92."( A randomized, double-blind, crossover study on the pharmacokinetics of a novel formulation of CoQ₁₀ with pyridoxal 5'-phosphate and phosphatidyl choline.
Evans, M; Guthrie, N; Sharma, P, 2010
)
0.36
" The CoQ(10)/s-SEDDS was prepared by spray-drying an emulsion preconcentrate containing CoQ(10), medium-chain triglyceride, sucrose ester of fatty acid, and hydroxypropyl cellulose, and its physicochemical, photochemical, and pharmacokinetic properties were evaluated."( Novel solid self-emulsifying drug delivery system of coenzyme Q₁₀ with improved photochemical and pharmacokinetic behaviors.
Hatanaka, J; Kato, M; Kuriyama, K; Miyoshi, H; Nakamura, T; Onoue, S; Seto, Y; Tanaka, T; Uchida, A; Yamada, S, 2012
)
0.38
" From the results of physicochemical and pharmacokinetic studies, the CoQ10 nanoparticles had high solubility in water and possessed less crystalline structure, which can enhance the bioavailability of CoQ10, and provide a water-soluble solid dosage form of CoQ10."( Characterization and pharmacokinetics of coenzyme Q10 nanoparticles prepared by a rapid expansion of supercritical solution process.
Jiang, S; Li, Q; Meng, X; Sang, M; Zhao, X; Zu, Y, 2012
)
0.64
" In vivo evaluation performed by liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) demonstrated that liposomal encapsulation largely prolonged half-lives and improved bioavailability for vectors prepared with either lipid component, and the liposomes composed of both cholesterol and PEG-lipid possessed the best pharmacokinetic properties."( Preparation, in vitro Characterization and Pharmacokinetic Study of Coenzyme Q10 Long-Circulating Liposomes.
Yang, S, 2018
)
0.72
" We have focused on the absorption mechanism of these food components that show low bioavailability, and have made efforts to improve their poor absorption based on their pharmacokinetic properties."( [Study of Formulation Development Based on the Pharmacokinetic Properties of Functional Food Components].
Sato, Y, 2019
)
0.51

Compound-Compound Interactions

The aim of this study was to investigate the effect of resistance training in combination with oral supplementation with coenzyme Q10 in patients with post-polio syndrome.

ExcerptReferenceRelevance
"An open, uncontrolled study was undertaken to measure the subjective effects of coenzyme Q10 combined with a Ginkgo biloba extract in volunteer subjects with clinically diagnosed fibromyalgia syndrome."( An open, pilot study to evaluate the potential benefits of coenzyme Q10 combined with Ginkgo biloba extract in fibromyalgia syndrome.
Lister, RE,
)
0.6
"The aim of this study was to evaluate the serum coenzyme Q10 concentrations of healthy elderly women before and after supplementation with coenzyme Q10 combined with multivitamins, selenium, and magnesium."( Plasma ubiquinone status and response to six-month supplementation combined with multivitamins in healthy elderly women--results of a randomized, double-blind, placebo-controlled study.
Hahn, A; Wolters, M, 2003
)
0.57
"In order to evaluate the effect of coenzyme Q10 (CQ) or combined with carotenoids (lycopene and lutein, LL) or/and mineral nutrients (zinc and selenium, ZS) on the antioxidant defense system, The rats were randomized into 6 groups: control, CQ [CQ 10 mg/(kg x d)], CQ+ ZS[CQ 10 mg/(kg x d), Zn 1 mg/(kg x d), Se 4 microg/(kg x d)], CQ+ LL [CQ 10 mg/(kg x d), Lutein 1 mg/(kg x d), Lycopene 2 mg/(kg x d)], CQ + ZS + LL [CQ 10 mg/(kg x d), Zn 1 mg/(kg x d), Se 4 microg/(kg x d), Lutein 1 mg/(kg x d), Lycopene 2 mg/(kg x d)] and VE [VE 2 mg/(kg x d)], and then fed with a diet based on AIN-76 rodent diet but containing 4% lard as well as 4% corn oil."( [Effects of coenzyme Q10 or combined with micronutrients on antioxidant defense system in rats].
Wang, H; Yin, S; Zhao, X, 2008
)
1
" The aim of this study was to investigate the effect of resistance training in combination with oral supplementation with coenzyme Q10 in patients with post-polio syndrome regarding muscle strength and endurance as well as functional capacity and health-related quality of life."( Effects of resistance training in combination with coenzyme Q10 supplementation in patients with post-polio: a pilot study.
Borg, K; Heiwe, S; Krossén, C; Skough, K; Theorell, H, 2008
)
0.81
" We compared the effects of two statins (rosuvastatin and atorvastatin) combined with exercise on coenzyme Q10 and HDL-C levels in CAD patients."( Rosuvastatin combined with regular exercise preserves coenzyme Q10 levels associated with a significant increase in high-density lipoprotein cholesterol in patients with coronary artery disease.
Iwasaki, Y; Jinnouchi, H; Matsui, K; Ogawa, H; Oka, H; Sugiyama, S; Sumida, H; Tanaka, T; Tayama, S; Toyama, K, 2011
)
0.83
"Compared to atorvastatin, rosuvastatin combined with exercise significantly preserved ubiquinol levels associated with an increase in HDL-C."( Rosuvastatin combined with regular exercise preserves coenzyme Q10 levels associated with a significant increase in high-density lipoprotein cholesterol in patients with coronary artery disease.
Iwasaki, Y; Jinnouchi, H; Matsui, K; Ogawa, H; Oka, H; Sugiyama, S; Sumida, H; Tanaka, T; Tayama, S; Toyama, K, 2011
)
0.62
"To investigate the effects of tamoxifen (TMX) combined with coenzyme Q10 (CoQ10) on idiopathic oligoasthenospermia."( [Tamoxifen combined with coenzyme Q10 for idiopathic oligoasthenospermia].
Liu, RZ; Tang, KF; Wang, XY; Wu, CY; Xing, JP; Xing, Y, 2011
)
0.91
"Tamoxifen combined with CoQ10 can significantly improve sperm concentration, motility and morphology in patients with idiopathic oligoasthenospermia."( [Tamoxifen combined with coenzyme Q10 for idiopathic oligoasthenospermia].
Liu, RZ; Tang, KF; Wang, XY; Wu, CY; Xing, JP; Xing, Y, 2011
)
0.67
"This study was aimed to investigate the therapeutic potential of coenzyme Q10 and its combination with metformin on streptozotocin (STZ)-nicotinamide-induced diabetic nephropathy (DN)."( Effect of coenzyme Q10 alone and its combination with metformin on streptozotocin-nicotinamide-induced diabetic nephropathy in rats.
Balaraman, R; Maheshwari, RA; Sen, AK; Seth, AK,
)
0.77
" We aimed to test the safety and efficacy of plant polyprenols in combination with CoQ10 for alleviation of SIM."( Pilot study of safety and efficacy of polyprenols in combination with coenzyme Q10 in patients with statin-induced myopathy.
Erglis, A; Kletnieks, U; Latkovskis, G; Saripo, V; Sokolova, E; Upite, D; Vanaga, I, 2016
)
0.67
"Conifer-tree polyprenols in combination with CoQ10 may be generally safe in patients with SIM, but caution should be exercised in patients with glomerular filtration rate <60mL/min and routine monitoring of the liver enzymes and CK is advocated in all patients."( Pilot study of safety and efficacy of polyprenols in combination with coenzyme Q10 in patients with statin-induced myopathy.
Erglis, A; Kletnieks, U; Latkovskis, G; Saripo, V; Sokolova, E; Upite, D; Vanaga, I, 2016
)
0.67
"To evaluate the clinical therapeutic effect of L-carnitine (LC) in combination with coenzyme Q10 (CoQ10) on idiopathic oligoasthenozoospermia (iOAT)."( [L-carnitine combined with coenzyme Q10 for idiopathic oligoasthenozoospermia: A double-blind randomized controlled trial].
Cheng, JB; Jiang, H; Ni, F; Zhu, J,
)
0.65
"Using the computer-generated random number sequence, we randomly assigned 262 infertile men with iOAT to four groups to receive oral administration of LC at 10 mL bid (n = 62), CoQ10 (n = 63) at 20 mg tid, LC combined with CoQ10 at the above dose (n = 63), and vitamin B1 as the placebo control (n = 74)."( [L-carnitine combined with coenzyme Q10 for idiopathic oligoasthenozoospermia: A double-blind randomized controlled trial].
Cheng, JB; Jiang, H; Ni, F; Zhu, J,
)
0.43
" This study assessed the potential protective effects of coenzyme Q10 (CoQ10) alone or combined with N-acetyl cysteine (NAC) or atorvastatin against CIN in diabetic rats."( Evaluation of coenzyme Q10 combined with or without N-acetyl cysteine or atorvastatin for preventing contrast-induced kidney injury in diabetic rats.
Alshogran, OY; Alzoubi, KH; El-Elimat, T; Nusair, SD; Obeidat, A; Sweidan, M, 2021
)
1.23
" Following the intraperitoneal (IP) administration of AFB1 at dose of 2 mg/kg, minocycline (45 and 90 mg/kg, IP) and dexamethasone (5 and 20 mg/kg, IP) were administered alone and combined with NAC (200 mg/kg, IP) and vitamin E (600 mg/kg, IP)."( The effects of dexamethasone and minocycline alone and combined with N-acetylcysteine and vitamin E on serum matrix metalloproteinase-9 and coenzyme Q10 levels in aflatoxin B1 administered rats.
Bahcivan, E; Dik, B; Eser Faki, H; Ozdemir Kutahya, Z; Tras, B; Uney, K, 2022
)
0.92

Bioavailability

The relative bioavailability of coenzyme Q10 (CoQ10) is markedly influenced by its delivery systems. Supercritical fluid technology was successfully used for the preparation and analysis of CoQ10-SD for the first time.

ExcerptReferenceRelevance
" The bioavailability of CoQ10 from the lipid microsphere formulation was superior to conventional formulations."( Intestinal absorption enhancement of coenzyme Q10 with a lipid microsphere.
Akimoto, M; Hayashi, H; Koyama, I; Mizushima, Y; Murayama, H; Ozawa, Y; Yamagata, Y, 1986
)
0.54
"The bioavailability of four different Coenzyme Q10 (CoQ) formulations was compared in ten healthy volunteers in a four-way randomised cross-over trial."( Bioavailability of four oral coenzyme Q10 formulations in healthy volunteers.
Mortensen, SA; Møller-Sonnergaard, J; Poulsen, G; Rasmussen, SN; Rassing, MR; Weis, M, 1994
)
0.85
" Bioavailability of both the granular and the oil-based Q10 preparation was similar during the long-term supplementation, but one dose of 30 mg had only a marginal effect on the plasma levels of Q10."( Effect of oral coenzyme Q10 supplementation on the oxidation resistance of human VLDL+LDL fraction: absorption and antioxidative properties of oil and granule-based preparations.
Hayn, M; Kaikkonen, J; Metsä-Ketelä, T; Nyyssönen, K; Porkkala-Sarataho, E; Poulsen, HE; Salonen, JT; Salonen, R, 1997
)
0.65
" However, dosing, clinical application, bioavailability and dissolution of CoQ10 deserve careful scrutiny whenever employing the nutrient."( Refractory congestive heart failure successfully managed with high dose coenzyme Q10 administration.
Sinatra, ST, 1997
)
0.53
"The relative bioavailability of typical commercially available forms of coenzyme Q10 (CoQ10) was compared with that of Q-Gel, a new solubilized form of CoQ10, in human subjects in two separate trials."( Relative bioavailability of coenzyme Q10 formulations in human subjects.
Bhagavan, HN; Chopra, RK; Goldman, R; Sinatra, ST, 1998
)
0.83
" We further found that oral CoQ10 was well absorbed in parkinsonian patients and caused a trend toward increased complex I activity."( A possible role of coenzyme Q10 in the etiology and treatment of Parkinson's disease.
Beal, MF; Haas, RH; Shults, CW, 1999
)
0.63
"The goals of our investigations are to develop and characterize self-emulsifying drug delivery systems (SEDDS) of coenzyme Q10 (CoQ10), using polyglycolyzed glycerides (PGG) as emulsifiers and to evaluate their bioavailability in dogs."( Self-emulsifying drug delivery systems (SEDDS) of coenzyme Q10: formulation development and bioavailability assessment.
Gurley, B; Khan, MA; Kommuru, TR; Reddy, IK, 2001
)
0.77
"Studies of the therapeutic efficacy of coenzyme Q10 (CoQ10) have been confounded by the variable bioavailability of numerous CoQ10 preparations."( Similar therapeutic serum levels attained with emulsified and oil-based preparations of coenzyme Q10.
Lyon, W; Marasco, S; Pepe, S; Rosenfeldt, FL; Van den Brink, O; Wowk, M, 2001
)
0.8
"The purpose of this investigation was to compare the bioavailability of three coenzyme Q10 (CoQ10) formulations in dogs using an open, randomized, multiple-dose crossover design."( Bioavailability assessment of oral coenzyme Q10 formulations in dogs.
Bhagavan, H; Chopra, R; Gurley, B; Khan, M; Reddy, I; Zaghloul, AA, 2002
)
0.82
" Daily supplementation of CoQ10 could protect against heart disease but the bioavailability of CoQ10 supplements depends on the formulation taken."( Relative bioavailability and antioxidant potential of two coenzyme q10 preparations.
Bassoo, E; Deutsch, L; Dresser, G; Freeman, DJ; Kurowska, EM, 2003
)
0.56
" Consistent laboratory monitoring of patients treated with this compound would help ease interpretation of the results of the treatment, especially because so many formulations of Q10 exist in the marketplace, each with its own bioavailability characteristics."( Clinical laboratory monitoring of coenzyme Q10 use in neurologic and muscular diseases.
DeGrauw, AJ; Miles, MV; Steele, PE; Tang, PH, 2004
)
0.6
" Moreover, the poor bioavailability in those peripheral tissues tested may not reflect the effects the agents are having in liver and muscle, the tissues commonly affected in those patients who do not tolerate statins."( The effect of HMG-CoA reductase inhibitors on coenzyme Q10: possible biochemical/clinical implications.
Duncan, AJ; Hargreaves, IP; Heales, SJ; Land, JM, 2005
)
0.59
" We investigated the bioavailability of DSM Nutritional Products Ltd."( A new Coenzyme Q10 tablet-grade formulation (all-Q) is bioequivalent to Q-Gel and both have better bioavailability properties than Q-SorB.
Leuenberger, B; Metzner, J; Perkins, J; Schulz, C; Ullmann, U, 2005
)
0.81
" Thus, this study demonstrates the utility of coupled in vitro digestion-Caco-2 cell model as a cost-effective screening tool that will provide useful information for the optimal design of human trials to assess the bioavailability of CoQ10 and also other bioactive compounds."( Assessment of coenzyme Q10 absorption using an in vitro digestion-Caco-2 cell model.
Bhagavan, HN; Chitchumroonchokchai, C; Chopra, RK; Craft, NE; Failla, ML, 2007
)
0.7
"The relative bioavailability of coenzyme Q10 (CoQ10) is markedly influenced by its delivery systems."( Comparison of the relative bioavailability of different coenzyme Q10 formulations with a novel solubilizate (Solu Q10).
Bernhardt, J; Biesalski, HK; Hasselwander, O; Obermüller-Jevic, UC; Schulz, C,
)
0.66
"Coenzyme Q10 (CoQ10) is an antioxidant with well-established pharmacological activities against several chronic diseases; however, it is marketed only as a nutritional supplement without any claims of its therapeutic activity and one of the reasons for this could be the poor oral bioavailability rendering difficulties in administering this molecule to achieve therapeutic concentrations."( Development of potent oral nanoparticulate formulation of coenzyme Q10 for treatment of hypertension: can the simple nutritional supplements be used as first line therapeutic agents for prophylaxis/therapy?
Ankola, DD; Bhardwaj, V; Kumar, MN; Ramarao, P; Viswanad, B, 2007
)
2.03
" Solubilized formulations of CoQ10 (both ubiquinone and ubiquinol) have superior bioavailability as evidenced by their enhanced plasma CoQ10 responses."( Plasma coenzyme Q10 response to oral ingestion of coenzyme Q10 formulations.
Bhagavan, HN; Chopra, RK, 2007
)
0.79
"PureSorb-Q40 (water-soluble type CoQ10 powder, CoQ10 content is 40 w/w%; hereinafter referred to as P40) is reported in the single-dose human and rat studies to have a greater absorption rate and absorbed volume of CoQ10 even taken postprandially, than those of regular CoQ10, which is lipid-soluble and generally taken in the form of soft-gel capsules."( Safety assessment of PureSorb-Q40 in healthy subjects and serum coenzyme Q10 level in excessive dosing.
Matsuoka, Y; Miyawaki, H; Nuku, K; Sato, K; Yamagishi, T, 2007
)
0.58
" Glyoxal-modified LDL aggregate in the incubation medium with a significantly higher rate than LDL modified by MDA, and MDA-modified LDL are markedly more poorly absorbed by cultured human macrophages and significantly more slowly eliminated from the rat bloodstream upon intravenous injection."( Mechanisms of oxidative modification of low density lipoproteins under conditions of oxidative and carbonyl stress.
Belenkov, YN; Kapel'ko, VI; Konovalova, GG; Lankin, VZ; Panasenko, OM; Shepel'kova, GS; Shumaev, KB; Tikhaze, AK, 2007
)
0.34
" The bioavailability of CoQ(10) increased fivefold after administration of the NanoSolve formulation, and the bioavailability of vitamin E was enhanced 10-fold both compared to the pure substances."( Increase of bioavailability of coenzyme Q(10) and vitamin E.
Schaffer, T; Wajda, R; Zirkel, J, 2007
)
0.34
"The bioavailability of a novel water-soluble inclusion complex of CoQ10, prepared in our laboratory was determined and compared with the bioavailability of commercially available oil-based form of CoQ10."( Bioavailability of water-soluble CoQ10 in beagle dogs.
Butinar, J; Fir, MM; Krizman, M; Lukanc, B; Milivojevic, L; Prosek, M; Smidovnik, A, 2008
)
0.35
" Due to its insolubility in water, the enrichment of most food products is not easily achievable and its in vivo bioavailability is known to be poor."( Relative bioavailability of two forms of a novel water-soluble coenzyme Q10.
Fir, M; Pravst, I; Prosek, M; Smidovnik, A; Walczak, J; Zmitek, J; Zmitek, K, 2008
)
0.59
"The study revealed that the absorption and bioavailability of CoQ10 in the novel formulations are significantly increased, probably due to the enhanced water solubility."( Relative bioavailability of two forms of a novel water-soluble coenzyme Q10.
Fir, M; Pravst, I; Prosek, M; Smidovnik, A; Walczak, J; Zmitek, J; Zmitek, K, 2008
)
0.59
" However, CoQ(10) was found to be poorly soluble in water, so that its bioavailability was low and variable depending on food intake."( Physicochemical and pharmacokinetic characterization of water-soluble Coenzyme Q(10) formulations.
Hatanaka, J; Kimura, Y; Lai-Fu, Z; Onoue, S; Yamada, S, 2008
)
0.35
" Additionally, analysis of CoQ10 bioavailability or its pharmacokinetics provides the pertinent safety evaluation for CoQ10."( Safety assessment of coenzyme Q10 (CoQ10).
Fujii, K; Fukutomi, N; Funahashi, I; Hidaka, T; Hosoe, K, 2008
)
0.66
" Solubilized coenzyme Q10 exhibited high absorption creating higher plasma concentrations of the drug, as a result of which its bioavailability constituted 264% of that for the powder."( Pharmacokinetics of coenzyme q10.
Gorodetskaya, EA; Kalenikova, EI; Medvedev, OS, 2008
)
1.04
"This study aimed to evaluate the bioavailability of two pharmaceutical products of ubidecarenone (coenzyme Q10, CoQ10)."( Comparison of bioavailability of two ubidecarenone products in healthy Korean volunteers.
Choi, JW; Chun, IK; Gwak, HS; Kang, EY, 2009
)
0.57
" In conclusion, it was found that bioavailability of CoQ10 was significantly different depending on the formulations, and dissolution could be one of the important factors affecting CoQ10 absorption."( Comparison of bioavailability of two ubidecarenone products in healthy Korean volunteers.
Choi, JW; Chun, IK; Gwak, HS; Kang, EY, 2009
)
0.35
" The relative bioavailability of CoQ10 has been shown in National Institutes of Health-funded clinical trials to be increased by its delivery system."( Relative bioavailability comparison of different coenzyme Q10 formulations with a novel delivery system.
Artmann, C; Liu, ZX,
)
0.39
"To enhance the solubility and bioavailability of poorly water-soluble Coenzyme Q(10) (CoQ(10)), self-emulsifying drug delivery system (SEDDS) composed of oil, surfactant and cosurfactant for oral administration of CoQ(10) was formulated."( Enhanced oral bioavailability of Coenzyme Q10 by self-emulsifying drug delivery systems.
Balakrishnan, P; Choi, HG; Jee, JP; Kim, DD; Kim, JO; Lee, BJ; Lee, YB; Lee, YI; Oh, DH; Woo, JS; Yong, CS, 2009
)
0.63
" MitoQ(10) treatment significantly improved thoracic aorta NO bioavailability (1."( Mitochondria-targeted antioxidant MitoQ10 improves endothelial function and attenuates cardiac hypertrophy.
Beattie, E; Cochemé, HM; Dominiczak, AF; Graham, D; Hamilton, CA; Huynh, NN; Murphy, MP; Smith, RA, 2009
)
0.35
" The bioavailability of CoQ(10) following its oral administration might be improved with nanoliposomes as the delivery system."( Nanoliposomes mediate coenzyme Q10 transport and accumulation across human intestinal Caco-2 cell monolayer.
Wang, Z; Xia, S; Xu, S; Zhang, X; Zhong, F, 2009
)
0.67
" The present investigation is geared towards reduction of the dose required/improve the bioavailability of the combination of antioxidants, ellagic acid and coenzyme Q10 by co-encapsulating them into nanoparticles and study the possible synergism in ameliorating hyperlipidemia in high fat diet fed rats."( The co-encapsulated antioxidant nanoparticles of ellagic acid and coenzyme Q10 ameliorates hyperlipidemia in high fat diet fed rats.
Chandraiah, G; Kumar, MN; Meena, AK; Ramarao, P; Ratnam, DV, 2009
)
0.79
"Coenzyme Q(10) (CoQ(10)) was formulated into self-nanoemulsifying drug delivery systems (SNEDDS) to overcome low bioavailability attributed to hydrophobic nature of the drug."( Preparation and in vitro-in vivo evaluation of Witepsol H35 based self-nanoemulsifying drug delivery systems (SNEDDS) of coenzyme Q(10).
Choi, HK; Han, HK; Nepal, PR, 2010
)
0.36
" In conclusion, emulsification of CoQ(10) using gum arabic increased bioavailability in both rats and humans and improved suitability for food processing."( Emulsification of coenzyme Q10 using gum arabic increases bioavailability in rats and human and improves food-processing suitability.
Morishita, K; Muromachi, A; Okamoto, T; Ozaki, A; Sakai, Y; Sumi, M, 2010
)
0.69
" However, the bioavailability of topical CoQ10 is poor; the development of a practical topical formulation is therefore highly desirable."( Preparation and characterization of liposomal coenzyme Q10 for in vivo topical application.
Lee, WC; Tsai, TH, 2010
)
0.62
" Complementary administration of antioxidants with high bioavailability should be considered if oxidative stress is present."( Treatment of CoQ(10) deficient fibroblasts with ubiquinone, CoQ analogs, and vitamin C: time- and compound-dependent effects.
Area, E; Dimauro, S; Hirano, M; López, LC; Naini, A; Quinzii, CM; Rahman, S; Salviati, L; Schuelke, M, 2010
)
0.36
" Several advancements have been made to enhance the bioavailability of CoQ10 using various approaches like size reduction, solubility enhancement (by solid dispersion, prodrug, complexation, ionization) and use of novel drug carriers such as liposomes, microspheres, nanoparticles, nanoemulsions and self-emulsifying system."( Bioavailability enhancement of coenzyme Q10: an extensive review of patents.
Beg, S; Javed, S; Kohli, K, 2010
)
0.65
" CoQ10-NPs showed improved oral bioavailability (4."( Oral bioavailability, therapeutic efficacy and reactive oxygen species scavenging properties of coenzyme Q10-loaded polymeric nanoparticles.
Das, M; Godugu, C; Jain, AK; Jain, S; Singh, RP; Swarnakar, NK, 2011
)
0.59
" This study compared the relative bioavailability of CoQ₁₀ solubilized in low-dose soybean phytosterols (SterolQ₁₀) with a generic CoQ₁₀ solubilizate."( Pharmacokinetic comparison of a generic coenzyme Q₁₀ solubilizate and a formulation with soybean phytosterols.
Florkowski, CM; Frampton, CM; George, PM; Molyneux, SL; Scott, RS; Young, JM, 2012
)
0.38
" EV olive oil enriched with both doses of CoQ(10) significantly affects its bioavailability and plasma redox status."( Olive oil supplemented with Coenzyme Q(10): effect on plasma and lipoprotein oxidative status.
Bacchetti, T; Brugè, F; Littarru, GP; Principi, F; Scarpa, ES; Tiano, L,
)
0.13
" However, the extremely poor solubility of CoQ10 in water is hampering its bioavailability as a therapeutic agent."( Characterization and pharmacokinetics of coenzyme Q10 nanoparticles prepared by a rapid expansion of supercritical solution process.
Jiang, S; Li, Q; Meng, X; Sang, M; Zhao, X; Zu, Y, 2012
)
0.64
" To improve the bioavailability of CoQ(10), we have proposed to formulate a nanoemulsion consisting of salmon oil, salmon lecithin, CoQ(10) and water."( Formulation, characterization and pharmacokinetic studies of coenzyme Q₁₀ PUFA's nanoemulsions.
Arab-Tehrany, E; Belhaj, N; Denis, FM; Dupuis, F; Lartaud, I; Linder, M; Paris, C, 2012
)
0.38
" The effects of particle size on their solubility, dissolution, and oral bioavailability were investigated."( Effect of particle size on solubility, dissolution rate, and oral bioavailability: evaluation using coenzyme Q₁₀ as naked nanocrystals.
Deng, Y; She, Z; Sui, Y; Sun, J; Wang, C; Wang, F; Zhai, W, 2012
)
0.38
" A deficiency in either its bioavailability or its biosynthesis can lead to one of several disease states."( Primary and secondary coenzyme Q10 deficiency: the role of therapeutic supplementation.
Pepper, MS; Potgieter, M; Pretorius, E, 2013
)
0.7
" Q10 NLC) was more effective than the Ubidecarenone (Coenzyme Q10) solution form on DPPH scavenging, anti-lipid peroxidation, lowers the effect of amnesia induced by scopolamine and increased bioavailability observed in Cmax, Tmax, and AUC."( Formulation and characterization of nanostructured lipid carrier of ubiquinone (Coenzyme Q10).
Kadam, VT; Manvi, FV; Nanjwade, BK, 2013
)
0.87
" In an oral bioavailability study, the CoQ10 plasma level after administering CoQ10-LNCs was higher than that after administering a CoQ10 tablet over 24 hours, and the relative bioavailability of CoQ10 was improved to 176."( Improvement of the oral bioavailability of coenzyme Q10 with lecithin nanocapsules.
Duan, M; Liu, G; Long, Y; Xia, Q; Zhang, J; Zhou, H, 2013
)
0.65
" However, the oral bioavailability of CoQ10 is poor due to its extremely low solubility in aqueous media."( Enhanced water dispersibility of coenzyme Q10 by complexation with albumin hydrolysate.
Baba, Y; Matsushita, N; Oshima, T; Takahashi, H, 2013
)
0.67
"Nanostructured lipid carriers (NLC) represent an emerging tool for drug delivery and are characterized by important features which promote increased bioavailability and epithelial penetration of lipophilic compounds."( Nanostructured lipid carriers loaded with CoQ10: effect on human dermal fibroblasts under normal and UVA-mediated oxidative conditions.
Armeni, T; Brugè, F; Damiani, E; Littarru, GP; Offerta, A; Puglia, C; Tiano, L, 2013
)
0.39
" Despite this remarkable observation, there exist no data on the bioavailability and pharmacological benefits of tea anthocyanins (ACNs) in the brain tissue."( Kenyan purple tea anthocyanins ability to cross the blood brain barrier and reinforce brain antioxidant capacity in mice.
Isaac, AO; Murilla, G; Nyabuga, JN; Rashid, K; Wachira, FN; Wanyonyi, B, 2014
)
0.4
" Treatment is however still problematic given the poor bioavailability of CoQ10."( Effect of vanillic acid on COQ6 mutants identified in patients with coenzyme Q10 deficiency.
Airik, R; Bergdoll, M; Doimo, M; Hildebrandt, F; Navas, P; Pierrel, F; Salviati, L; Santos-Ocaña, C; Trevisson, E, 2014
)
0.64
" This paper presents a review of the most recent studies on the complexes formed between several important types of antioxidant compounds and cyclodextrins, focusing on the contradictory data reported in the literature concerning to the antioxidant activity of the host/guest molecule complexes, the different complexation constants reported for identical complexes, the bioavailability of the antioxidant compound in the presence of cyclodextrins and recommendation concerning the use of natural or modified cyclodextrins."( Cyclodextrins and antioxidants.
García-Carmona, F; López-Nicolás, JM; Rodríguez-Bonilla, P, 2014
)
0.4
" We previously reported that the bioavailability of CoQ10 powder was less than 10%."( Emulsification using highly hydrophilic surfactants improves the absorption of orally administered coenzyme Q10.
Iseki, K; Mutoh, H; Sato, Y; Sugawara, M; Suzuki, M; Takekuma, Y, 2013
)
0.61
" In all variants of the study, Q10 stimulated eNOS expression and increases NO bioavailability by reducing the levels of total cholesterol and LDL and increasing HDL content in blood serum."( Effects of endogenous regulators of endothelial NO synthase on nitric oxide homeostasis and blood serum lipoproteins during experimental diabetes mellitus.
Dzugkoev, SG; Dzugkoeva, FS; Metel'skaya, VA, 2013
)
0.39
" Oral bioavailability and hepatoprotective effects of orally dosed CoQ10 samples were also evaluated in rats."( Biopharmaceutical characterization of nanocrystalline solid dispersion of coenzyme Q10 prepared with cold wet-milling system.
Hashimoto, N; Nakamura, T; Onoue, S; Terasawa, N; Yamada, S; Yuminoki, K, 2014
)
0.63
"2μm) and oil digestibility (corn oil versus mineral oil) on the bioavailability of a model long chain fatty acid (heptadecanoic acid) and lipophilic nutraceutical (Coenzyme Q10) was investigated using a rat feeding study."( Droplet size and composition of nutraceutical nanoemulsions influences bioavailability of long chain fatty acids and Coenzyme Q10.
Cho, HT; Kim, J; McClements, DJ; Park, Y; Salvia-Trujillo, L; Xiao, H, 2014
)
0.81
"67-fold increase in oral bioavailability was observed in the case of GLCQ and PLCQ, respectively."( Lyotropic liquid crystalline nanoparticles of CoQ10: implication of lipase digestibility on oral bioavailability, in vivo antioxidant activity, and in vitro-in vivo relationships.
Jain, S; Swarnakar, NK; Thanki, K, 2014
)
0.4
"To improve the bioavailability of orally administered lipophilic coenzyme Q10 (CoQ10), we formulated a novel lipid-free nano-CoQ10 system stabilized by various surfactants."( Novel lipid-free nanoformulation for improving oral bioavailability of coenzyme Q10.
Duan, M; Liu, G; Sun, N; Xia, Q; Yan, Z; Zhang, J; Zhou, H, 2014
)
0.87
" This water-soluble formulation of coenzyme Q 10 shows better bioavailability than the native form and has been found to have a protective effect on outer hair cells after exposure to noise in animal models."( Activity of coenzyme Q 10 (Q-Ter multicomposite) on recovery time in noise-induced hearing loss.
Bellussi, L; Cambi, J; Mezzedimi, C; Passali, D; Staffa, P,
)
0.13
"This study aimed to design the chitosan coated TPGS liposome to enhance the bioavailability of Coenzyme Q10 (CoQ10)."( TPGS-chitosome as an effective oral delivery system for improving the bioavailability of Coenzyme Q10.
Han, HK; Shao, Y; Yang, L, 2015
)
0.86
" However, CoQ10 has low oral bioavailability due to its lipophilic nature, large molecular weight, regional differences in its gastrointestinal permeability and involvement of multitransporters."( Strategies for oral delivery and mitochondrial targeting of CoQ10.
Zaki, NM, 2016
)
0.43
" We found a decrease in the bioavailability of nitric oxide due to the increase in the content of oxidized low density lipids, total cholesterol and cholesterol-lowering lipids high density."( [The changes in the biochemical indices of blood in cobalt intoxication on the background of the regulators of the expression of endothelial NO-synthase].
Dzugkoev, SG; Dzugkoeva, FS; Gigolaeva, LB; Margieva, OI; Mozhayeva, IV; Tedtoeva, AI,
)
0.13
" Especially the bioavailability of natural compounds in complex mixtures, where the different ingredients may interfere with each other, is unknown."( Bioavailabilty of a liquid Vitamin Trace Element Composition in healthy volunteers.
Endler, T; Mosgoeller, W; Muss, C, 2015
)
0.42
"To learn more about the bioavailability of the ingredients in the complex compound LaVita® we examined blood levels of subjects, who ingested the multivitamin and trace element composition for 6 month continuously."( Bioavailabilty of a liquid Vitamin Trace Element Composition in healthy volunteers.
Endler, T; Mosgoeller, W; Muss, C, 2015
)
0.42
" The formulation was evaluated using dissolution study and in-vivo oral bioavailability using rat model."( Preparation, in-vitro and in-vivo characterisation of CoQ10 microparticles: electrospraying-enhanced bioavailability.
Fung, WY; Liong, MT; Yuen, KH, 2016
)
0.43
"Based on the findings in this study, electrospraying is a highly prospective technology to produce functional nano- and micro-structures as delivery vehicles for drugs with poor oral bioavailability due to rate-limiting solubility."( Preparation, in-vitro and in-vivo characterisation of CoQ10 microparticles: electrospraying-enhanced bioavailability.
Fung, WY; Liong, MT; Yuen, KH, 2016
)
0.43
" We also examined an approach to improve intestinal absorption of a poorly absorbed water-insoluble component, coenzyme Q10 (CoQ10), by this mechanism."( An Approach to Improve Intestinal Absorption of Poorly Absorbed Water-Insoluble Components via Niemann-Pick C1-Like 1.
Imai, M; Iseki, K; Noto, K; Sato, Y; Sugawara, M; Sumi, M; Takekawa, Y; Takekuma, Y; Yamaki, Y, 2016
)
0.65
" Bioavailability in normal rats was additionally assessed in various tissues and subcellular fractions after short-term and long-term coenzyme Q10 supplementation."( An Improvement of Oxidative Stress in Diabetic Rats by Ubiquinone-10 and Ubiquinol-10 and Bioavailability after Short- and Long-Term Coenzyme Q10 Supplementation.
Kettawan, A; Okamoto, T; Okuno, M; Posuwan, J; Prangthip, P, 2016
)
0.84
"Conduct a preliminary comparison of the bioavailability between two formulations: commercial grade coenzyme Q10 (CoQ10) powder (solid formulation) and a new oil-in-water liquid emulsion and their effect on other antioxidants."( Relative bioavailability of coenzyme Q10 formulation for paediatric individualized therapy.
Buontempo, F; Höcht, C; Lucangioli, S; Martinefski, M; Samassa, P; Tripodi, V, 2017
)
0.97
"The differences in the pharmacokinetic parameters of maximum plasma concentration, area under the curve between 0-360 and 0-4 h, elimination half-life were statistically significant with a relative bioavailability of 489% increase over solid CoQ10 formulation."( Relative bioavailability of coenzyme Q10 formulation for paediatric individualized therapy.
Buontempo, F; Höcht, C; Lucangioli, S; Martinefski, M; Samassa, P; Tripodi, V, 2017
)
0.75
"The results obtained showed that liquid emulsion improves the bioavailability of CoQ10 respect to solid form which not only facilitates the individualized administration for the child but in turn could increase the therapeutic efficacy, which should be confirmed by further studies."( Relative bioavailability of coenzyme Q10 formulation for paediatric individualized therapy.
Buontempo, F; Höcht, C; Lucangioli, S; Martinefski, M; Samassa, P; Tripodi, V, 2017
)
0.75
"Coenzyme Q10 (CoQ10) solid dispersion was prepared to improve its oral bioavailability due to the poor solubility of CoQ10."( An improvement of separation and response applying post-column compensation and one-step acetone protein precipitation for the determination of coenzyme Q10 in rat plasma by SFC-MS/MS.
Li, Y; Liu, C; Xu, Y; Yang, R; Zhang, T; Zhao, L, 2016
)
2.08
" SNEDDS formulation components were rationally selected and optimized for maximum drug loading by applying the design of experiments and further evaluated for stability in simulated gastrointestinal fluids, functional stability of antioxidants, in vitro release, Caco-2 cell uptake, oral bioavailability and prophylactic anticancer activity."( α-Tocopherol as functional excipient for resveratrol and coenzyme Q10-loaded SNEDDS for improved bioavailability and prophylaxis of breast cancer.
Agrawal, AK; Dora, CP; Garg, T; Jain, S; Kushwah, V; Thanki, K, 2017
)
0.7
" Thus, mucoadhesive CS/DS NPs may be an effective oral delivery platform for improving bioavailability of CoQ10."( Preparation and Characterization of Mucoadhesive Nanoparticles for Enhancing Cellular Uptake of Coenzyme Q10.
Kim, ES; Lee, HG; Lee, JS; Suh, JW, 2017
)
0.67
"Supercritical fluid technology was successfully used for the preparation and analysis of CoQ10-SD for the first time and significantly improved the dissolution and bioavailability of coenzyme Q10."( Application of scCO
Du, P; Li, J; Li, Y; Liu, C; Yang, R; Zhang, T, 2018
)
0.67
" Their ability to solubilise poorly water soluble drugs indicates their potential utility in improving bioavailability of drugs where solubility limits their bioavailability."( A new lipid excipient, phosphorylated tocopherol mixture, TPM enhances the solubilisation and oral bioavailability of poorly water soluble CoQ
Boyd, BJ; Gavin, P; Libinaki, R; Pham, AC; Ramirez, G, 2017
)
0.46
" Although CoQ10 is an efficient antioxidant, its poor bioavailability has limited the applications of this useful agent."( Protective effects of coenzyme Q10 nanoparticles on dichlorvos-induced hepatotoxicity and mitochondrial/lysosomal injury.
Ahmadian, E; Azami, A; Eftekhari, A; Eghbal, MA; Johari-Ahar, M, 2018
)
0.8
" In vivo evaluation performed by liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) demonstrated that liposomal encapsulation largely prolonged half-lives and improved bioavailability for vectors prepared with either lipid component, and the liposomes composed of both cholesterol and PEG-lipid possessed the best pharmacokinetic properties."( Preparation, in vitro Characterization and Pharmacokinetic Study of Coenzyme Q10 Long-Circulating Liposomes.
Yang, S, 2018
)
0.72
"Emulsion-based delivery systems have been developed to increase the topical bioavailability of lipophilic active compounds within skin membrane."( Nanoemulsions and topical creams for the safe and effective delivery of lipophilic antioxidant coenzyme Q10.
Arab-Tehrany, E; Belhaffef, A; Desobry, S; Dostert, G; Kaci, M; Menu, P; Meziane, S; Velot, É, 2018
)
0.7
" Crystalline CoQ10 is lipophilic, water-insoluble, and poorly absorbed in the gut."( High-dose coenzyme Q10-loaded oleogels for oral therapeutic supplementation.
Lucangioli, S; Martinefski, MR; Masotta, NE; Rojas, AM; Tripodi, VP, 2019
)
0.92
" Co-Q10 soft capsules can effectively improve the bioavailability and reduce medical costs for patients."( A Simple and Accurate Method for the Determination of Related Substances in Coenzyme Q10 Soft Capsules.
Bao, K; Cai, L; Feng, G; Guo, Y; He, J; Jiang, C; Liao, S; Xie, S; Zhang, C, 2019
)
0.74
"The results further highlights the potential of TPM as an additive in lipid formulations to improve the solubilization and oral bioavailability of poorly water-soluble compounds."( Differential Effects of TPM, A Phosphorylated Tocopherol Mixture, and Other Tocopherol Derivatives as Excipients for Enhancing the Solubilization of Co-Enzyme Q10 as a Lipophilic Drug During Digestion of Lipid- Based Formulations.
Boyd, BJ; Gavin, PD; Khan, JT; Libinaki, R; Pham, A; Ramirez, G, 2019
)
0.51
" This detected dose-related bioavailability of coenzyme Q10 phytosome was even observed with no alterations in vital signs, neither in the physical examination nor in ECG, and no changes of clinical and biochemical parameters were observed."( A New Food-grade Coenzyme Q10 Formulation Improves Bioavailability: Single and Repeated Pharmacokinetic Studies in Healthy Volunteers.
Allegrini, P; De Combarieu, E; Frattini, E; Petrangolini, G; Riva, A; Ronchi, M, 2019
)
1.11
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" Thus, the SD7 formulation is expected to show improved bioavailability and effectiveness in the treatment of aging-related and cardiovascular diseases."( Design of Coenzyme Q10 solid dispersion for improved solubilization and stability.
Choi, JS; Park, JS; Park, JW, 2019
)
0.92
" More bioavailability through intravitreal route of administration and longer duration of effect with sustained release forms may possibly help enhalting the RGC loss, especially incipience of neurodegenerative diseases."( Salvage of the retinal ganglion cells in transition phase in Alzheimer's disease with topical coenzyme Q10: is it possible?
Karakahya, RH; Özcan, TŞ, 2020
)
0.78
" As so, such the aim of this review is to summarize the recent findings regarding neuroprotective substances, their mechanisms of action, as well as to point out therapeutic considerations, including their bioavailability and safety for humans."( An Overview of Crucial Dietary Substances and Their Modes of Action for Prevention of Neurodegenerative Diseases.
Ota, A; Pogačnik, L; Ulrih, NP, 2020
)
0.56
" The latest pharmaceutical approach to increase CoQ10 bioavailability and efficiency is the formulation of its reduced form."( Quantification of reduced and oxidized coenzyme Q10 in supplements and medicines by HPLC-UV.
Kristl, A; Roškar, R; Temova Rakuša, Ž, 2020
)
0.83
"CoQ10 and Vitamin E are used in medicinal applications, but they are both lipophilic molecules and the poor solubility in aqueous media results in an inefficient administration, poor bioavailability and potential toxicity."( Synthesis and controlled drug delivery studies of a novel Ubiquinol-Polyethylene glycol-Vitamin E adduct.
Cateni, F; Procida, G; Zacchigna, M, 2020
)
0.56
" To defeat this issue, it was planned to develop polymeric liposome formulations that are using for their bioavailability and enhancer impact in oral epilepsy treatment."( Chitosan-coated liposome-containing carbamazepine and coenzyme Q10: design, optimization and evaluation.
Sağıroğlu, AA, 2021
)
0.87
" Microencapsulation technology is one way to optimize drug bioavailability and absorption profile."( Microencapsulation of Coenzyme Q10 and bile acids using ionic gelation vibrational jet flow technology for oral delivery.
Al-Salami, H; Brown, D; Ionescu, CM; Jones, M; Kovacevic, B; Mooranian, A; Wagle, SR; Walker, D, 2020
)
0.87
"Coenzyme Q10 (CoQ10), is a promising antioxidant; however, low bioavailability owing to lipid-solubility is a limiting factor."( Water-soluble coenzyme Q10 provides better protection than lipid-soluble coenzyme Q10 in a rat model of chronic tacrolimus nephropathy.
Bae, SK; Chung, BH; Chung, SJ; Cui, S; Kim, HL; Kim, JH; Ko, EJ; Lee, KE; Lim, SW; Luo, K; Quan, Y; Shin, YJ; Yang, CW, 2021
)
2.42
"The purpose of this study was to investigate the potential of bacterial cellulose nanofiber suspension (BCNs) as stabilizer in anti-solvent precipitation and its effect on improving bioavailability of coenzyme Q10."( Improved water dispersion and bioavailability of coenzyme Q10 by bacterial cellulose nanofibers.
Li, S; Li, Y; Liu, B; Liu, Y; Yang, Q; Zhang, Q; Zhao, X, 2022
)
1.16
" Nevertheless, Liposomal drug delivery system is a promising era in the field of Nano-medicine and have the advantageous of increasing drug bioavailability and retention phenomena in addition to targeting organ for all mentioned the present study was designed to investigate the hypothesis that messenger RNA gene expression of Signal transducer and activator of transcription- 5 A (STAT-5A), Phosphatase and tensin homolog (PTEN), phosphoinositol kinase (PI3K) and alpha serine/threonine-protein kinase (AKT) can trigger HgCl3 induced nephrotoxicity post Ubidecarenone and liposomal Ubidecarenone therapy."( Ubiquitous toxicity of Mercuric Chloride in target tissues and organs: Impact of Ubidecarenone and liposomal-Ubidecarenone STAT 5A/ PTEN /PI3K/AKT signaling pathways.
Abdel Megeed, RM; Kadry, MO, 2022
)
0.72
" Issues addressed include (i) whether the bioavailability of CoQ10 could be improved; (ii) whether CoQ10 could be administered intravenously; (iii) whether CoQ10 could be administered via alternative routes; (iv) whether CoQ10 can cross the blood-brain barrier; (v) how CoQ10 is transported into and within target cells; (vi) why some clinical trials supplementing CoQ10 may have been unsuccessful; and (vii) which is the most appropriate tissue for the clinical assessment of CoQ10 status."( Coenzyme Q10 Metabolism: A Review of Unresolved Issues.
Hargreaves, IP; Lopez-Lluch, G; Mantle, D, 2023
)
2.35
" Coenzyme Q10 (CoQ10) loaded with HIPPEs increased the bioavailability from 13."( Construction of whey protein gels prepared by three methods to stabilize high internal phase Pickering emulsions loaded with CoQ10 under different pH.
Li, X; Liu, J; Marchioni, E; Zhang, M; Zhou, L, 2023
)
1.82

Dosage Studied

Coenzyme Q10 (CoQ10) and retinaldehyde (RAL) co-loaded nanostructured lipid carriers (NLCs) have activity on different targets of photoageing. Subacute dosing with coenzyme Q 10 ameliorated some of the diabetes-induced changes in oxidative stress.

ExcerptRelevanceReference
" At the dosage of CoQ10 used in the study (2 mg/kg/day) the therapy requires long administration time before a response is demonstrable."( Multicenter trial with ubidecarenone: treatment of 44 patients with mitochondrial myopathies.
Angelini, C; Bresolin, N; Carenzi, A; Castelli, E; Comi, G; Doriguzzi, C; Moroni, I; Scarlato, G, 1991
)
0.28
" The absence of an isotope effect in the disposition of d5-CoQ10 in man was confirmed from the plasma concentration time curves after simultaneous oral dosing of d5-CoQ10 and unlabelled CoQ10."( Pharmacokinetic study of deuterium-labelled coenzyme Q10 in man.
Hasegawa, J; Morishita, N; Motegi, K; Seki, T; Tomono, Y, 1986
)
0.53
" These changes were dependent on the dosage of CPZ."( A protective action of coenzyme Q10 on chlorpromazine-induced cell damage in the cultured rat myocardial cells.
Chiba, M, 1984
)
0.58
" In retrospect, a dosage of 100 mg was too low although effective and safe."( Two successful double-blind trials with coenzyme Q10 (vitamin Q10) on muscular dystrophies and neurogenic atrophies.
Folkers, K; Simonsen, R, 1995
)
0.56
" Continuing this research, three additional breast cancer patients also underwent a conventional protocol of therapy which included a daily oral dosage of 390 mg of vitamin Q10 (Bio-Quinone of Pharma Nord) during the complete trials over 3-5 years."( Progress on therapy of breast cancer with vitamin Q10 and the regression of metastases.
Folkers, K; Lockwood, K; Moesgaard, S; Yamamoto, T, 1995
)
0.29
" Thereafter they received a daily dosage of 100 mg coenzyme Q10 (Bio-Quinone) and 100 mcg selenium (Bio-Selenium in the form of 1-seleno-methionine) for a period of one year."( Coenzyme Q10 and antioxidants in acute myocardial infarction.
Fähnrich, A; Kuklinski, B; Weissenbacher, E, 1994
)
1.98
" The daily dosage of CoQ10 was 50-150 mg orally, with the majority of patients (78%) receiving 100 mg/day."( Italian multicenter study on the safety and efficacy of coenzyme Q10 as adjunctive therapy in heart failure. CoQ10 Drug Surveillance Investigators.
Baggio, E; Carmosino, G; Gandini, R; Passeri, M; Plancher, AC, 1994
)
0.53
" The dosage of CoQ10 was not fixed and was adjusted according to clinical response and blood CoQ10 levels."( Treatment of essential hypertension with coenzyme Q10.
Folkers, K; Langsjoen, P; Willis, R, 1994
)
0.55
" In one of these 6 cases, the dosage of CoQ10 was increased to 390 mg."( Partial and complete regression of breast cancer in patients in relation to dosage of coenzyme Q10.
Folkers, K; Lockwood, K; Moesgaard, S, 1994
)
0.51
" They were randomly assigned to receive either placebo (n = 322, mean age 67 years, range 30-88 years) or coenzyme Q10 (n = 319, mean age 67 years, range 26-89 years) at the dosage of 2 mg/kg per day in a 1-year double-blind trial."( Effect of coenzyme Q10 therapy in patients with congestive heart failure: a long-term multicenter randomized study.
Condorelli, M; Morisco, C; Trimarco, B, 1993
)
0.9
"In order to determine the effect of oral Coenzyme Q10 (CoQ10) dosing on exercise capacity, 15 middle-aged men (44."( The effect of oral coenzyme Q10 on the exercise tolerance of middle-aged, untrained men.
Costill, DL; Fink, WJ; Folkers, K; Krzeminski, K; Porter, DA; Wagner, E; Zachwieja, JJ, 1995
)
0.89
" In the first, standard softgel capsules containing CoQ10 suspension in oil, powder-filled hardshell capsules and powder-based tablets were tested along with Q-Gel using a daily dosage of 120 mg for three weeks."( Relative bioavailability of coenzyme Q10 formulations in human subjects.
Bhagavan, HN; Chopra, RK; Goldman, R; Sinatra, ST, 1998
)
0.59
"5 mg/kg) of warfarin either alone or on day 4 of an 8-day oral dosing regimen of 10 mg/kg CoQ10 daily."( Accuracy of repeated blood sampling in rats: a new technique applied in pharmacokinetic/pharmacodynamic studies of the interaction between warfarin and co-enzyme Q10.
Chan, E; Zhou, Q, 1998
)
0.3
" The present summarizing study reports the history of the discovery and research, properties, biochemical effects, dosage of Co Q10 deficiency in the human body."( [Coenzyme Q10--its importance, properties and use in nutrition and cosmetics].
Hojerová, J, 2000
)
1.22
" Subacute dosing with coenzyme Q10 ameliorated some of the diabetes-induced changes in oxidative stress."( Effects of coenzyme Q10 treatment on antioxidant pathways in normal and streptozotocin-induced diabetic rats.
Rauscher, FM; Sanders, RA; Watkins, JB, 2001
)
1.02
" The purpose of this review is to provide recommendations regarding the safety, efficacy, and dosing of CoQ10 in the management of chronic heart failure (CHF), angina, and hypertension."( Role of coenzyme Q10 in chronic heart failure, angina, and hypertension.
Giles, JT; Kennedy, DT; Mitchell, TM; Tran, MT, 2001
)
0.74
" The P value for the primary analysis, a test for a linear trend between the dosage and the mean change in the total UPDRS score, was."( Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline.
Beal, MF; Carter, J; Haas, R; Harrison, M; Juncos, JL; Kieburtz, K; Kompoliti, K; Kurlan, R; Lew, M; Molho, E; Nutt, J; Oakes, D; Perlmutter, JS; Plumb, S; Reich, S; Shoulson, I; Shults, CW; Stern, M; Watts, RL, 2002
)
0.7
" Blood samples were collected from each animal prior to dosing to determine the endogenous plasma CoQ10 concentrations."( Bioavailability assessment of oral coenzyme Q10 formulations in dogs.
Bhagavan, H; Chopra, R; Gurley, B; Khan, M; Reddy, I; Zaghloul, AA, 2002
)
0.59
" The geometric mean dosage of warfarin did not change during the treatment periods: Ginkgo biloba 36."( [Effect of Coenzyme Q10 and Ginkgo biloba on warfarin dosage in patients on long-term warfarin treatment. A randomized, double-blind, placebo-controlled cross-over trial].
Engelsen, J; Hansen, KF; Nielsen, JD, 2003
)
0.71
" The subjects received an escalating dosage of coenzyme Q10--1200, 1800, 2400, and 3000 mg/day with a stable dosage of vitamin E (alpha-tocopherol) 1200 IU/day."( Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson's disease.
Flint Beal, M; Fontaine, D; Shults, CW; Song, D, 2004
)
0.87
"The aim of this study was to systematically obtain a model of factors that would yield an optimized self-nanoemulsified capsule dosage form (SNCDF) of a highly lipophilic model compound, Coenzyme Q10 (CoQ)."( Response surface methodology for optimization and characterization of limonene-based coenzyme Q10 self-nanoemulsified capsule dosage form.
Khan, MA; Nutan, MT; Palamakula, A, 2004
)
0.74
" Therefore CoQ formulations should be made with an aim to target the duodenum to get maximum dosage effect."( Regional permeability of coenzyme Q10 in isolated rat gastrointestinal tracts.
Khan, MM; Palamakula, A; Soliman, M, 2005
)
0.63
"5 months of intake, in homogenates and mitochondria of liver, heart, kidney, skeletal muscle, and brain increased with the dosage and duration of CoQ10 intake in all the tissues except brain."( Effect of coenzyme Q10 intake on endogenous coenzyme Q content, mitochondrial electron transport chain, antioxidative defenses, and life span of mice.
Ferguson, M; Forster, MJ; Heinrich, KR; Kamzalov, S; Rebrin, I; Sohal, RS; Sumien, N, 2006
)
0.74
"The objective of this study was to evaluate the effect of some processing parameters on the release of lipid formulation from a tablet dosage form."( Controlled release of a self-emulsifying formulation from a tablet dosage form: stability assessment and optimization of some processing parameters.
Khan, MA; Nazzal, S, 2006
)
0.33
" In some diseases supplementation of antioxidants in the proper form and dosage may be irrelevant."( [The role of antioxidants in prevention].
Feher, J; Lengyel, G; Nagy, V; Németh, E, 2006
)
0.33
"Controlled studies of coenzyme Q(10) dosing and tolerance have been reported in adults, but not in pediatric patients."( Coenzyme Q10 absorption and tolerance in children with Down syndrome: a dose-ranging trial.
Chalfonte-Evans, M; Hickey, FJ; Horn, PS; Hotze, SL; Miles, MV; Patterson, BJ; Schapiro, MB, 2006
)
1.78
" Reports of nausea and other adverse gastrointestinal effects of CoQ10 cannot be causally related to the active ingredient because there is no dose-response relationship: the adverse effects are no more common at daily intakes of 1200 mg than at a 60 mg."( Risk assessment for coenzyme Q10 (Ubiquinone).
Hathcock, JN; Shao, A, 2006
)
0.66
" This study demonstrates that lifelong intake of a low dosage of CoQ(10) enhances plasma levels of CoQ(9), CoQ(10), alpha-tocopherol and retinol."( Life-long supplementation with a low dosage of coenzyme Q10 in the rat: effects on antioxidant status and DNA damage.
Battino, M; Frías, ML; Gutierrez-Rios, P; Huertas, JR; Mataix, J; Nepomuceno, EA; Ochoa, JJ; Quiles, JL, 2005
)
0.59
" In the present study we demonstrate that CoQ(10) supplementation reduces the dosage of corticosteroids in these patients."( Coenzyme Q10 supplementation reduces corticosteroids dosage in patients with bronchial asthma.
Bartkovjaková, M; Gazdík, FE; Gazdíková, K; Gvozdjáková, A; Kucharská, J, 2005
)
1.77
" A reduction in the dosage of corticosteroids required by the patients following antioxidant supplementation was observed, indicating lower incidence of potential adverse effects of the drugs, decreased oxidative stress."( Coenzyme Q10 supplementation reduces corticosteroids dosage in patients with bronchial asthma.
Bartkovjaková, M; Gazdík, FE; Gazdíková, K; Gvozdjáková, A; Kucharská, J, 2005
)
1.77
" In the present study, 84 breast cancer patients were randomized to receive a daily supplement of 100 mg coenzyme Q10 (CoQ10), 10 mg riboflavin and 50 mg niacin (CoRN) one dosage per day along with 10 mg tamoxifen (TAM) twice a day."( Effect of coenzyme Q10, riboflavin and niacin on serum CEA and CA 15-3 levels in breast cancer patients undergoing tamoxifen therapy.
Gangadaran, SG; Premkumar, VG; Sachdanandam, P; Vijayasarathy, K; Yuvaraj, S, 2007
)
0.96
" Improved CoQ10 dosing and drug level monitoring guidelines are suggested for adult and pediatric patient populations."( The uptake and distribution of coenzyme Q10.
Miles, MV, 2007
)
0.63
"Nanoparticular CoQ(10) at a dosage of 300 mg/d is safe and well tolerated and leads to plasma levels similar to 1200 mg/d of standard formulations."( Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease.
Durner, J; Fuchs, G; Greulich, W; Henningsen, H; Herting, B; Jost, WH; Koch, R; Kuhn, W; Kupsch, A; Müller, T; Niklowitz, P; Oertel, WH; Reichmann, H; Spiegel, J; Storch, A; Vieregge, P, 2007
)
0.34
" In the present study, 84 breast cancer patients were randomized to receive a daily supplement of CoQ(10) 100 mg, riboflavin 10 mg and niacin 50 mg, one dosage per day along with tamoxifen 10 mg twice a day."( Serum cytokine levels of interleukin-1beta, -6, -8, tumour necrosis factor-alpha and vascular endothelial growth factor in breast cancer patients treated with tamoxifen and supplemented with co-enzyme Q(10), riboflavin and niacin.
Gangadaran, SG; Premkumar, VG; Sachdanandam, P; Vijayasarathy, K; Yuvaraj, S, 2007
)
0.34
" These results show that any CoQ10 product using P40 can be quickly and reliably absorbed by the body regardless of dosage form or intake time."( Comparison of uptake between PureSorb-Q40 and regular hydrophobic coenzyme Q10 in rats and humans after single oral intake.
Kettawan, A; Miyawaki, H; Nukui, K; Okamoto, T; Sato, K; Yamagishi, T, 2007
)
0.58
" The finding that CoQ10 is effective in a chronic dosing model of MPTP toxicity, is of particular interest, as this may be more relevant to PD."( Therapeutic effects of coenzyme Q10 (CoQ10) and reduced CoQ10 in the MPTP model of Parkinsonism.
Beal, MF; Calingasan, NY; Cleren, C; Lorenzo, B; Schomer, A; Sireci, A; Wille, EJ; Yang, L, 2008
)
0.66
" While earlier no treatment was available, in the recent decade an antioxidant therapy became very popular using combinations of high dosage antioxidant vitamins C, E, beta carotene and zinc."( [Metabolic therapy for early treatment of age-related macular degeneration].
Corrado Balacco, G; Fehér, J; Kovács, B; Kovács, I; Schvöller, M, 2007
)
0.34
" Hematological and blood chemistry parameters were evaluated at both the end of the dosing period and the end of the recovery period."( Toxicity of coenzyme Q(10): a report of 90-day repeated dose toxicity study in rats.
Jingru, M; Min, J; Mingkai, L; Shuyu, C; Xiaoxing, L; Xue, M; Yumei, W; Zhipeng, W, 2007
)
0.34
" Subjects in the CoQ10 group took 300 mg CoQ10 per d for 20 d, while subjects in the placebo group took the same dosage of a placebo."( Reducing exercise-induced muscular injury in kendo athletes with supplementation of coenzyme Q10.
Akimoto, T; Kimura, F; Kon, M; Kono, I; Okamoto, T; Shimizu, K; Tanabe, K; Tanimura, Y, 2008
)
0.57
" In the present study, 84 breast cancer patients were randomized to receive a daily supplement of CoQ(10) 100 mg, riboflavin 10 mg and niacin 50 mg (CoRN), one dosage per day along with tamoxifen (TAM) 10 mg twice a day."( Anti-angiogenic potential of CoenzymeQ10, riboflavin and niacin in breast cancer patients undergoing tamoxifen therapy.
Premkumar, VG; Sachdanandam, P; Sathish, S; Shanthi, P; Yuvaraj, S,
)
0.13
" The method proposed does not require any pretreatment of the pharmaceutical dosage forms."( Voltammetric determination of coenzyme Q10 in pharmaceutical dosage forms.
Michalkiewicz, S, 2008
)
0.63
"The mean increase of CoQ10 plasma concentrations after dosing with Q10Vital forms was determined to be over the reference formulation and the area under the curve values, extrapolated to infinity (AUC(inf)), were also higher with the tested forms; statistically significant 120 and 79% increases over the reference were calculated for the Q10Vital liquid and powder, respectively."( Relative bioavailability of two forms of a novel water-soluble coenzyme Q10.
Fir, M; Pravst, I; Prosek, M; Smidovnik, A; Walczak, J; Zmitek, J; Zmitek, K, 2008
)
0.59
" The pharmacokinetic study of each dosage form, in comparison to a CoQ(10) crystal suspension, was also carried out in rats after a single oral dose."( Physicochemical and pharmacokinetic characterization of water-soluble Coenzyme Q(10) formulations.
Hatanaka, J; Kimura, Y; Lai-Fu, Z; Onoue, S; Yamada, S, 2008
)
0.35
" The in vivo pharmacokinetic study using TDS with 6% fatty acids in DGME-PGML (60:40) showed that the absorption of CoQ(10) decreased in the following order: TDS containing linoleic acid > oral dosage form > TDS with oleic acid > TDS with lauric acid > TDS with caprylic acid > TDS with capric acid."( Formulation and evaluation of ubidecarenone transdermal delivery systems.
Choi, YJ; Chun, IK; Gwak, HS; Jung, SY; Kang, EY; Lee, BK, 2009
)
0.35
" Thus, this self-micro emulsifying drug delivery system should be an effective oral dosage form for improving oral bioavailability of lipophilic drug, CoQ(10)."( Enhanced oral bioavailability of Coenzyme Q10 by self-emulsifying drug delivery systems.
Balakrishnan, P; Choi, HG; Jee, JP; Kim, DD; Kim, JO; Lee, BJ; Lee, YB; Lee, YI; Oh, DH; Woo, JS; Yong, CS, 2009
)
0.63
" Eight full-thickness bladder strips were isolated from each of 4 treated and 4 control rabbit bladders, and a dose-response curve to H(2)O(2) (0."( Differential effects of coenzyme Q10 and α-lipoic acid on two models of in vitro oxidative damage to the rabbit urinary bladder.
Leggett, RE; Levin, RM; Li, HT; Schuler, C, 2011
)
0.68
" Statin-intolerant patients may be successfully treated with either low-dose statins, alternate-day dosing, or using twice-weekly dosing with longer half-life statins."( Evidence-based management of statin myopathy.
Harper, CR; Jacobson, TA, 2010
)
0.36
"Coenzyme Q10 (CoQ(10)), a potential neuroprotective compound, was previously investigated at a dosage of 600 mg/day in Huntington's disease (HD) patients and demonstrated a trend toward slowing disease progression."( Safety and tolerability of high-dosage coenzyme Q10 in Huntington's disease and healthy subjects.
Beal, MF; Browne, SE; Como, P; Cudkowicz, ME; Daigneault, S; de Blieck, EA; Ferrante, K; Ferrante, RJ; Frank, S; Goldstein, M; Hunt, V; Hyson, HC; Jennings, D; Kelsey, T; Kieburtz, K; McDermott, M; Metakis, LJ; Newhall, K; Ravina, B; Shoulson, I; Walker, F; Watts, A; Weber, J; Zimmerman, C, 2010
)
2.07
" Since ozone itself is a radical, using a small dosage of it is known to create an oxidative preconditioning in the body and trigger a strong antioxidant response against that."( The effects of ozone therapy and coenzyme Q₁₀ combination on oxidative stress markers in healthy subjects.
Dokumacioglu, A; Inal, M; Özcelik, E; Ucar, O, 2011
)
0.37
"Sixty-six patients were given either ubiquinol or ubiquinone orally at a dosage of 100 mg/day, or a placebo for 1 month, and salivary secretion and salivary CoQ10 content were analyzed before and after treatment."( Effects of coenzyme Q10 on salivary secretion.
Arikawa, K; Fujii, K; Ito, A; Ryo, K; Saito, I; Seido, T; Shinpo, K; Tai, Y; Takatori, R; Tamaki, Y; Yamada, T; Yamamoto, Y, 2011
)
0.76
" These data confirm that CoQ10 may be beneficial in HD but suggest that maximum benefit may be observed when treatment is begun at early stages of the disease and that dosage may be critical."( Evidence for behavioral benefits of early dietary supplementation with CoEnzymeQ10 in a slowly progressing mouse model of Huntington's disease.
Chesselet, MF; Franich, NR; Hickey, MA; Levine, MS; Medvedeva, V; Zhu, C, 2012
)
0.38
" Both C (max) and AUC increased with increasing dosage of CoQ₁₀."( Oral repeated-dose toxicity studies of coenzyme Q10 in beagle dogs.
Beal, MF; Blieck, EA; Cudkowicz, ME; Funahashi, I; Hosoe, K; Kieburtz, K; Kitano, M; Watanabe, D; Yerramilli-Rao, P,
)
0.4
"Coenzyme Q10 supplementation at a dosage of 150 mg appears to decrease the inflammatory marker IL-6 in patients with CAD."( Effects of coenzyme Q10 supplementation on inflammatory markers (high-sensitivity C-reactive protein, interleukin-6, and homocysteine) in patients with coronary artery disease.
Chen, SJ; Huang, YC; Lee, BJ; Lin, PT, 2012
)
2.21
" From the improved physicochemical and pharmacokinetic data, the s-SEDDS approach upon spray-drying might be a suitable dosage option for enhancing nutraceutical and pharmaceutical values of CoQ(10)."( Novel solid self-emulsifying drug delivery system of coenzyme Q₁₀ with improved photochemical and pharmacokinetic behaviors.
Hatanaka, J; Kato, M; Kuriyama, K; Miyoshi, H; Nakamura, T; Onoue, S; Seto, Y; Tanaka, T; Uchida, A; Yamada, S, 2012
)
0.38
" From the results of physicochemical and pharmacokinetic studies, the CoQ10 nanoparticles had high solubility in water and possessed less crystalline structure, which can enhance the bioavailability of CoQ10, and provide a water-soluble solid dosage form of CoQ10."( Characterization and pharmacokinetics of coenzyme Q10 nanoparticles prepared by a rapid expansion of supercritical solution process.
Jiang, S; Li, Q; Meng, X; Sang, M; Zhao, X; Zu, Y, 2012
)
0.64
" Patients currently receiving a statin who developed new-onset myalgias in ≥ 2 extremities within 60 days of initiation or a dosage increase were eligible."( Effect of coenzyme Q10 supplementation on statin-induced myalgias.
Bookstaver, DA; Burkhalter, NA; Hatzigeorgiou, C, 2012
)
0.78
" Twenty-four hours post the last dosage of antioxidants, CO2 was used to euthanize the mice after which the brain was excised and used for various biochemical analyses."( Kenyan purple tea anthocyanins ability to cross the blood brain barrier and reinforce brain antioxidant capacity in mice.
Isaac, AO; Murilla, G; Nyabuga, JN; Rashid, K; Wachira, FN; Wanyonyi, B, 2014
)
0.4
" Oral bioavailability and hepatoprotective effects of orally dosed CoQ10 samples were also evaluated in rats."( Biopharmaceutical characterization of nanocrystalline solid dispersion of coenzyme Q10 prepared with cold wet-milling system.
Hashimoto, N; Nakamura, T; Onoue, S; Terasawa, N; Yamada, S; Yuminoki, K, 2014
)
0.63
" These results lead to the hypothesis that the therapeutic response to CoQ10 depends on baseline levels of ubiquinol and whether the dosage of CoQ10 used can ameliorate the burden of oxidative damage."( Does high-dose coenzyme Q10 improve oxidative damage and clinical outcomes in Parkinson's disease?
Chong, WL; Chow, AW; Halliwell, B; Lim, EC; Ng, MP; Ong, CN; Quek, AM; Seet, RC; Tan, JJ, 2014
)
0.76
" This dosage was selected on the basis of its expected -20% efficacy in reducing low-density lipoprotein-cholesterol."( Nutraceutical approach to moderate cardiometabolic risk: results of a randomized, double-blind and crossover study with Armolipid Plus.
Arnoldi, A; Bosisio, R; Calabresi, L; Gomaraschi, M; Macchi, C; Magni, P; Mombelli, G; Pavanello, C; Pazzucconi, F; Ruscica, M; Sirtori, CR,
)
0.13
"CoQ10 supplementation at a dosage of 500 mg appears to decrease the inflammatory markers (TNF-α, IL-6, and MMP-9) in patients with MS."( Coenzyme Q10 supplementation ameliorates inflammatory markers in patients with multiple sclerosis: a double blind, placebo, controlled randomized clinical trial.
Aryaeian, N; Azimi, A; Eghtesadi, S; Gohari, MR; Jazayeri, S; Khalili, M; Khodadadi, B; Sanoobar, M, 2015
)
1.86
" Dosage effects should also be explored."( Effects of coenzyme Q10 supplementation on metabolic profile in diabetes: a systematic review and meta-analysis.
Juanak, N; Poolsup, N; Suksomboon, N, 2015
)
0.81
" Subjects in the placebo group took the same dosage of placebo."( Coenzyme Q10 supplementation downregulates the increase of monocytes expressing toll-like receptor 4 in response to 6-day intensive training in kendo athletes.
Akama, T; Hanaoka, Y; Kimura, F; Kon, M; Kono, I; Shimizu, K; Tanimura, Y, 2015
)
1.86
"The present study suggested that CoQ10 supplement at a dosage of 100 mg could be effective for improving the systemic inflammation and biochemical variables in NAFLD."( Functions of Coenzyme Q10 Supplementation on Liver Enzymes, Markers of Systemic Inflammation, and Adipokines in Patients Affected by Nonalcoholic Fatty Liver Disease: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial.
Alavinejad, P; Engali, KA; Farsi, F; Mohammadshahi, M; Rezazadeh, A; Zarei, M,
)
0.5
"An age-dependent model of the periodontium was reproduced to evaluate the effect of life-long feeding on a low coenzyme Q10 dosage in n-6, n-3 polyunsaturated fatty acid or monounsaturated fatty acid-based diets on periodontal tissues of young and old rats."( Coenzyme Q Protects Against Age-Related Alveolar Bone Loss Associated to n-6 Polyunsaturated Fatty Acid Rich-Diets by Modulating Mitochondrial Mechanisms.
Battino, M; Bullon, P; Cordero, MD; Ochoa, JJ; Quiles, JL; Ramirez-Tortosa, CL; Ramirez-Tortosa, MC; Rubini, C; Varela-Lopez, A; Zizzi, A, 2016
)
0.65
"01), while lower mean total gonadotropin dosage was administered after D + C supplementation compared with D (3414 ± 1141 IUs versus 3877 ± 1143 IUs respectively, p = 0."( The use of coenzyme Q10 and DHEA during IUI and IVF cycles in patients with decreased ovarian reserve.
Balakier, H; Blanco Mejia, S; Claessens, A; Gat, I; Librach, CL; Ryan, EA, 2016
)
0.82
" Concentrations required for effective simvastatin- or resveratrol-induced inhibition of mitochondrial respiration were found much higher than concentrations achieved under standard dosing of these drugs."( Effect of Simvastatin, Coenzyme Q10, Resveratrol, Acetylcysteine and Acetylcarnitine on Mitochondrial Respiration.
Fišar, Z; Hroudová, J; Kopřivová, A; Macečková, D; Singh, N, 2016
)
0.74
" In contrast, Q10 assisted in boosting of IL-10 with higher dosage (200 mg/kg)."( Antioxidant and Anti-Inflammatory Effects of Coenzyme Q10 on L-Arginine-Induced Acute Pancreatitis in Rat.
Gholamrezaei Boushehrinejad, A; Jangholi, E; Kardeh, B; Mirmalek, SA; Parsa, T; Parsa, Y; Salimi-Tabatabaee, SA; Shahverdi, E; Yadollah-Damavandi, S; Yavari, H, 2016
)
0.69
" Those in the placebo group ingested the same dosage of a placebo."( Coenzyme Q10 does not prevent exercise-induced muscle damage and oxidative stress in sedentary men.
Belviranli, M; Okudan, N; Torlak, S, 2018
)
1.92
" The method was further applied for quantification of the analytes in selected liquid and solid dosage forms, registered as nutritional supplements and prescription medicines, which confirmed its suitability for routine analysis."( Novel HPLC-UV Method for Simultaneous Determination of Fat-soluble Vitamins and Coenzyme Q10 in Medicines and Supplements.
Roškar, R; Srečnik, E; Temova-Rakuša, Ž, 2017
)
0.68
"This study depicts coenzyme Q10 (CoQ10) and retinaldehyde (RAL) co-loaded nanostructured lipid carriers (NLCs); having activity on different targets of photoageing, which can overcome deficits of conventional topical dosage forms."( Coenzyme Q10 and retinaldehyde co-loaded nanostructured lipid carriers for efficacy evaluation in wrinkles.
Jain, S; Katiyar, SS; Kushwah, V; Nayak, K, 2018
)
2.25
"Animals dosed with 10 mg/kg presented the worst neurological function and brain damage in the acute phase of stroke injury."( Coenzyme Q10 supplementation improves acute outcomes of stroke in rats pretreated with atorvastatin.
Faizi, M; Khodagholi, F; Naderi, N; Nasoohi, S; Nikseresht, S; Simani, L, 2019
)
1.96
", 4 years) treatment with coenzyme Q10 (ubiquinone) at the dosage of 4 mg/kg/d does not affect whole body DNA and RNA oxidation."( The effect of long-term treatment with coenzyme Q10 on nucleic acid modifications by oxidation in children with Down syndrome.
Bergholdt, HKM; Gabrielli, O; Henriksen, T; Larsen, EL; Littarru, GP; Orlando, P; Padella, L; Poulsen, HE; Santoro, L; Tiano, L, 2018
)
1.05
"As a new dosage form, coenzyme Q10 (Co-Q10) soft capsules are easily absorbed and utilized by the human body."( A Simple and Accurate Method for the Determination of Related Substances in Coenzyme Q10 Soft Capsules.
Bao, K; Cai, L; Feng, G; Guo, Y; He, J; Jiang, C; Liao, S; Xie, S; Zhang, C, 2019
)
1.06
" Subgroup analysis revealed that dosage of Q10 and trial duration could not differ the results of Q10 supplementation."( Effect of Q10 supplementation on body weight and body mass index: A systematic review and meta-analysis of randomized controlled clinical trials.
Falahi, E; Khosroshahi, MZ; Mardani, M; Nouri, Y; Rad, EY; Saboori, S,
)
0.13
"The addition of CoQ10 with half dosage statin in patients with previous intolerance to statins improves the perception of clinical symptoms such as asthenia, myalgia or pain."( Coenzyme q10 liquid supplementation in dyslipidemic subjects with statin-related clinical symptoms: a double-blind, randomized, placebo-controlled study.
D'Angelo, A; Derosa, G; Maffioli, P, 2019
)
1.96
" Coenzyme Q10 has several disadvantages to be formulated in topical dosage forms, such as low water solubility and large molecular weight."( Coenzyme Q10 nanostructured lipid carriers as an inducer of the skin fibroblast cell and its irritability test in a mice model.
Erawati, T; Shoviantari, F; Soeratri, W, 2019
)
2.87
" Therefore, CoQ10 can be used for treating asthenozoospermic infertility with the dosage and duration depending upon the severity of the disorder and the patient's response to the treatment."( Coenzyme Q10 effect on semen parameters: Profound or meagre?
Alahmar, AT; Gupta, G; Rajender, S; Vishvkarma, R, 2020
)
2
"Developing new delivery dosage forms with robust delivery and safety profiles remains a challenge to the pharmaceutical industry in terms of optimum gut absorption, consistent dosing and bioavailability; particularly for orally administered drugs that are poorly water soluble."( Microencapsulation of Coenzyme Q10 and bile acids using ionic gelation vibrational jet flow technology for oral delivery.
Al-Salami, H; Brown, D; Ionescu, CM; Jones, M; Kovacevic, B; Mooranian, A; Wagle, SR; Walker, D, 2020
)
0.87
" We aimed to assess the dose-response relation between CoQ10 and BP, and quantify the effect of CoQ10 supplementation on the concentration of circulating CoQ10 by synthesizing available evidence from randomized controlled trials (RCTs)."( Dose-Response Effect of Coenzyme Q10 Supplementation on Blood Pressure among Patients with Cardiometabolic Disorders: A Grading of Recommendations Assessment, Development, and Evaluation (GRADE)-Assessed Systematic Review and Meta-Analysis of Randomized C
Dai, S; Dong, X; Hou, S; Liang, Y; Liu, M; Liu, Z; Tian, Z; Yang, Y; Zhan, Y; Zhao, D, 2022
)
1.03
" Besides pregabalin (150 mg/day), the patients, upon their group assignment, received CoQ10 at a dosage of 100 mg every 8 h or matched placebo for 8 consecutive weeks."( Coenzyme Q10 as a potential add-on treatment for patients suffering from painful diabetic neuropathy: results of a placebo-controlled randomized trial.
Amini, P; Mehrpooya, M; Mirjalili, M; Mohammadi, Y; Sajedi, F, 2022
)
2.16
"This study conducted a meta-analysis to determine the effects of CoQ10 on lipid profiles and assess their dose-response relationships in adults."( Effects of Coenzyme Q10 Supplementation on Lipid Profiles in Adults: A Meta-analysis of Randomized Controlled Trials.
Dai, S; Dong, X; Hou, S; Liang, Y; Liu, M; Liu, Z; Tian, Z; Yang, Y; Zhao, D, 2022
)
1.11
" The novel single-stage restricted cubic spline regression model was applied to explore nonlinear dose-response relationships."( Effects of Coenzyme Q10 Supplementation on Lipid Profiles in Adults: A Meta-analysis of Randomized Controlled Trials.
Dai, S; Dong, X; Hou, S; Liang, Y; Liu, M; Liu, Z; Tian, Z; Yang, Y; Zhao, D, 2022
)
1.11
" The dose-response analysis showed an inverse J-shaped nonlinear pattern between CoQ10 supplementation and TC in which 400-500 mg/day CoQ10 largely reduced TC (χ2 = 48."( Effects of Coenzyme Q10 Supplementation on Lipid Profiles in Adults: A Meta-analysis of Randomized Controlled Trials.
Dai, S; Dong, X; Hou, S; Liang, Y; Liu, M; Liu, Z; Tian, Z; Yang, Y; Zhao, D, 2022
)
1.11
"CoQ10 supplementation decreased the TC, LDL-C, and TG levels, and increased HDL-C levels in adults, and the dosage of 400 to 500 mg/day achieved the greatest effect on TC."( Effects of Coenzyme Q10 Supplementation on Lipid Profiles in Adults: A Meta-analysis of Randomized Controlled Trials.
Dai, S; Dong, X; Hou, S; Liang, Y; Liu, M; Liu, Z; Tian, Z; Yang, Y; Zhao, D, 2022
)
1.11
"After pretreatment, basal FSH, total Gn dosage and duration were comparable among the three groups (all p-value > 0."( Effect of Coenzyme Q10 and transcutaneous electrical acupoint stimulation in assisted reproductive technology: a retrospective controlled study.
Chen, K; Liang, Q; Qi, S; Wen, J; Yang, L; Zhou, X, 2022
)
1.12
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Occurs in Manufacturing (131 Product(s))

Product Categories

Product CategoryProducts
Other7
en:Syrups1
Vitamins & Supplements60
Beauty & Personal Care29
Active Lifestyle & Fitness7
Professional Supplements21
Herbs, Botanicals & Homeopathy2
Pet Supplies4

Products

ProductBrandCategoryCompounds Matched from IngredientsDate Retrieved
Sukrinsirup GoldSukrin,Funksjonell Maten:Syrupserythritol2024-02-13
AC Grace Unique E -- 60 SoftgelsAC GraceVitamins & Supplements astaxanthin, Vitamin D3, Coenzyme Q10, Vitamin E, EPA, Vitamin E, lycopene2024-11-29 10:47:42
Acure Brightening Vitamin C Sunset Serum -- 1 fl ozAcureBeauty & Personal Careorange, ascorbic acid, astaxanthin, CoQ10, ubiquinone2024-11-29 10:47:42
Acure Incredibly Clear Mattifying Moisturizer -- 1.7 fl ozAcureBeauty & Personal Caretocopherol acetate, chamomile, calendula, cetearyl alcohol, coq10, glycerin, glyceryl laurate, glyceryl caprylate, ubiquinone2024-11-29 10:47:42
Amazing Nutrition CoQ10 with Bioperine -- 400 mg - 60 SoftgelsAmazing NutritionVitamins & SupplementsCoenzyme Q102024-11-29 10:47:42
Andalou Naturals Age Defying Apricot Probiotic Cleansing Milk -- 6 fl ozAndalou NaturalsBeauty & Personal Careorange, allantoin, cetyl alcohol, CoQ10, tocopherol, ethylhexylglycerin, tocopherol, vitamin e, glyceryl stearate, glyceryl monolaurate, phenethyl alcohol, resveratrol, ubiquinone2024-11-29 10:47:42
Andalou Naturals Age Defying Deep Wrinkle Dermal Filler -- 0.6 fl ozAndalou NaturalsBeauty & Personal CareAllantoin, Vitamin C, Cetyl Alcohol, CoQ10, Tocopherol, Ethylhexylglycerin, Tocopherol, Glyceryl Stearate, Phenethyl Alcohol, Resveratrol, Stearyl Alcohol, Ubiquinone2024-11-29 10:47:42
Andalou Naturals Age Defying DIY Booster Facial Serum SPF 30 Unscented -- 2 fl ozAndalou NaturalsBeauty & Personal CareCetyl Alcohol, CoQ10, Ethylhexylglycerin, Phenethyl Alcohol, Resveratrol, Stearyl Alcohol, Ubiquinone2024-11-29 10:47:42
Andalou Naturals Age Defying Fruit Stem Cell Revitalize Serum -- 1.1 fl ozAndalou NaturalsBeauty & Personal CareOrange, Allantoin, Vitamin C, Kelp, Cetyl Alcohol, CoQ10, Tocopherol, Panthenol, Ethylhexylglycerin, Tocopherol, Glyceryl Stearate, Melatonin, Glyceryl Laurate, Phenethyl Alcohol, Resveratrol, Riboflavin, Stearyl Alcohol, Ubiquinone2024-11-29 10:47:42
Andalou Naturals Age Defying Goji Peptide Perfecting Cream -- 1.7 ozAndalou NaturalsBeauty & Personal CareOrange, Allantoin, Vitamin C, Bisabolol, Cetyl Alcohol, CoQ10, Tocopherol, Panthenol, Ethylhexylglycerin, Tocopherol, Glyceryl Stearate, Glyceryl Laurate, Phenethyl Alcohol, Resveratrol, Riboflavin, Stearic Acid, Ubiquinone2024-11-29 10:47:42
Andalou Naturals Age Defying Toning Refresher Blossom + Leaf -- 6 fl ozAndalou NaturalsBeauty & Personal CareAllantoin, Vitamin C, CoQ10, Tocopherol, Panthenol, Ethylhexylglycerin, Tocopherol, Phenethyl Alcohol, Resveratrol, Ubiquinone2024-11-29 10:47:42
Andalou Naturals Age Defying Ultra Sheer Daily Defense Facial Lotion SPF 18 -- 2.7 fl ozAndalou NaturalsBeauty & Personal CareOrange, Allantoin, Chamomile, Vitamin C, Kelp, Cetyl Alcohol, CoQ10, Tocopherol, Panthenol, Ethylhexylglycerin, Tocopherol, Dimethicone, Phenethyl Alcohol, Resveratrol, Stearic Acid, Stearyl Alcohol, Ubiquinone2024-11-29 10:47:42
Andalou Naturals Firming Body Butter Lavender Shea -- 8 fl ozAndalou NaturalsBeauty & Personal CareAllantoin, CoQ10, Tocopherol, Panthenol, Ethylhexylglycerin, Tocopherol, Glyceryl Stearate, Phenethyl Alcohol, Stearic Acid, Stearyl Alcohol, Ubiquinone2024-11-29 10:47:42
Andalou Naturals Hyaluronic DMAE Lift & Firm Cream Age Defying -- 1.7 ozAndalou NaturalsBeauty & Personal Careorange, allantoin, vitamin C, bisabolol, CoQ10, tocopherol, dimethylaminoethanol, panthenol, ethylhexylglycerin, tocopherol, glyceryl stearate, phenethyl alcohol, resveratrol, riboflavin, ubiquinone2024-11-29 10:47:42
Andalou Naturals Resveratrol Q10 Night Repair Cream -- 1.7 fl ozAndalou NaturalsBeauty & Personal Careallantoin, vitamin c, cetyl alcohol, coq10, comfrey, tocopherol, ethylhexylglycerin, tocopherol, glyceryl stearate, phenethyl alcohol, resveratrol, riboflavin, stearyl alcohol, ubiquinone2024-11-29 10:47:42
Animal PAK - The Ultimate Training Pack -- 30 PacksAnimalActive Lifestyle & FitnessLipase, Alanine, Arginine, Vitamin C, Aspartic Acid, Biotin, Carnitine, Choline, Chromium, Coenzyme Q10, Cystine, Vitamin E, Folate, Vitamin E, Glutamic Acid, Glutamine, Glycine, Histidine, Hydroxyproline, Inositol, Iodine, Isoleucine, Leucine, Lutein, Lycopene, Lysine, Manganese, menaquinone-4, Methionine, Niacin, Ornithine, Pantothenic Acid, Phenylalanine, Phosphorus, Proline, Vitamin B6, Vitamin A, Riboflavin, Selenium, Serine, L-Taurine, Thiamin, Alpha Lipoic Acid, Threonine, Tryptophan, Tyrosine, Valine, Vitamin B12, Vitamin B6, phytonadione, Vitamin K2024-11-29 10:47:42
Animal PAK - The Ultimate Training Pack -- 44 PacksAnimalActive Lifestyle & FitnessLipase, Alanine, Arginine, Vitamin C, Aspartic Acid, Biotin, Carnitine, Choline, Chromium, Coenzyme Q10, Cystine, Vitamin E, Folate, Vitamin E, Glutamic Acid, Glutamine, Glycine, Histidine, Hydroxyproline, Inositol, Iodine, Isoleucine, Leucine, Lutein, Lycopene, Lysine, Manganese, menaquinone-4, Methionine, Niacin, Ornithine, Pantothenic Acid, Phenylalanine, Phosphorus, Proline, Vitamin B6, Vitamin A, Riboflavin, Selenium, Serine, L-Taurine, Thiamin, Alpha Lipoic Acid, Threonine, Tryptophan, Tyrosine, Valine, Vitamin B12, Vitamin B6, phytonadione, Vitamin K2024-11-29 10:47:42
Animal Pak Ultimate Foundation Powder Cherry Bomb -- 30 ServingsAnimalActive Lifestyle & FitnessLipase, Vitamin C, Betaine Anhydrous, Biotin, dicalcium phosphate, Choline, Chromium, Coenzyme Q10, Vitamin E, Folate, Vitamin E, L-Glutamine, L-Histidine, Inositol, Iodine, L-Isoleucine, calcium carbonate, Lutein, Lycopene, Manganese, menaquinone-4, Niacin, Pantothenic Acid, L-Phenylalanine, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, L-Taurine, Thiamin, L-Valine, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Animal Pak Ultimate Foundation Powder Fruit Punch -- 14.7 ozAnimalActive Lifestyle & FitnessLipase, Vitamin C, Betaine Anhydrous, Biotin, dicalcium phosphate, Choline, Chromium, Coenzyme Q10, Vitamin E, Folate, Vitamin E, L-Glutamine, L-Histidine, Inositol, Iodine, L-Isoleucine, calcium carbonate, Lutein, Lycopene, Manganese, menaquinone-4, Niacin, Pantothenic Acid, L-Phenylalanine, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, L-Taurine, Thiamin, L-Valine, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Animal Pak Ultimate Foundation Powder Orange Crushed -- 14.5 ozAnimalActive Lifestyle & FitnessLipase, Vitamin C, Betaine Anhydrous, Biotin, dicalcium phosphate, Choline, Chromium, Coenzyme Q10, Vitamin E, Folate, Vitamin E, L-Glutamine, L-Histidine, Inositol, Iodine, L-Isoleucine, calcium carbonate, Lutein, Lycopene, Manganese, menaquinone-4, Niacin, Pantothenic Acid, L-Phenylalanine, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, L-Taurine, Thiamin, L-Valine, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Animal Stak All-in-1 Pill Packs -- 21 PacketsAnimalActive Lifestyle & FitnessDiindolylmethane, Astaxanthin, Coenzyme Q10, L-Glutamine, Glycine, Vitamin B6, Quercetin Dihydrate, Alpha-Lipoic Acid, Vitamin B62024-11-29 10:47:42
Aurora NutraScience Mega-Liposomal CoQ10-PQQ + Vitamin C Organic Fruit -- 16 fl ozAurora NutraScienceVitamins & SupplementsVitamin C, Coenzyme Q102024-11-29 10:47:42
Aurora NutraScience Mega-Liposomal R-ALA Organic Fruit -- 16 fl ozAurora NutraScienceVitamins & SupplementsR-Alpha-Lipoic Acid, Coenzyme Q10, L-Carnitine2024-11-29 10:47:42
Avalon Organics Wrinkle Therapy Cleansing Milk -- 8.5 fl ozAvalon OrganicsBeauty & Personal Carebenzyl alcohol, cetearyl alcohol, cetyl alcohol, citronellol, CoQ10, geraniol, glycerin, phenethyl alcohol, potassium hydroxide, ribose, sodium benzoate, sorbitol, stearic acid, ubiquinone2024-11-29 10:47:42
Avalon Organics Wrinkle Therapy Day Cream -- 1.75 ozAvalon OrganicsBeauty & Personal CareCetyl Alcohol, Citral, Citronellol, CoQ10, Geraniol, Glyceryl Stearate, Glycerin, Phenethyl Alcohol, Ribose, Sodium Benzoate, Stearyl Alcohol, Ubiquinone2024-11-29 10:47:42
Avalon Organics Wrinkle Therapy Facial Serum -- 0.55 fl ozAvalon OrganicsBeauty & Personal Carecetyl alcohol, citral, citronellol, CoQ10, geraniol, glyceryl stearate, phenethyl alcohol, ribose, sodium benzoate, squalane, ubiquinone2024-11-29 10:47:42
Avalon Organics Wrinkle Therapy Firming Body Lotion with CoQ10 & Rosehip -- 8 fl ozAvalon OrganicsBeauty & Personal CareBenzyl Alcohol, Bisabolol, Cetyl Alcohol, Citral, Citronellol, CoQ10, Geraniol, Glycerin, Phenethyl Alcohol, Potassium Hydroxide, Ribose, Sodium Benzoate, Stearic Acid, Stearyl Alcohol, Ubiquinone2024-11-29 10:47:42
Beauty Without Cruelty Hand and Body Lotion Vitamin C with CoQ10 -- 8.5 fl ozBeauty Without CrueltyBeauty & Personal Careallantoin, chamomile, ascorbic acid, kelp, cetyl alcohol, CoQ-10, panthenol, palmarosa, glycerin, dimethicone, phenoxyethanol, sodium cocoyl glutamate, sorbitol, stearic acid, tocopherols2024-11-29 10:47:42
Beauty Without Cruelty Vitality Serum Vitamin C With CoQ10 -- 1 fl ozBeauty Without CrueltyBeauty & Personal Careallantoin, tocopherol acetate, kelp, calendula, cetearyl alcohol, cetyl alcohol, CoQ10, tocopherol, panthenol, tocopherol, glyceryl stearate, glycerin, melatonin, glyceryl monolaurate, ubiquinone2024-11-29 10:47:42
Beauty Without Cruelty Vitamin C Renewal Cream with CoQ10 -- 2 ozBeauty Without CrueltyBeauty & Personal Careallantoin, calendula, cetearyl alcohol, CoQ10, tocopherol, panthenol, ethylhexylglycerin, tocopherol, glyceryl stearate, glycerin, dimethicone, glyceryl monolaurate, phenoxyethanol, stearic acid, ubiquinone2024-11-29 10:47:42
Beauty Without Cruelty Vitamin C With CoQ10 Facial Cleanser -- 8.5 fl ozBeauty Without CrueltyBeauty & Personal Careorange, citric acid, allantoin, chamomile, calendula, citric acid, cocamidopropyl betaine, CoQ-10, tocopherol, panthenol, tocopherol, glycerin, sodium benzoate, ubiquinone2024-11-29 10:47:42
Beverly International Lean Out -- 120 CapsulesBeverly InternationalActive Lifestyle & FitnessBiotin, Choline, Chromium, Coenzyme Q10, Inositol, L-Carnitine, Vitamin B122024-11-29 10:47:42
Bio Nutrition Blood Pressure Wellness -- 60 TabletsBio NutritionVitamins & SupplementsVitamin D3, Coenzyme Q10, citrate, citrate2024-11-29 10:47:42
Bio Nutrition Cholesterol Wellness -- 60 Vegetarian CapsulesBio NutritionVitamins & SupplementsPolicosanol, Omega-3, Coenzyme Q10, Niacin2024-11-29 10:47:42
Bluebonnet Nutrition CholesteRice® Red Yeast Rice Complex -- 90 Vcaps®Bluebonnet NutritionVitamins & SupplementsPolicosanol, CoQ10, Pantethine2024-11-29 10:47:42
Codeage Liposomal Urolithin A Supplement - Resveratrol Betaine CoQ10 -- 60 CapsulesCodeageProfessional SupplementsUrolithin A, Betaine Anhydrous, Coenzyme Q10, Trans-Resveratrol2024-11-29 10:47:42
Codeage Teen Daily Multivitamin - Vitamins A B C D E K Zinc Biotin & Probiotics Vegan Supplement -- 60 CapsulesCodeageProfessional SupplementsVitamin C, Astaxanthin, Biotin, Boron, Omega-3, Vitamin D3, Chromium, Coenzyme Q10, Vitamin E, Vitamin E, Inositol, Iodine, Lutein, Lycopene, Manganese, Vitamin K2, Vitamin K2, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Rutin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Zeaxanthin2024-11-29 10:47:42
Codeage Teen Daily Multivitamin - Vitamins A B C D E K Zinc Biotin & Probiotics Vegan Supplement -- 60 Capsules Each / Pack of 2CodeageProfessional SupplementsVitamin C, Astaxanthin, Biotin, Boron, Omega-3, Vitamin D3, Chromium, Coenzyme Q10, Vitamin E, Vitamin E, Inositol, Iodine, Lutein, Lycopene, Manganese, Vitamin K2, Vitamin K2, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Rutin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Zeaxanthin2024-11-29 10:47:42
Country Life Simply CoQ10 -- 100 mg - 120 Vegan SoftgelsCountry LifeVitamins & SupplementsCoenzyme Q102024-11-29 10:47:42
Cymbiotika Heart Health With CoQ10 Organic Orange Cream -- 30 ServingsCymbiotikaVitamins & SupplementsCoenzyme Q10, Inositol2024-11-29 10:47:42
Cymbiotika Liposomal Glutathione Organic Citrus Berry -- 25 ServingsCymbiotikaVitamins & SupplementsCoQ10, Vitamin B2, Alpha-Lipoic Acid2024-11-29 10:47:42
Cymbiotika Vitamin D3 + K2 + CoQ10 Tangerine -- 5000 IU - 2 fl ozCymbiotikaVitamins & SupplementsVitamin D3, CoQ10, Selenium2024-11-29 10:47:42
DaVinci Laboratories CholestSure™ -- 90 CapsulesDaVinci LaboratoriesProfessional SupplementsCampesterol, Chromium, Coenzyme Q10, Beta Sitosterol, Stigmasterol2024-11-29 10:47:42
DaVinci Laboratories Coenzyme Q10 ChewMelt -- 100 mg - 60 Chewable TabletsDaVinci LaboratoriesProfessional SupplementsCoenzyme Q10, Vitamin E, Vitamin E2024-11-29 10:47:42
DaVinci Laboratories Daily Best™ Ultra Multivitamin -- 60 CapsulesDaVinci LaboratoriesProfessional SupplementsVitamin C, Biotin, Boron, Vitamin D3, Choline, Chromium, Coenzyme Q10, Vitamin E, Folate, Vitamin E, Inositol, Iodine, Lutein, Lycopene, Manganese, Vitamin K2, Vitamin K2, Molybdenum, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Alpha-Lipoic Acid, Vitamin B12, Vitamin B6, Zeaxanthin2024-11-29 10:47:42
DaVinci Laboratories Spectra™ Senior Multi -- 180 TabletsDaVinci LaboratoriesProfessional Supplements lipase, Octacosanol, PABA, Vitamin C, L-Aspartic Acid, Betaine HCl, Biotin, Boron, Vitamin D3, Choline, Chromium, Coenzyme Q10, L-Cysteine, Vitamin E, Folic Acid, Gamma Linolenic Acid, Vitamin E, Glutamic Acid, Hesperidin, Inositol, Iodine, Lutein, Lycopene, Manganese, Molybdenum, Niacin, PABA, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Rutin, Selenium, Silicon, Thiamin, Alpha-Lipoic Acid, Vanadium, Vitamin B12, Vitamin B6, Vitamin K12024-11-29 10:47:42
Desert Essence Activated Charcoal Toothpaste Fresh Mint -- 6.25 ozDesert EssenceBeauty & Personal Carecalcium ascorbate, coenzyme Q10, glycerin, Calcium carbonate, wintergreen, phytic acid, sodium lauroyl sarcosinate, sodium bicarbonate, ubiquinone2024-11-29 10:47:42
Designs for Sport Mito NRG Complex - NSF Certified for Sport -- 120 Vegetarian CapsulesDesigns for SportProfessional SupplementsCoenzyme Q10, Creatine, L-Carnitine, Malic Acid, Manganese, Niacin, Pantethine, Vitamin B6, Trans-Resveratrol, Riboflavin, D-Ribose, Succinic Acid, Thiamin, Alpha-Lipoic Acid, Vitamin B12, Vitamin B62024-11-29 10:47:42
Dr. Mercola CoQ10 -- 100 mg - 30 CapsulesDr. MercolaProfessional SupplementsCoQ102024-11-29 10:47:42
Eco-dent Ultimate Daily Rinse Spicy Cool Cinnamon -- 8 fl ozEco-dentBeauty & Personal Careorange, geranium, anethole, CoQ10, golden seal, basil, menthol, stevia, baking soda, ubiquinone2024-11-29 10:47:42
Eco-dent Ultimate Essential MouthCare -- 8 fl ozEco-dentBeauty & Personal Careorange, geranium, anethole, CoQ10, golden seal, basil, glycerin, menthol, stevia, ubiquinone2024-11-29 10:47:42
Emerald Labs Complete Clinical Plus Multi -- 120 Vegetable CapsulesEmerald LabsVitamins & SupplementsBeta Carotene, Biotin, Boron, Vitamin D3, Chromium, CoQ10, Inositol, Iodine, Lutein, Lycopene, Manganese, Molybdenum, Vitamin B3, Vitamin B5, P-5-P, Pyridoxine HCl, Vitamin B6, Vitamin A, Vitamin B2, R-5-P, Rutin, Selenium, Vitamin B1, Alpha Lipoic Acid, Vanadium, Vitamin B12, Vitamin B62024-11-29 10:47:42
Enzyme Science Complete Digestion -- 30 CapsulesEnzyme ScienceProfessional Supplements CoQ102024-11-29 10:47:42
Enzyme Science Complete Digestion -- 90 CapsulesEnzyme ScienceProfessional Supplements CoQ102024-11-29 10:47:42
Enzyme Science Critical Digestion -- 30 CapsulesEnzyme ScienceProfessional Supplements CoQ102024-11-29 10:47:42
Enzyme Science Critical Digestion -- 90 CapsulesEnzyme ScienceProfessional Supplements CoQ102024-11-29 10:47:42
Enzyme Science Digest Gold -- 240 CapsulesEnzyme ScienceProfessional Supplements CoQ10, Magnesium citrate, Alpha Lipoic Acid2024-11-29 10:47:42
Enzyme Science Digest Gold -- 90 CapsulesEnzyme ScienceProfessional Supplements CoQ10, Magnesium citrate, Alpha Lipoic Acid2024-11-29 10:47:42
Enzyme Science Intolerance Complex -- 30 CapsulesEnzyme ScienceProfessional Supplements CoQ102024-11-29 10:47:42
Enzyme Science Intolerance Complex -- 90 CapsulesEnzyme ScienceProfessional Supplements CoQ102024-11-29 10:47:42
ForestLeaf Red Yeast Rice + CoQ10 -- 1215 mg - 90 CapsulesForestLeafVitamins & SupplementsCoenzyme Q10, Alpha-Lipoic Acid2024-11-29 10:47:42
Futurebiotics Pressur-Lo® -- 270 TabletsFuturebioticsVitamins & SupplementsVitamin C, Betaine HCl, Chloride, Chromium, CoQ10, calcium carbonate, Manganese, Niacin, Pantothenic Acid, potassium chloride, Vitamin B6, Resveratrol, Vitamin A, Riboflavin, Rutin, Selenium, citrate, citrate, L-Taurine, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Futurebiotics Pressur-Lo™ -- 90 TabletsFuturebioticsVitamins & SupplementsVitamin C, Betaine HCl, Chloride, Chromium, CoQ10, calcium carbonate, Manganese, Niacin, Pantothenic Acid, potassium chloride, Vitamin B6, Vitamin A, Riboflavin, Rutin, Selenium, citrate, citrate, L-Taurine, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Garden of Life Vitamin Code® 50 & Wiser Women Whole Food Multivitamin -- 120 Vegetarian CapsulesGarden of LifeVitamins & SupplementsVitamin C, Biotin, Boron, Vitamin D3, Chromium, CoQ10, Vitamin E, Folate, Vitamin E, Iodine, Manganese, Vitamin K2, Vitamin K2, Molybdenum, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vanadium, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Garden of Life Vitamin Code® 50 & Wiser Women Whole Food Multivitamin -- 240 Vegetarian CapsulesGarden of LifeVitamins & SupplementsVitamin C, Biotin, Boron, Vitamin D3, Chromium, CoQ10, Vitamin E, Folate, Vitamin E, Iodine, Manganese, Vitamin K2, Vitamin K2, Molybdenum, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vanadium, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Goli Nutrition Beets Cardio Gummies -- 60 GummiesGoli NutritionVitamins & SupplementsCoQ10, Vitamin B122024-11-29 10:47:42
Havasu Nutrition Beet Root Gummies Mixed Berry -- 120 GummiesHavasu NutritionHerbs, Botanicals & Homeopathycitric acid, citric acid, Coenzyme Q10, sodium citrate, cane sugar2024-11-29 10:47:42
Havasu Nutrition Beet Root Gummies Mixed Berry -- 60 GummiesHavasu NutritionHerbs, Botanicals & Homeopathycitric acid, citric acid, Coenzyme Q10, Pomegranate Juice, sodium citrate, cane sugar2024-11-29 10:47:42
Healthy Origins CoQ10 -- 200 mg - 150 SoftgelsHealthy OriginsVitamins & SupplementsCoenzyme Q10, glycerin2024-11-29 10:47:42
Healthy Origins CoQ10 -- 200 mg - 60 SoftgelsHealthy OriginsVitamins & SupplementsCoenzyme Q10, glycerin2024-11-29 10:47:42
Healthy Origins CoQ10 -- 300 mg - 60 SoftgelsHealthy OriginsVitamins & SupplementsCoenzyme Q10, glycerin2024-11-29 10:47:42
Healthy Origins CoQ10 Gels -- 100 mg - 150 SoftgelsHealthy OriginsVitamins & SupplementsCoenzyme Q10, glycerin2024-11-29 10:47:42
Irwin Naturals Steel-Libido RED -- 150 Liquid SoftgelsIrwin NaturalsVitamins & Supplementsannatto, leaf, CoQ10, glycerin, Theobromine2024-11-29 10:47:42
Jarrow Formulas Co-Q10 -- 100 mg - 60 Veggie CapsulesJarrow FormulasVitamins & SupplementsCoenzyme Q10, Microcrystalline cellulose2024-11-29 10:47:42
Jarrow Formulas Co-Q10 -- 200 mg - 60 Veggie CapsulesJarrow FormulasVitamins & SupplementsCoenzyme Q10, Microcrystalline cellulose2024-11-29 10:47:42
Jarrow Formulas Q-absorb -- 100 mg - 120 SoftgelsJarrow FormulasVitamins & SupplementsCoenzyme Q10, glycerin2024-11-29 10:47:42
Jarrow Formulas Red Yeast Rice + Co-Q10 -- 120 Veggie CapsulesJarrow FormulasVitamins & SupplementsCoenzyme Q10, microcrystalline cellulose2024-11-29 10:47:42
Jigsaw Health CoQ10 with SRT -- 60 CapsulesJigsaw HealthVitamins & Supplementsß-cyclodextrin, Cellulose, Coenzyme Q102024-11-29 10:47:42
Kiss My Face Triple Action Toothpaste Herbal Mint Gel -- 4.5 ozKiss My FaceBeauty & Personal CareCo-Q10, glycerin, menthol, stevia, sodium lauroyl sarcosinate, ubiquinone, xylitol2024-11-29 10:47:42
Kyolic Aged Garlic Extract™ CoQ10 Formula 110 -- 100 CapsulesKyolicVitamins & SupplementsCoenzyme Q102024-11-29 10:47:42
Kyolic Aged Garlic Extract™ Red Yeast Rice plus CoQ10 -- 1200 mg - 75 CapsulesKyolicVitamins & Supplements Cellulose, Coenzyme Q102024-11-29 10:47:42
Lifetime Lifegevity Series Resveratrol Acai and Co-Q10 -- 60 Vegetarian CapsulesLifetimeVitamins & Supplementscellulose, Coenzyme Q10, Resveratrol2024-11-29 10:47:42
Mason Natural Co Q-10 -- 100 mg - 30 SoftgelsMason NaturalVitamins & SupplementsCoenzyme Q102024-11-29 10:47:42
MRM Complete E -- 60 SoftgelsMRMVitamins & SupplementsVitamin C, d-Beta Tocopherol, Coenzyme Q10, d-Alpha-Tocopherol, d-delta tocopherol, d-Gamma Tocopherol, d-Gamma Tocotrienol, Vitamin E, glycerin, Phytosterols, Alpha-Lipoic Acid, d-Alpha Tocotrienol2024-11-29 10:47:42
MRM CoQ-10 -- 100 mg - 60 SoftgelsMRMVitamins & SupplementsCoenzyme Q10, Vitamin E, Vitamin E, glycerin2024-11-29 10:47:42
MRM Nutrition CoQ-10 Resveratrol Red Yeast Rice -- 60 SoftgelsMRMVitamins & SupplementsCoenzyme Q-10, glycerin2024-11-29 10:47:42
MyChelle Dermaceuticals Brighten Perfect C Serum 17% Vitamin C -- 0.5 fl ozMyChelle DermaceuticalsBeauty & Personal Cared-alpha, astaxanthin, benzyl alcohol, beta-carotene, CoQ10, tocopherol, tocopherol, glycerin, glycolic acid, aminoguanidine HCL, retinol, sodium hydroxide, tocotrienols, ubiquinone2024-11-29 10:47:42
Natural Factors Coenzyme Q10 -- 100 mg - 120 SoftgelsNatural FactorsVitamins & SupplementsCoenzyme Q10, glycerin2024-11-29 10:47:42
NutriBiotic Skin Serum -- 1 fl ozNutriBioticBeauty & Personal Careascorbyl palmitate, CoQ10, tocopherol, DMAE, tocopherol, glycerin, imidazolidinyl urea, linalool, linoleic acid, mannitol, methylparaben, phenoxyethanol, propylparaben, retinyl palmitate, betasitosterol, sodium metabisulfite, alpha lipoic acid, tocotrienol, ubiquinone2024-11-29 10:47:42
Nutricost CoQ10 -- 200 mg - 60 CapsulesNutricostVitamins & SupplementsCoenzyme Q102024-11-29 10:47:42
OceanBlue Professional Omega 3 - 2100 with CoQ10 -- 90 SoftgelsOceanBlueProfessional SupplementsCoenzyme Q10, EPA, glycerin2024-11-29 10:47:42
Olly Daily Energy Tropical Passion -- 60 GummiesOllyVitamins & Supplementscitric acid, citric acid, Coenzyme Q10, lactic acid, beet sugar, Vitamin B122024-11-29 10:47:42
Olly Extra Strength Daily Energy Gummies Berry Yuzu -- 60 GummiesOllyVitamins & Supplementscitric acid, citric acid, Coenzyme Q10, sugar, Vitamin B122024-11-29 10:47:42
Olympian Labs Alpha Lipoic COQ10 -- 200 mg - 60 Vegetarian CapsulesOlympian LabsVitamins & SupplementsCoenzyme Q10, microcrystalline cellulose2024-11-29 10:47:42
Olympian Labs Co Q10 -- 300 mg - 60 Vegetarian CapsulesOlympian LabsVitamins & SupplementsCoenzyme Q10, microcrystalline cellulose2024-11-29 10:47:42
Olympian Labs CoQ10 with Bioperine -- 150 mg - 60 Vegetarian CapsulesOlympian LabsVitamins & SupplementsCoenzyme Q10, microcrystalline cellulose2024-11-29 10:47:42
Sante Active PuraSun™ -- 120 SoftgelsSante ActiveVitamins & Supplementscoenzyme Q10, betasitosterol, squalene, stigmasterol2024-11-29 10:47:42
Snap Supplements Heart Health -- 90 CapsulesSnap SupplementsVitamins & SupplementsChloride, Vitamin D3, Coenzyme Q102024-11-29 10:47:42
Source Naturals Life Force™ Multiple No Iron -- 180 CapsulesSource NaturalsVitamins & SupplementsN-Acetyl L-Cysteine, Vitamin C, Astaxanthin, Biotin, Boron, Vitamin D3, Choline, Chromium, Coenzyme Q10, Vitamin E, DMAE, Folate, Vitamin E, microcrystalline cellulose, Inositol, Iodine, calcium carbonate, Lutein, Lycopene, Manganese, Molybdenum, N-Acetyl-L-Tyrosine, Niacin, Pantethine, Pantothenic Acid, Vitamin B6, Quercetin, Vitamin A, Riboflavin, Rutin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Vitamin K12024-11-29 10:47:42
Spry Mouth Wash Healing Blend with Xylitol - Alcohol-Free Herbal Mint -- 16 fl ozSpryBeauty & Personal Carechamomile, ascorbic acid, CoQ10, erythritol, potassium nitrate, xylitol2024-11-29 10:47:42
TheraNeem Naturals - Neem Tooth & Gum Oil -- 0.5 fl ozTheraNeemBeauty & Personal Carecamphora, eugenia caryophyllata, co-q10, menthol, ashwagandha, withania somnifera2024-11-29 10:47:42
Thorne Research CoQ10 - Formerly Q-Best 100 -- 100 mg - 60 Gel CapsThorne ResearchProfessional SupplementsCoenzyme Q10, glycerin2024-11-29 10:47:42
Thorne Research Red Yeast Rice + CoQ10 -- 120 CapsulesThorne ResearchProfessional SupplementsCoenzyme Q102024-11-29 10:47:42
Tropical Oasis Mega Premium Multi-Vitamin -- 32 fl ozTropical OasisVitamins & SupplementsPABA, Vitamin C, Biotin, Choline, CoQ10, Vitamin E, Folate, Vitamin E, Inositol, Vitamin B3, PABA, Pantothenic Acid, Vitamin B6, Quercetin, Vitamin A, Vitamin B2, Vitamin B1, Vitamin B12, Vitamin B6, xylitol2024-11-29 10:47:42
TruSkin Eye Cream -- 0.5 ozTruSkinBeauty & Personal Carebutylene glycol, ascorbic acid, carbomer, cetostearyl alcohol, cetyl alcohol, coq10, glyceryl stearate, glycolic acid, isopropyl palmitate, lactic acid, phenoxyethanol, phytic acid, propylene glycol, potassium stearate, stearyl alcohol, thioctic acid2024-11-29 10:47:42
Twinlab Choline Cocktail™ -- 750 mg - 13.33 ozTwinlabVitamins & Supplementscitric acid, Vitamin C, Biotin, Choline, Chromium, citric acid, Coenzyme Q10, Vitamin E, fructose, DMAE, Folate, Vitamin E, L-Carnitine, Maltodextrin, Niacin, Pantothenic Acid, Vitamin B6, Reb A, Vitamin A, Riboflavin, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Vitacost CoQ10 -- 100 mg - 120 CapsulesVitacost BrandVitamins & SupplementsCoenzyme Q102024-11-29 10:47:42
Vitacost CoQ10 -- 100 mg - 60 CapsulesVitacost BrandVitamins & SupplementsCoenzyme Q102024-11-29 10:47:42
Vitacost-Synergy 3000 Multivitamin -- 180 CapsulesVitacost-SynergyVitamins & SupplementsVitamin C, d-beta tocopherol, Biotin, Boron, calcium citrate, cholecalciferol, Chromium, Coenzyme Q10, Vitamin E, d-delta tocopherol, Folate, Vitamin E, Iodine, Lutein, Manganese, Molybdenum, Niacin, Pantothenic Acid, Vitamin B6, Quercetin, retinyl palmitate, Vitamin A, Riboflavin, Selenium, Thiamin, Alpha Lipoic Acid, Vitamin B12, Vitamin B6, phytonadione, Vitamin K, Zeaxanthin2024-11-29 10:47:42
Vitacost-Synergy Basic® Multivitamin -- 60 CapsulesVitacost-SynergyVitamins & Supplementsd-alpha tocopheryl succinate, Vitamin C, d-beta tocopherol, Biotin, dicalcium phosphate, Chromium, Coenzyme Q10, Vitamin E, d-delta tocopherol, Folate, Vitamin E, Iodine, Lutein, Manganese, Molybdenum, Niacin, Pantothenic Acid, Vitamin B6, Quercetin, Vitamin A, Riboflavin, Selenium, Thiamin, Alpha Lipoic Acid, Vitamin B12, Vitamin B6, phytonadione, Vitamin K, Zeaxanthin2024-11-29 10:47:42
Vitacost-Synergy Maximum Absorption CoQ10 featuring Q-Gel® and ETS™ -- 100 mg - 60 SoftgelsVitacost-SynergyVitamins & SupplementsCoenzyme Q10, sorbitol2024-11-29 10:47:42
Vitacost-Synergy Mega EFA CoQ10 - 1200 mg Omega-3 EPA & DHA - 100 mg CoQ10 per serving -- 120 SoftgelsVitacost-SynergyVitamins & SupplementsCoenzyme Q10, Docosahexaenoic Acid2024-11-29 10:47:42
Vitacost-Synergy Mega EFA® + CoQ10 - 1200 mg Omega-3 EPA & DHA with 100 mg CoQ10 per serving -- 60 SoftgelsVitacost-SynergyVitamins & SupplementsCoenzyme Q10, Docosahexaenoic Acid2024-11-29 10:47:42
Vitacost-Synergy Mitochondrial Energy Booster† 15-Nutrient Blend -- 120 CapsulesVitacost-SynergyVitamins & SupplementsBenfotiamine, cholecalciferol, Chromium, Coenzyme Q10, Vitamin E, Vitamin E, microcrystalline cellulose, D3, Niacin, Vitamin B6, Riboflavin, Selenium, Thiamin, Alpha Lipoic Acid, Vitamin B12, Vitamin B62024-11-29 10:47:42
Vitacost-Synergy Once Daily® Multivitamin -- 60 CapsulesVitacost-SynergyVitamins & SupplementsVitamin C, Biotin, Chromium, Coenzyme Q10, Vitamin E, Folate, Vitamin E, microcrystalline cellulose, Iodine, Lutein, Manganese, Molybdenum, Niacin, Pantothenic Acid, Vitamin B6, Quercetin, Vitamin A, Riboflavin, Selenium, Thiamin, Alpha Lipoic Acid, Vitamin B12, Vitamin B6, Vitamin K, Zeaxanthin2024-11-29 10:47:42
Vitacost-Synergy ToCoQ10® -- 100 mg - 120 SoftgelsVitacost-SynergyVitamins & SupplementsCoenzyme Q10, Vitamin E, Vitamin E, Tocotrienols2024-11-29 10:47:42
Vitacost-Synergy Twice Daily Energy† Multivitamin -- 60 CapsulesVitacost-SynergyVitamins & SupplementsVitamin C, Benfotiamine, Biotin, cholecalciferol, Chromium, Coenzyme Q10, Vitamin E, Folate, Vitamin E, Iodine, Lutein, Manganese, Vitamin K2, Menaquinone-7, Vitamin K2, Molybdenum, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Alpha Lipoic Acid, Vitamin B12, Vitamin B6, phytonadione, Vitamin K, Zeaxanthin2024-11-29 10:47:42
Vital Nutrients Once Daily Multivitamin Complete Daily Vegan For Overall Wellness -- 60 Vegan CapsulesVital NutrientsProfessional SupplementsVitamin C, Biotin, Cellulose, Chromium, Coenzyme Q10, Vitamin E, Folate, Vitamin E, Iodine, Lutein, Lycopene, Manganese, Vitamin K2, Vitamin K2, Molybdenum, Niacinamide, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Zeaxanthin2024-11-29 10:47:42
Viteyes Complete Eye & Total Body Health Multivitamin -- 180 CapsulesViteyesVitamins & SupplementsN-Acetyl Cysteine, Vitamin C, Biotin, Boron, Chromium, Coenzyme Q10, Vitamin E, Folate, Vitamin E, Inositol, Iodine, Lutein, Lycopene, Manganese, Molybdenum, Niacin, Nickel, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Taurine, Thiamin, Alpha-Lipoic Acid, Vitamin B12, Vitamin B6, Vitamin K, Zeaxanthin2024-11-29 10:47:42
Viteyes Optic Nerve Support -- 90 TabletsViteyesVitamins & SupplementsN-Acetyl Cysteine, Vitamin C, Dicalcium phosphate, Coenzyme Q10, Vitamin E, Folate, Vitamin E, microcrystalline cellulose, Quercetin Dihydrate, stearic acid, Taurine, Alpha-Lipoic Acid, Vitamin B122024-11-29 10:47:42
Zesty Paws 8-in-1 Multivitamin Bites Supplement for Dogs Chicken -- 90 Soft ChewsZesty PawsPet Supplies Lipase, Vitamin C, Biotin, Cellulase, Vitamin D3, Coenzyme Q10, Vitamin E, Folic Acid, Vitamin E, Manganese, Niacin, Pantothenic Acid, Vitamin B6, Vitamin B2, sorbic acid, Vitamin B1, Vitamin B12, Vitamin B62024-11-29 10:47:42
Zesty Paws Ancient Elements 8-in-1 Bites Multi-functional Supplement Dogs Bison -- 90 Soft ChewsZesty PawsPet Supplies Lipase, Biotin, Cellulase, Vitamin D3, Coenzyme Q10, Methylsulfonylmethane, Folic Acid, Vitamin A2024-11-29 10:47:42
Zesty Paws Hemp Elements 8-in-1 Multivitamin Supplement for Dogs Chicken -- 90 Soft ChewsZesty PawsPet Supplies Lipase, citric acid, Vitamin C, Biotin, Cellulase, Vitamin D3, citric acid, Coenzyme Q10, Vitamin E, Folic Acid, Vitamin E, powdered cellulose, Manganese, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Vitamin B2, Vitamin B1, Vitamin B-12, Vitamin B62024-11-29 10:47:42
Zesty Paws Senior Advanced 11-in-1 Multivitamin Glucosamine Supplement for Dogs Chicken -- 90 Soft ChewsZesty PawsPet Supplieslipase, Vitamin C, Biotin, cellulase, Vitamin D3, Coenzyme Q10, Vitamin E, methylsulfonylmethane, folic acid, vitamin E, powdered cellulose, Lutein, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Vitamin B2, sorbic acid, vitamin B1, vitamin B12, vitamin B62024-11-29 10:47:42

Roles (3)

RoleDescription
antioxidantA substance that opposes oxidation or inhibits reactions brought about by dioxygen or peroxides.
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
ferroptosis inhibitorAny substance that inhibits the process of ferroptosis (a type of programmed cell death dependent on iron and characterized by the accumulation of lipid peroxides) in organisms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
ubiquinonesAny benzoquinone derived from 2,3-dimethoxy-5-methylbenzoquinone; one of a group of naturally occurring homologues. The redox-active quinoid moiety usually carries a polyprenoid side chain at position 6, the number of isoprenoid units in which is species-specific. Ubiquinones are involved in the control of mitochondrial electron transport, and are also potent anti-oxidants.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (40)

PathwayProteinsCompounds
Metabolism14961108
The citric acid (TCA) cycle and respiratory electron transport14756
Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins.11019
Respiratory electron transport9113
Nucleotide metabolism89125
Nucleotide biosynthesis1246
Pyrimidine biosynthesis321
Amino acid and derivative metabolism250260
Sulfur amino acid metabolism2763
Degradation of cysteine and homocysteine1538
Sulfide oxidation to sulfate615
Citric Acid Cycle2127
Mitochondrial Electron Transport Chain2016
Congenital Lactic Acidosis2127
Fumarase Deficiency2127
Mitochondrial Complex II Deficiency2127
2-Ketoglutarate Dehydrogenase Complex Deficiency2127
Pyruvate Dehydrogenase Deficiency (E3)2127
Pyruvate Dehydrogenase Deficiency (E2)2127
Warburg Effect4652
The Oncogenic Action of 2-Hydroxyglutarate2734
The Oncogenic Action of Succinate2933
The Oncogenic Action of Fumarate2934
Glutaminolysis and Cancer3536
The Oncogenic Action of L-2-Hydroxyglutarate in Hydroxyglutaric aciduria2835
The Oncogenic Action of D-2-Hydroxyglutarate in Hydroxyglutaric aciduria2936
Renz2020 - GEM of Human alveolar macrophage with SARS-CoV-20490
Ethylmalonic encephalopathy311
Riboflavin and CoQ disorders1627
Farnesyl to CoQ10 metabolism09
rhodoquinone-10 biosynthesis05
respiration (anaerobic)-- electron acceptors reaction list021
ubiquinone-10 biosynthesis (eukaryotic)318
ubiquinone-10 biosynthesis (prokaryotic)15
Pyrimidine metabolism and related diseases1844
Ferroptosis133
TCA cycle (aka Krebs or citric acid cycle)024
TCA cycle (plant)721
Pyrimidine metabolism: de novo synthesis of UMP221
De novo synthesis of UMP221

Protein Targets (2)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency0.64240.005612.367736.1254AID624032
lamin isoform A-delta10Homo sapiens (human)Potency0.01120.891312.067628.1838AID1487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (29)

Assay IDTitleYearJournalArticle
AID642427Growth inhibition of human FRDA primary patient fibroblasts after 48 hrs by calcein-AM-based cell viability assay2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Towards a modern definition of vitamin E-evidence for a quinone hypothesis.
AID379646Antibacterial activity against sSerratia marcescens SBUG 9 at 100 ug/disk after 18 hrs by agar diffusion method2000Journal of natural products, Mar, Volume: 63, Issue:3
Ganomycins A and B, new antimicrobial farnesyl hydroquinones from the basidiomycete Ganoderma pfeifferi.
AID379643Antibacterial activity against Micrococcus flavus SBUG 16 at 100 ug/disk after 48 hrs by agar diffusion method2000Journal of natural products, Mar, Volume: 63, Issue:3
Ganomycins A and B, new antimicrobial farnesyl hydroquinones from the basidiomycete Ganoderma pfeifferi.
AID1255828Neuroprotective activity against rotenone-induced cell damage in rat PC12 cells assessed as cell viability at 10 uM after 48 hrs by MTT assay (Rvb = 53.9 +/- 7.1%)2015Journal of natural products, Oct-23, Volume: 78, Issue:10
Forsythoneosides A-D, Neuroprotective Phenethanoid and Flavone Glycoside Heterodimers from the Fruits of Forsythia suspensa.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1091094Termiticidal activity against Coptotermes formosanus placed on 1 % wt/wt compound treated filter paper assessed as termite mortality measured 21 days post compound exposure2008Journal of agricultural and food chemistry, Jun-11, Volume: 56, Issue:11
Activity of 1,4-benzoquinones against formosan subterranean termites (Coptotermes formosanus).
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID379640Antibacterial activity against Staphylococcus aureus ATCC 29213 at 100 ug/disk after 18 hrs by agar diffusion method2000Journal of natural products, Mar, Volume: 63, Issue:3
Ganomycins A and B, new antimicrobial farnesyl hydroquinones from the basidiomycete Ganoderma pfeifferi.
AID379645Antibacterial activity against sEscherichia coli SBUG 13 at 100 ug/disk after 18 hrs by agar diffusion method2000Journal of natural products, Mar, Volume: 63, Issue:3
Ganomycins A and B, new antimicrobial farnesyl hydroquinones from the basidiomycete Ganoderma pfeifferi.
AID379638Antibacterial activity against Staphylococcus aureus ATCC 6538 at 100 ug/disk after 18 hrs by agar diffusion method2000Journal of natural products, Mar, Volume: 63, Issue:3
Ganomycins A and B, new antimicrobial farnesyl hydroquinones from the basidiomycete Ganoderma pfeifferi.
AID611407Cytoprotectant activity against L-buthionine-(S,R)-sulfoximine-induced cell death in Leigh syndrome patient fibroblasts assessed as increase of cell viability up to 1000 nM2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
α-Tocotrienol quinone modulates oxidative stress response and the biochemistry of aging.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID379639Antibacterial activity against Staphylococcus aureus ATCC 25923 at 100 ug/disk after 18 hrs by agar diffusion method2000Journal of natural products, Mar, Volume: 63, Issue:3
Ganomycins A and B, new antimicrobial farnesyl hydroquinones from the basidiomycete Ganoderma pfeifferi.
AID1091127Antifeedant activity against Coptotermes formosanus placed on 1 % wt/wt compound treated filter paper assessed as filter paper consumption measured 21 days post compound exposure (Rvb = 85 +/- 15.1 mg)2008Journal of agricultural and food chemistry, Jun-11, Volume: 56, Issue:11
Activity of 1,4-benzoquinones against formosan subterranean termites (Coptotermes formosanus).
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1091095Termiticidal activity against Coptotermes formosanus placed on 1 % wt/wt compound treated filter paper assessed as termite mortality measured 11 days post compound exposure2008Journal of agricultural and food chemistry, Jun-11, Volume: 56, Issue:11
Activity of 1,4-benzoquinones against formosan subterranean termites (Coptotermes formosanus).
AID379642Antibacterial activity against Bacillus subtilis SBUG 14 at 100 ug/disk after 18 hrs by agar diffusion method2000Journal of natural products, Mar, Volume: 63, Issue:3
Ganomycins A and B, new antimicrobial farnesyl hydroquinones from the basidiomycete Ganoderma pfeifferi.
AID379641Antibacterial activity against Staphylococcus aureus SG511 at 100 ug/disk after 18 hrs by agar diffusion method2000Journal of natural products, Mar, Volume: 63, Issue:3
Ganomycins A and B, new antimicrobial farnesyl hydroquinones from the basidiomycete Ganoderma pfeifferi.
AID379647Antibacterial activity against Proteus mirabilis SBUG 47 at 100 ug/disk after 18 hrs by agar diffusion method2000Journal of natural products, Mar, Volume: 63, Issue:3
Ganomycins A and B, new antimicrobial farnesyl hydroquinones from the basidiomycete Ganoderma pfeifferi.
AID1091096Termiticidal activity against Coptotermes formosanus placed on 1 % wt/wt compound treated filter paper assessed as termite mortality measured 3 days post compound exposure2008Journal of agricultural and food chemistry, Jun-11, Volume: 56, Issue:11
Activity of 1,4-benzoquinones against formosan subterranean termites (Coptotermes formosanus).
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID736826Neuroprotective activity in mouse HT22 cells assessed as prevention from tBuOOH-induced oxidative cell death after 3 hrs by MTS assay2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Structure-activity relationship study of vitamin k derivatives yields highly potent neuroprotective agents.
AID611405Cytoprotectant activity against L-buthionine-(S,R)-sulfoximine-induced cell death in Friedreich ataxia patient fibroblasts assessed as increase of cell viability up to 1000 nM2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
α-Tocotrienol quinone modulates oxidative stress response and the biochemistry of aging.
AID379644Antibacterial activity against Pseudomonas aeruginosa ATCC 15442 at 100 ug/disk after 18 hrs by agar diffusion method2000Journal of natural products, Mar, Volume: 63, Issue:3
Ganomycins A and B, new antimicrobial farnesyl hydroquinones from the basidiomycete Ganoderma pfeifferi.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (3,228)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990233 (7.22)18.7374
1990's357 (11.06)18.2507
2000's865 (26.80)29.6817
2010's1360 (42.13)24.3611
2020's413 (12.79)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 79.59

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index79.59 (24.57)
Research Supply Index8.25 (2.92)
Research Growth Index4.94 (4.65)
Search Engine Demand Index269.63 (26.88)
Search Engine Supply Index3.72 (0.95)

This Compound (79.59)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials445 (13.10%)5.53%
Reviews453 (13.33%)6.00%
Case Studies140 (4.12%)4.05%
Observational8 (0.24%)0.25%
Other2,352 (69.22%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (123)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Blastocyst Aneuploidy Rates From Advanced Maternal Age Patients Supplemented With Coenzyme Q10 (CoQ10) Versus Those That Are Not: a Pilot Study [NCT02119117]21 participants (Actual)Interventional2014-04-30Completed
CoEnzyme Q10 in Statin Myopathy [NCT01140308]135 participants (Anticipated)Interventional2009-09-30Active, not recruiting
The Effect of Concomitant Co Enzyme Q10 Use on Pregnancy Outcome of IVF [NCT01048385]34 participants (Actual)Interventional2009-12-31Terminated(stopped due to A new study had shown that polar body biopsies might negatively effect the implantation potential of the embryo.)
Bioavailability and Impact of the Administration of Coenzyme Q10, on Mitochondrial Function Associated With Exercise Under Stress Conditions in Physically Active Individuals of Senescence Age [NCT03893864]Phase 122 participants (Actual)Interventional2018-03-01Completed
Clinical Study Evaluating the Role of Coenzyme Q10 as Adjuvant Therapy to Angiotensin Converting Enzyme Inhibitor on Blood Pressure, Proteinuria and Bone Metabolism in Patients With Chronic Kidney Disease [NCT05942027]Phase 444 participants (Anticipated)Interventional2023-07-15Not yet recruiting
Is Oxidative Stress in Semen Reduced by Lifestyle Intervention [NCT03898752]31 participants (Actual)Interventional2018-11-01Completed
The Effect of Ischemic Preconditioning and Physical Exercise on the Endocrine Function of Skeletal Muscle - the Effect of CoQ10 Supplementation. In Vivo and in Vitro Studies. [NCT05412888]100 participants (Anticipated)Interventional2023-03-01Not yet recruiting
Impact of Coenzyme Q10 and Selenium on Seminal Fluid Parameters and Antioxidant Status in Men With Idiopathic Infertility [NCT03834831]70 participants (Actual)Interventional2018-06-01Completed
Spa Rehabilitation, Antioxidant and Bioenergetic Supportive Treatment of Patients With Post-Covid-19 Syndrome [NCT05178225]51 participants (Actual)Interventional2021-05-01Completed
Efficacy of Ubiquinone and Combined Antioxidant Therapy on Progression, Oxidative Stress Markers and Mitochondrial Dysfunction in Non-proliferative Diabetic Retinopathy: A Phase 2a Randomized Double-blind Placebo-controlled Study [NCT02062034]Phase 261 participants (Actual)Interventional2011-02-28Completed
Reducing Symptom Burden in Patients With Heart Failure With Preserved Ejection Fraction Using Ubiquinol and/or D-ribose [NCT03133793]Phase 2216 participants (Actual)Interventional2018-02-05Completed
The Effect of 12-week Dietary Intake of Syrup Containing CoQ10 and Collagen on Dermis Density and Other Skin Parameters: Randomised Double-blind Placebo-controlled Study [NCT03811756]34 participants (Actual)Interventional2018-10-15Completed
Phase I Randomized, Placebo-Controlled, Cross-Over, Dose-Finding Pharmacokinetic Study of CoQ10 During One Cycle of Doxorubicin Treatment for Breast Cancer [NCT00976131]Phase 17 participants (Actual)Interventional2009-09-30Completed
[NCT01163500]Phase 2/Phase 359 participants (Actual)Interventional2008-07-31Completed
Effects of Armolipid Plus on Indices of Insulin Resistance in Patients With Metabolic Syndrome [NCT01087632]66 participants (Actual)Interventional2009-09-30Completed
Effect of Ubiquinone (Coenzyme Q10) on Early Wound Healing Following Gingival Recession Coverage: a Pilot Study [NCT04487652]30 participants (Actual)Interventional2020-09-01Completed
Effects of Coenzyme Q10 Supplementation on Oxidative Stress, Antioxidant Capacity, Inflammatory Responses, Fatigue Elimination, and Exercise Performance in Athletes From Different Sports: Cross-sectional, Interventional, and Follow-up Studies [NCT03321110]43 participants (Actual)Interventional2017-12-01Completed
Analysis of Q10 Coenzyme Efficacy for Long-term Treatment of Cyclic Vomiting Syndrome in Children [NCT03295760]15 participants (Actual)Observational2016-12-01Completed
Causal Effect of Coenzyme Q10 Nutrition and Cognitive Dysfunction in the Metabolic Storm (Hyperglycemia and Sarcopenia) and Brain-derived Neurotrophic Factor [NCT06040905]100 participants (Anticipated)Interventional2023-11-01Not yet recruiting
A Randomized and Double-blind Clinical Trial of Jiajian Guishen Granules on the Modulation of Ovarian Function in Patients With Poor Ovarian Response [NCT06089395]Early Phase 160 participants (Anticipated)Interventional2023-11-01Not yet recruiting
Assessing Bioavailability and Effects of Ubiquinol Supplementation on Biomarkers of Mitochondrial Function/Integrity, Metabolic Dysfunction, and Circulating Alarmins in Burn Patients [NCT02251626]Early Phase 150 participants (Anticipated)Interventional2014-04-30Recruiting
Neotililty Trial: Effect of Coenzyme Q10 on Semen Parameters in Men With Idiopathic Infertility [NCT03104998]Phase 40 participants (Actual)Interventional2017-08-01Withdrawn(stopped due to No further patient enrollment)
[NCT02218476]50 participants Interventional2013-09-30Recruiting
The Efficacy and Safety of Products Containing Marine Collagen Peptide and Coenzyme Q10 for Skin Rejuvenation in Malaysian Women [NCT05680857]32 participants (Actual)Interventional2022-12-01Completed
A Phase 2 Study of BPM31510 (Ubidecarenone, USP) Nanosuspension Injection Administered Intravenously With Gemcitabine as 2nd/3rdline Therapy in Advanced Pancreatic Cancer Patients [NCT02650804]Phase 249 participants (Actual)Interventional2016-07-06Completed
The Effect of Two Doses of Coenzyme Q10 on Seminal Fluid Parameters and Antioxidant Status: A Randomised Controlled Trial [NCT03850561]65 participants (Actual)Interventional2018-06-01Completed
PITT0908: Clinical Trial of Coenzyme Q10 and Lisinopril in Muscular Dystrophies [NCT01126697]Phase 2/Phase 363 participants (Actual)Interventional2010-02-28Completed
Combined Coenzyme Q10 and Clomiphene Citrate for Ovulation Induction in Clomiphene-citrate-resistant Polycystic Ovary Syndrome [NCT04302532]Phase 4149 participants (Actual)Interventional2020-07-01Completed
11 El-Saraya St. - Manial - Cairo [NCT04091698]Phase 134 participants (Anticipated)Interventional2019-10-01Not yet recruiting
Follicular Fluid Coenzyme Q10 Level in Women Undergoing Intracytoplasmic Sperm Injection [NCT04515134]100 participants (Anticipated)Observational2021-09-14Recruiting
Living With Statins - The Impact of Cholesterol Lowering Drugs on Health, Lifestyle and Well-being [NCT02796378]Phase 430 participants (Anticipated)Interventional2016-06-30Active, not recruiting
The proBNPage Reduction (PBAR) Randomized Trial: a Pilot Study to Define the Characteristics of Future Randomized Trials Aimed at Evaluating the Effects of Anti-aging Treatments on a Surrogate of Biological Age in Healthy Older Adults [NCT05500742]120 participants (Actual)Interventional2022-07-22Active, not recruiting
A Phase I Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Orally Administered BPM 31510 in Healthy Subjects [NCT02486055]Phase 120 participants (Actual)Interventional2015-11-30Completed
Coenzyme Q10 in the Amelioration of Cognitive Deficits and Symptoms in Schizophrenia and Schizoaffective Disorder [NCT03576911]72 participants (Actual)Interventional2016-11-30Active, not recruiting
A Randomized Controlled Study Using Alpha Lipoic Acid and CoQ-10 to Determine if Vestibular Function Can be Improved or Maintained Over the Course of One Year [NCT05945160]Early Phase 10 participants (Actual)Interventional2024-01-31Withdrawn(stopped due to Funding was terminated, the study will not enroll any subjects)
Safety and Tolerability of Coenzyme Q10 in Adult-Onset Sporadic Spinocerebellar Ataxia [NCT00957216]Phase 11 participants (Actual)Interventional2008-04-30Completed
"Cardiac Transfer of SARS-CoV-2 Spike Protein Circulation Techniques - Medicine Induced Hemodialysis on Vaccinated Immune Attacks" [NCT05711810]Phase 41 participants (Actual)Interventional2023-01-02Completed
Impact of Coenzyme Q10 and Meclofenoxate on Frequency and Severity of Hepatic Encephalopathy [NCT03961087]300 participants (Anticipated)Interventional2019-05-23Recruiting
Anti-oxidant Therapy and Postoperative Cardiac Events (ACE) Trial, Preoperative Intervention in Vascular Surgery [NCT03956017]Early Phase 1341 participants (Anticipated)Interventional2013-08-05Active, not recruiting
Coenzyme Q10 in Huntington's Disease (HD) [NCT00608881]Phase 3609 participants (Actual)Interventional2008-03-31Terminated(stopped due to Futility analysis failed to showed likelihoo of benefit of CoQ 2400 mg/day.)
The Effect of Ubiquinol Treatment on Cardiac Function in Patients With Heart Failure With Preserved Ejection Fraction [NCT02779634]Phase 260 participants (Anticipated)Interventional2016-07-31Not yet recruiting
A Multi-Center, Double-Blind, Randomized, Parallel Group Tolerability Study of Coenzyme Q10 (UbiquinonE)in PRE-manifest Huntington's Disease [NCT00920699]Phase 290 participants (Actual)Interventional2010-02-28Completed
Effects of Coenzyme Q10 in PSP and CBD, A Randomized, Placebo-Controlled, Double Blind Cross Over Pilot Study [NCT00532571]Phase 2/Phase 30 participants Interventional2004-01-31Completed
The Effect of Coenzyme Q10 Supplementation on the Clinical Outcome of Juvenile Idiopathic Arthritis Patients [NCT05871086]Phase 2/Phase 360 participants (Anticipated)Interventional2023-05-01Recruiting
Safety, Tolerability and Efficacy of Coenzyme Q10 in Hemodialysis Patients: Aim 1 [NCT00908297]20 participants (Actual)Interventional2010-02-28Completed
Q10 for Gulf War Veterans [NCT01011348]58 participants (Actual)Interventional2008-07-31Completed
A Randomised, Double-Blind, Placebo-Controlled Study Assessing the Effect of Fenofibrate, Coenzyme Q10 and Their co-Administration on Ventricular Diastolic Function in Patients With Type 2 Diabetes [NCT00703482]Phase 2278 participants (Actual)Interventional2003-05-31Completed
Effects of Coenzyme Q10 in Parkinson Disease - Phase III [NCT00740714]Phase 3600 participants (Actual)Interventional2008-12-31Terminated(stopped due to The investigational drug is unlikely to demonstrate efficacy over placebo for this indication. However, no safety issues were discovered.)
Effect of Coenzyme Q 10 Supplementation on Myalgia Induced by HMG-CoA Reductase Inhibitors [NCT00716612]37 participants (Actual)Interventional2009-01-31Completed
A Study of Efficacy and Safety of Idebenone vs. Placebo in Prodromal Parkinson Disease (SEASEiPPD) [NCT04152655]Phase 2/Phase 3180 participants (Anticipated)Interventional2020-01-01Recruiting
Clinical Evaluation of the Antioxidant and Neuroprotective Effects of CoQ10-MINIACTIVES® (COQUN® OS) 100 mg BID Oral Administration in Patients Affected by Primary Open Angle Glaucoma (POAG): a Randomized, Double Blind Study [NCT04038034]70 participants (Anticipated)Interventional2019-09-01Recruiting
Role of Coenzyme Q in Treatment of Attention Deficit Hyperactivity Disorder in Children [NCT04216186]Phase 340 participants (Anticipated)Interventional2018-11-01Recruiting
The Effect of Montelukast Versus Co Enzyme Q10 on the Clinical Outcome of Patients With Sepsis [NCT05293132]Phase 2/Phase 390 participants (Actual)Interventional2022-02-01Completed
Efficacy of Coenzyme Q10 Supplementation on Multi-Organ Dysfunction in Severely Burned Patients [NCT03968640]Phase 30 participants (Actual)Interventional2018-07-01Withdrawn(stopped due to Sponsor terminated award)
Assessing the Effect of the Dietary Supplement Coenzyme Q10 on Biomarkers of Oxidative Stress, Systemic Inflammation, and Endothelial Function in Hemodialysis Patients [NCT01408680]66 participants (Actual)Interventional2011-11-30Completed
Benefit of CoQ-10 in Patients on Statins [NCT00997269]37 participants (Actual)Interventional2009-09-30Completed
Pharmacokinetic Study on Three Formulations of Coenzyme Q10 With Different Carriers [NCT04035525]30 participants (Anticipated)Interventional2020-03-04Recruiting
PITT0503: Clinical Trial of Coenzyme Q10 and Prednisone in Duchenne Muscular Dystrophy [NCT00308113]Phase 33 participants (Actual)Interventional2007-04-30Terminated(stopped due to New enrollment has been suspended, currently following previously enrolled participants)
The Influence of Concomitant Co Enzyme Q10 Use on Pregnancy Outcome in Intrauterine Insemination [NCT00878124]100 participants (Anticipated)Interventional2009-06-30Terminated(stopped due to Very low recruitment rate)
The Effect of Supplemental Adjuvants for Intracellular Nutrition and Treatment on Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration [NCT00893724]60 participants (Anticipated)Interventional2009-06-30Active, not recruiting
A Randomized, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Efficacy of Coenzyme Q10 in Improving Mitochondrial Function in Older Athletes Treated With Statin Medications [NCT01026311]Phase 420 participants (Actual)Interventional2009-11-30Completed
Combined Coenzyme Q10 and Clomiphene Citrate (CC) for Ovulation Induction in CC-resistant Patients With Polycystic Ovary Syndrome [NCT01910766]110 participants (Actual)Interventional2010-01-31Completed
Influence of a Short Term Supplementation With Ubiquinol on Diverse Aspects Related to the Physical Activity (Muscle Function, Oxidative Stress and Inflammatory Signaling) [NCT01940627]Phase 2/Phase 3100 participants (Actual)Interventional2013-04-30Completed
[NCT01964001]Phase 2/Phase 371 participants (Actual)Interventional2014-01-31Completed
THE EFFECT OF COQ10 SUPPLEMENTATION ON FOLLICULAR CELLS' BIOLOGY/PROPERTIES IN ELDERLY IVF PATIENTS [NCT02010164]100 participants (Anticipated)Interventional2016-12-31Recruiting
Coenzyme Q10 and Aging: A Planning Grant [NCT02012322]44 participants (Actual)Interventional2008-11-30Completed
The Effect of the Nutritional Supplements: Ultra Q10 and L-carnitine on the Clinical Course of Myelodysplastic Syndrome [NCT02042482]Phase 2/Phase 340 participants (Anticipated)Interventional2013-05-31Recruiting
[NCT00590408]Phase 410 participants (Actual)Interventional2006-03-31Terminated(stopped due to Lack of recruitment)
Naturopathic Treatment for the Prevention of Cardiovascular Disease: a Pragmatic Randomized Controlled Trial [NCT00718796]Phase 3300 participants (Anticipated)Interventional2008-04-30Completed
Watermelon/UBIQuinone Study (WUBI-Q Trial) [NCT04972552]84 participants (Anticipated)Interventional2021-11-15Recruiting
Water-soluble Ubiquinol (a Reduced Form of Coenzyme Q10) Supplementation on Blood Glucose, Lipids, Oxidative Stress, and Inflammation in Patients With Type 2 Diabetes [NCT02622672]Phase 2/Phase 350 participants (Actual)Interventional2016-01-04Completed
Pharmacokinetics of Different CoQ10 Formulations - a Randomized, Double-blind, Single-dose, Crossover Study on the Bioavailability [NCT06151171]15 participants (Actual)Interventional2022-03-01Completed
A Randomized, Double-blind Placebo-controlled Phase III Trial of Coenzyme Q10 in Gulf War Illness [NCT02865460]Phase 3100 participants (Actual)Interventional2017-07-24Completed
Mono-center, Prospective, Double-blind, Placebo-controlled, Randomized Clinical Phase IIa Trial to Assess the Safety, Tolerability, and Immediate Biological Effects of Coenzyme Q10 - nanoQuinon® in Progressive Supranuclear Palsy [NCT00328874]Phase 220 participants (Actual)Interventional2006-05-31Completed
[NCT01424761]Phase 2/Phase 351 participants (Actual)Interventional2011-08-31Completed
Comparative Clinical Study to Evaluate the Possible Efficacy and Safety of Rosuvastatin Versus Coenzyme Q10 on Nonalcoholic Steatohepatitis [NCT05731596]Phase 346 participants (Anticipated)Interventional2023-06-30Not yet recruiting
The Effects of Exercise, Creatine, and Coenzyme Q10 Supplementation on Muscle Function in Children With Myositis [NCT04286178]15 participants (Anticipated)Interventional2021-04-06Recruiting
Clinical Trial of CoQ10 for Mild-to-Moderate Statin-Associated Muscle Symptoms [NCT01032993]Phase 2/Phase 368 participants (Actual)Interventional2009-12-31Completed
Effects of Coenzyme Q10 (CoQ10) on Subjects With Charcot-Marie-Tooth Disease (CMT):A Double Blind, Randomized, Controlled Trial With an Open Label Follow-up Study [NCT00541164]Phase 1/Phase 223 participants (Actual)Interventional2007-09-30Completed
Firefighter Aged Garlic Extract Investigation With CoQ10 as a Treatment for Heart Disease (FAITH) [NCT00860847]Phase 365 participants (Actual)Interventional2009-05-31Completed
Coenzyme Q10 Supplementation in Pregnant Women as Strategy to Reduce Maternal Morbidity Due to Preeclampsia [NCT00300937]Phase 3235 participants (Actual)Interventional2004-07-31Completed
The Effect of CoQ10 Administration on the Oxidative and Antioxidative Markers in Hemodialysis Patients [NCT00307996]Phase 440 participants Interventional2004-03-31Completed
Efficacy and Safety of Coenzyme Q10 in Pediatric Hemodialysis Patients [NCT05170893]36 participants (Actual)Interventional2022-01-17Completed
Effects of Coenzyme Q10 in Progressive Supranuclear Palsy (PSP): A Multicenter, Randomized, Placebo-controlled, Double Blind Study [NCT00382824]61 participants (Actual)Interventional2006-09-30Completed
A Pilot Study to Determine the Clinical Efficacy of Coenzyme Q10 And Curcumin in Patients With Myelodysplastic Syndromes [NCT00247026]Phase 1/Phase 250 participants Interventional2007-04-30Withdrawn(stopped due to No funding)
Impact of Co Enzyme Q10 as Adjuvant Therapy to Letrozole on Spermiogram and Sex Hormone in Iraqi Infertile Men; A Comparative Study [NCT05847257]Phase 274 participants (Actual)Interventional2021-12-01Completed
Evaluation of the Safety, Tolerability and Impact on Biomarkers of Anti-Oxidant Treatment of Mild to Moderate Alzheimer's Disease [NCT00117403]Phase 175 participants (Anticipated)Interventional2006-01-31Completed
A Multi-center, Double-blind, Pilot Study of CoQ10 and GPI 1485 in Subjects With Early Untreated Parkinson's Disease [NCT00076492]Phase 2195 participants Interventional2004-01-31Completed
[NCT00033189]Phase 215 participants Interventional2001-09-30Completed
Multicenter, Placebo Controlled, Randomized, Double-Blinded Study: Coenzyme Q10 Nanodispersion Versus Placebo as Symptomatic Treatment in Parkinson's Disease [NCT00180037]Phase 3132 participants Interventional2003-09-30Completed
Effect of Coenzyme Q10 (Ubiquinone) Supplementation on Ventricular Function of Children With Idiopathic Dilated Cardiomyopathy.A Randomised Clinical Trial [NCT02115581]Phase 438 participants (Actual)Interventional2006-09-30Completed
Oral Administration of CoQ10 and Phosphorus-31 Magnetization Transfer Magnetic Resonance Spectroscopy in Geriatric Bipolar Disorder and Healthy Older Adults [NCT00720369]42 participants (Actual)Interventional2008-07-31Completed
An Investigation Examining the Evidence for Mitochondrial Dysfunction in the Pathophysiology and Treatment of Bipolar Disorder [NCT00327756]Phase 20 participants (Actual)Interventional2006-05-31Withdrawn
Co Enzyme Q10 Improves IVF Outcome in With Advanced Reproductive Age [NCT01659788]100 participants (Anticipated)Interventional2012-09-30Not yet recruiting
[NCT01819701]Phase 2/Phase 347 participants (Actual)Interventional2013-01-31Completed
Effects of High-dose Coenzyme Q10 on Biomarkers of Oxidative Damage and Clinical Outcome in Parkinson Disease [NCT01892176]Phase 2/Phase 320 participants (Actual)Interventional2012-06-30Completed
Coenzyme Q10 as Treatment for Long Term COVID-19 [NCT04960215]Phase 2121 participants (Actual)Interventional2021-05-25Completed
A Phase I Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Orally Administered BPM31510 in Healthy Subjects [NCT03002935]Phase 125 participants (Actual)Interventional2017-01-31Completed
Evaluation of Ubiquinol on the Association of Statins and Mitochondrial Oxidative Capacity Using 31P Magnetic Resonance Imaging [NCT01702987]22 participants (Actual)Interventional2012-10-31Completed
The Effect of Coenzyme Q10 on Bone Regeneration in Jaw Defect After Cyst Enculation: A Randomized Controlled Clinical Trial [NCT05873673]Phase 220 participants (Anticipated)Interventional2023-06-11Not yet recruiting
Clinical Evaluation of Topical Coenzyme Q10 in Management of Oral Aphthous Ulcer [NCT03213769]52 participants (Anticipated)Interventional2017-07-31Not yet recruiting
The Effects of Dietary Supplement of Coenzyme Q10 on Dyslipidemia [NCT02407548]Phase 3150 participants (Actual)Interventional2015-07-31Completed
Coenzyme Q-10 in the Treatment of Pulmonary Arterial Hypertension [NCT01148836]18 participants (Actual)Interventional2010-01-31Completed
Coenzyme Q10 in Post-Cardiac Arrest Cerebral Resuscitation [NCT01319110]Phase 210 participants (Actual)Interventional2011-02-28Completed
[NCT01925937]30 participants (Anticipated)Interventional2013-06-30Recruiting
Effects of Coenzyme Q10 in Early Parkinson's Disease [NCT00004731]Phase 20 participants Interventional1998-09-30Completed
Pilot, Randomized, Placebo-controlled, Double-blind, 3-arm Parallel Groups Trial in Healthy Females to Assess Cerebral Haemodynamics and Energy Expenditure During Cognitive Performance After Supplementation With Two Different Multivitamin / Mineral Prepar [NCT02381964]106 participants (Actual)Interventional2012-03-31Completed
Evolution of Albumin on AOA1 Patients Supplemented With Coenzyme Q10 [NCT02333305]Phase 319 participants (Actual)Interventional2013-06-30Completed
Effect of Coenzyme Q10 on Markers of Endothelial Dysfunction in Pediatric Patients With Type 1 Diabetes Mellitus [NCT03111433]Phase 249 participants (Actual)Interventional2017-03-19Completed
The Efficacy and Safety of Rosuvastatin for Modifying Bone Mass and Cardiometabolic Disease Outcomes [NCT03113994]Phase 28 participants (Actual)Interventional2018-02-26Active, not recruiting
A Comparison Study to Assess the Value of Naturopathic Medicine Given Immediately and Continuously or Delayed Until Cycle 3 in Combination With Neo-Adjuvant Chemotherapy for Breast Cancer [NCT02486796]Phase 1/Phase 25 participants (Actual)Interventional2016-02-19Terminated(stopped due to Operational barriers prevent critical specimen analyses from being performed.)
A Phase I Study of BPM31510 Plus Vitamin K in Subjects With High-Grade Glioma That Has Recurred on a Bevacizumab Containing Regimen [NCT03020602]Phase 112 participants (Actual)Interventional2017-01-04Completed
Mitochondrial Complex I Dysfunction in Prader Willi Syndrome: A New Therapeutic Target [NCT03831425]Phase 214 participants (Anticipated)Interventional2023-06-01Not yet recruiting
Exploring the Effects of Coenzyme Q10 on Bioenergetics Metabolism in Geriatric Bipolar Depression: A 31 Phosphorus MR Spectroscopy Study [NCT01390389]19 participants (Actual)Interventional2011-07-31Completed
The Effect of Redox Status on Bioavailability of Ubiquinone and Ubiquinol in 10 Older Adults [NCT03020680]Phase 112 participants (Actual)Interventional2016-04-01Completed
Effect of Coenzyme Q10 Plus NADH Supplementation on the Changes in Fatigue Perception, Sleep Disturbances, Autonomic Function and Health-related Quality of Life in CFS/ME - A Randomized, Placebo-controlled, Double-blind Trial. [NCT03186027]282 participants (Actual)Interventional2017-06-28Completed
Clinical Trial of High Dose CoQ10 in ALS [NCT00243932]Phase 2185 participants (Actual)Interventional2005-04-30Completed
Real World, Open Label Prospective Experience of Supplementation With a Fixed Combination of Magnesium, Vitamin B2, Feverfew, Andrographis Paniculata and Coenzyme Q10 for Episodic Migraine Prophylaxis [NCT04463875]113 participants (Actual)Observational2018-04-01Completed
Effect of Coenzyme Q10 on the Outcome of Metabolic Dysfunction-Associated Fatty Liver Disease Patients [NCT05984745]Phase 2166 participants (Anticipated)Interventional2023-09-30Not yet recruiting
Efficacy of Combined Treatment With Co-enzyme Q10 and Methylphenidate in Children With Attention Deficit Hyperactivity Disorder [NCT02315651]60 participants (Anticipated)Interventional2015-01-31Not yet recruiting
Cross-over Randomized Controlled Trial of Coenzyme Q10 or Nicotinamide Riboside in Chronic Kidney Disease [NCT03579693]Phase 226 participants (Actual)Interventional2018-11-14Completed
Q10 Preloading Before Cardiac Surgery for Kidney Failure Reduction [NCT04445779]100 participants (Anticipated)Interventional2020-07-15Recruiting
The Effects of the Dietary Supplement Coenzyme Q10 on Inflammatory Responses in Individuals With Cardiac Surgery: A Randomized Controlled Trial [NCT04444349]300 participants (Anticipated)Interventional2020-08-01Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00243932 (1) [back to overview]Change in the ALS Functional Rating Scale-revised (ALSFRSr) Score.
NCT00382824 (5) [back to overview]Efficacy of Coenzyme Q10 (Unified Parkinson's Disease Rating Scale [UPDRS] AND Progressive Supranuclear Palsy Rating Scale [PSPRS])
NCT00382824 (5) [back to overview]Quality of Life Questionnaires: Parkinson's Disease Questionnaire - 39 [PDQ-39], Short Form-36 [SF-36]
NCT00382824 (5) [back to overview]Tolerability of Coenzyme Q10
NCT00382824 (5) [back to overview]Efficacy of Coenzyme Q10 (Mini-Mental State Examination [MMSE] and Activities of Daily Living [ADL] Scales)
NCT00382824 (5) [back to overview]Safety Profile of Coenzyme Q10
NCT00608881 (15) [back to overview]Change in Stroop Interference Test - Word Reading From Baseline to Month 60
NCT00608881 (15) [back to overview]Change in Stroop Interference Test - Color Naming From Baseline to Month 60
NCT00608881 (15) [back to overview]Change in Behavioral Frequency Score From Baseline to Month 60
NCT00608881 (15) [back to overview]Change in Behavioral Frequency x Severity Score From Baseline to Month 60
NCT00608881 (15) [back to overview]Change in Functional Checklist Score From Baseline to Month 60
NCT00608881 (15) [back to overview]Change in Independence Scale Score From Baseline to Month 60
NCT00608881 (15) [back to overview]Change in Stroop Interference Test - Interference From Baseline to Month 60
NCT00608881 (15) [back to overview]Change in Symbol Digit Modalities Test (SDMT) From Baseline to Month 60
NCT00608881 (15) [back to overview]Change in Total Functional Capacity (TFC) Score From Baseline to Month 60
NCT00608881 (15) [back to overview]Change in Total Motor Score From Baseline to Month 60
NCT00608881 (15) [back to overview]Change in Verbal Fluency Test From Baseline to Month 60
NCT00608881 (15) [back to overview]Joint Rank (Combination of Time to Death (for Subjects Who Died) and Change in Total Functional Capacity Score (TFC) From Baseline to Month 60 (for Subjects Who Survived))
NCT00608881 (15) [back to overview]Number Completing Study at Assigned Dosage Level
NCT00608881 (15) [back to overview]Time to a Three-Point Decline in TFC Score or Death
NCT00608881 (15) [back to overview]Time to a Two-Point Decline in TFC Score or Death
NCT00720369 (2) [back to overview]We Measured the Change in Rate Constant of Creatine Kinase in Individuals With Bipolar Depression Treated With CoQ 10 as Compared With Age and Gender Matched Controls. These Rate Constants Were Calculated Using Magnetic Resonance Imaging (MRI).
NCT00720369 (2) [back to overview]We Measured Response to Treatment of Depression (Using the Montgomery Asberg Depression Rating Scale)in Older Adults With Bipolar Disorder After an 8 Week Trial of CoQ10.
NCT00740714 (23) [back to overview]Change in Unified Parkinson's Disease Rating Scale (UPDRS) (Total Score (Sum of Parts I, II and III Ranges From 0 to 176))
NCT00740714 (23) [back to overview]CoQ10 Levels in Plasma
NCT00740714 (23) [back to overview]Adverse Experiences: Back Pain
NCT00740714 (23) [back to overview]Adverse Experiences: Anxiety
NCT00740714 (23) [back to overview]Adverse Experiences: Anxiety: Moderate/Severe
NCT00740714 (23) [back to overview]Adverse Experiences: Back Pain: Moderate/Severe
NCT00740714 (23) [back to overview]Adverse Experiences: Constipation
NCT00740714 (23) [back to overview]Adverse Experiences: Constipation: Moderate/Severe
NCT00740714 (23) [back to overview]Adverse Experiences: Depression
NCT00740714 (23) [back to overview]Adverse Experiences: Diarrhoea
NCT00740714 (23) [back to overview]Adverse Experiences: Headache
NCT00740714 (23) [back to overview]Adverse Experiences: Hypertension
NCT00740714 (23) [back to overview]Adverse Experiences: Insomnia
NCT00740714 (23) [back to overview]Adverse Experiences: Insomnia: Moderate/Severe
NCT00740714 (23) [back to overview]Adverse Experiences: Nasopharyngitis
NCT00740714 (23) [back to overview]Adverse Experiences: Nausea
NCT00740714 (23) [back to overview]Adverse Experiences: Tremor
NCT00740714 (23) [back to overview]Adverse Experiences: Urinary Tract Infection
NCT00740714 (23) [back to overview]Change in Hoehn & Yahr Score From Baseline to 16 Months
NCT00740714 (23) [back to overview]Change in Modified Rankin Scale From Baseline to 16 Months
NCT00740714 (23) [back to overview]Change in Modified Schwab & England Independence Scale From Baseline to 16 Months
NCT00740714 (23) [back to overview]Change in PD Quality of Life Scale From Baseline to 16 Months
NCT00740714 (23) [back to overview]Change in Symbol Digit Modalities Test From Baseline to 16 Months
NCT00860847 (1) [back to overview]Rate of Change in Total Coronary Calcium Scores by Computed Tomography
NCT00920699 (3) [back to overview]Tolerability as Assessed by Ability to Complete the Study on the Originally Randomized Treatment Assignment.
NCT00920699 (3) [back to overview]CoQ10 Levels
NCT00920699 (3) [back to overview]8OHdG Levels
NCT01032993 (4) [back to overview]Percentage of Participants With Adverse Effects
NCT01032993 (4) [back to overview]Continuation of Statin
NCT01032993 (4) [back to overview]Percentage of Participants With Improvement in Disability Related to Muscle Pain
NCT01032993 (4) [back to overview]Percentage of Participants With Reduction in Muscle Pain Associated With Statin Use
NCT01148836 (10) [back to overview]Red Blood Cells
NCT01148836 (10) [back to overview]Right Ventricle Myocardial Performance
NCT01148836 (10) [back to overview]Right Ventricular Outflow
NCT01148836 (10) [back to overview]Tricuspid Regurgitation Grade
NCT01148836 (10) [back to overview]Right Atrial Pressure
NCT01148836 (10) [back to overview]Hematocrit
NCT01148836 (10) [back to overview]Hemoglobin
NCT01148836 (10) [back to overview]Left Ventricular End Diastolic Volume
NCT01148836 (10) [back to overview]Mean Corpuscular Hemoglobin
NCT01148836 (10) [back to overview]Red Blood Cell Distribution Width
NCT01319110 (1) [back to overview]Prevalence of Low Serum CoQ10 Levels in Cardiac Arrest Patients
NCT01390389 (2) [back to overview]Mean Concentrations of Cerebral Energetic Metabolites in Geriatric BPD and Older Controls at Baseline
NCT01390389 (2) [back to overview]To Determine Effects of CoQ 10 on Bioenergetics (PCr and Beta NTP) in Older Adults With Bipolar Depression.
NCT01702987 (1) [back to overview]Phosphocreatine Recovery
NCT02115581 (3) [back to overview]Improvement in Left Ventricular Filling Abnormality
NCT02115581 (3) [back to overview]Improvement in Left Ventricular Ejection Fraction
NCT02115581 (3) [back to overview]Adverse Events
NCT02486796 (5) [back to overview]Subject Reported Quality of Life Score
NCT02486796 (5) [back to overview]Concentration of C-reactive Protein in Serum (mg/L)
NCT02486796 (5) [back to overview]Concentration of Circulating Tumor Cells in Blood (Cells Per Milliliter)
NCT02486796 (5) [back to overview]Sedimentation Rate of Erythrocytes in Blood (mm/hr)
NCT02486796 (5) [back to overview]Subject Reported Quality of Life Score
NCT02865460 (31) [back to overview]Response to Therapy on Hypothalamic-Pituitary-Gonadal (HPG) Axis: Progesterone
NCT02865460 (31) [back to overview]Response to Therapy on Hypothalamic-Pituitary-Gonadal (HPG) Axis: Testosterone
NCT02865460 (31) [back to overview]Response to Therapy on Hypothalamic-Pituitary-Thyroid (HPT) Axis: FT3
NCT02865460 (31) [back to overview]Response to Therapy on Hypothalamic-Pituitary-Thyroid (HPT) Axis: TSH
NCT02865460 (31) [back to overview]Veterans Short Form 36-Item Health Survey Physical Component Summary
NCT02865460 (31) [back to overview]Veterans Short Form 36-Item Health Survey: Mental Component Score (MCS)
NCT02865460 (31) [back to overview]Connors Continuous Performance Test (CPT-3):Omissions T-score
NCT02865460 (31) [back to overview]Connors Continuous Performance Test (CPT-3):Commissions T-score
NCT02865460 (31) [back to overview]Connors Continuous Performance Test (CPT-3): Hit Reaction Time
NCT02865460 (31) [back to overview]California Verbal Learning Test (CVLT-II): Short Delay
NCT02865460 (31) [back to overview]California Verbal Learning Test (CVLT-II): Correct Trials # 1-5
NCT02865460 (31) [back to overview]Brief Visual Memory Test (BVMT): Percent Retained
NCT02865460 (31) [back to overview]Brief Visual Memory Test (BVMT): Delayed Recall
NCT02865460 (31) [back to overview]Brief Pain Inventory
NCT02865460 (31) [back to overview]California Verbal Learning Test (CVLT-II): Long Delay Test
NCT02865460 (31) [back to overview]FitBit Sleep Measurement - Total Sleep
NCT02865460 (31) [back to overview]FitBit Sleep Measurement - Types of Sleep
NCT02865460 (31) [back to overview]Gulf War Illness Health Symptom Checklist
NCT02865460 (31) [back to overview]Hamilton Anxiety Scale (HAM-A)
NCT02865460 (31) [back to overview]Hamilton Depression Scale (HAM-D)
NCT02865460 (31) [back to overview]Multidimensional Fatigue Inventory (MFI)
NCT02865460 (31) [back to overview]Davidson Trauma Scale
NCT02865460 (31) [back to overview]Pittsburgh Sleep Quality Index
NCT02865460 (31) [back to overview]Response to Therapy of Gulf War Illness-associated Peripheral Blood Biomarkers - Complete Blood Count (CBC) Hemoglobin
NCT02865460 (31) [back to overview]Response to Therapy of Gulf War Illness-associated Peripheral Blood Biomarkers - Complete Blood Count (CBC) White Blood Cell Percentages
NCT02865460 (31) [back to overview]Response to Therapy of Gulf War Illness-associated Peripheral Blood Biomarkers - Complete Blood Count (CBC) Red Blood Cell (RBC) Counts
NCT02865460 (31) [back to overview]Response to Therapy of Gulf War Illness-associated Peripheral Blood Biomarkers - Complete Blood Count (CBC) White Blood Cell Counts and Platelets
NCT02865460 (31) [back to overview]Response to Therapy of Gulf War Illness-associated Peripheral Blood Biomarkers - Complete Blood Count (CBC) Hematocrit
NCT02865460 (31) [back to overview]Response to Therapy on Hypothalamic-Pituitary-Thyroid (HPT) Axis: FT4
NCT02865460 (31) [back to overview]Response to Therapy on Cortisol Levels
NCT02865460 (31) [back to overview]Response to Therapy on Hypothalamic-Pituitary-Gonadal (HPG) Axis: Estradiol
NCT03133793 (8) [back to overview]Change in Lactate
NCT03133793 (8) [back to overview]Change in 6 Minute Walk Test (6MWT)
NCT03133793 (8) [back to overview]Change in Adenosine Triphosphate (ATP)
NCT03133793 (8) [back to overview]Change in Vigor
NCT03133793 (8) [back to overview]Change in Health Status of Patients With HFpEF
NCT03133793 (8) [back to overview]Change in Venous Blood B-type Natriuretic Peptide (BNP) Levels
NCT03133793 (8) [back to overview]Change in Ejection Fraction (EF)
NCT03133793 (8) [back to overview]Change in Septal E/e'
NCT03579693 (2) [back to overview]Maximal Aerobic Capacity- CoQ10
NCT03579693 (2) [back to overview]Work Efficiency

Change in the ALS Functional Rating Scale-revised (ALSFRSr) Score.

The ALSFRSr, a questionnaire-based scale assessing daily living function ranging from 48 (best score) to 0 (worst), was administered to the patient, or to a proxy if the patient could not communicate effectively. Decline was defined as ALSFRSr at baseline minus ALSFRSr at month 9. Thus a positive value indicates worsening. (NCT00243932)
Timeframe: 9 months

Interventionunits on a scale (Mean)
2700mg CoQ108.80
Placebo9.44
1,800 mg CoQ1010.9

[back to top]

Efficacy of Coenzyme Q10 (Unified Parkinson's Disease Rating Scale [UPDRS] AND Progressive Supranuclear Palsy Rating Scale [PSPRS])

"Unified Parkinson's Disease Rating Scale [UPDRS]: Higher scores indicate a higher degree of impairment The total score is calculated by summing the subscores. Total scores range from 0 (normal) to 166 (severely impaired) Part I [Mentation, Behavior, & Mood] Scale: 0-16 Part II [Activities of Daily Living, Both ON & OFF] Scale:0-52 Part III [Motor Examination] Scale: 0-56 Part IV [Complications of Therapy] Scale: 0-34 Part V [Modified Hoehn & Yahr Staging] Scale: 0-8 Part VI [Schwab & England Activities of Daily Living Scale] Scale: 0 - 100%~Progressive Supranuclear Palsy Rating Scale [PSPRS] - Total Scale ranges from 0 (normal) to 128 (severely impaired) Section 1 [History] Scale: 0-31 Section 2 [Mentation] Scale: 0-20 Section 3 [Bulbar] Scale: 0-10 Section 4 [Ocular Motor] Scale: 0-20 Section 5 [Limb Motor] Scale: 0-22 Section 6 [Gait and midline] Scale: 0-25" (NCT00382824)
Timeframe: 12 months

,
Interventionunits on a scale (Mean)
Change in UPDRS scoresChange in PSPRS scores
Coenzyme Q10 (2400mg/Day)5.911.5
Placebo11.812.8

[back to top]

Quality of Life Questionnaires: Parkinson's Disease Questionnaire - 39 [PDQ-39], Short Form-36 [SF-36]

"Parkinson's Disease Questionnaire - 39 (PDQ-39): 39 Items. 8 subscales: mobility, activities of daily living, emotional well-being, stigma, social support , cognitions, communication, bodily discomfort. Subjects indicate never (0 pts), occasionally (1 pts), sometimes (2pts), often (3pts), or always/cannot do at all (4pts) for each item in each section. The sum of scores of each item in the dimension divided by the maximum possible score of all the items in the dimension, multiplied by 100. Range of scores for each dimension: 0-100. The sum of dimension total scores are divided by 8 to calculate the Parkinson's Disease Severity Index. Range of total score for the Parkinsons' Disease Severity Index: 0-100. Lower scores indicate better quality of life.~Short Form-36 (SF-36): 36 items 8 subscales: (2) General Health Sections, Limitations of Activities, Physical Health Problems, Emotional Health Problems, Pain, (2) Social Activities sections, and Energy and Emotions. Each qu" (NCT00382824)
Timeframe: 12 months

,
Interventionunits on a scale (Mean)
Change in Parkinson's Disease Questionnaire scoresChange in Short Form-36 Scores
Coenzyme Q10 (2400mg/Day)3.4-2.1
Placebo7.5-7.2

[back to top]

Tolerability of Coenzyme Q10

"The tolerability of Coenzyme Q10 as determined by the number of subjects who complete the study on their original treatment assignment, and~The tolerability of Coenzyme Q10 as determined by the number of subjects completing the study." (NCT00382824)
Timeframe: 12 months

InterventionParticipants (Number)
Coenzyme Q10 (2400mg/Day)20
Placebo16

[back to top]

Efficacy of Coenzyme Q10 (Mini-Mental State Examination [MMSE] and Activities of Daily Living [ADL] Scales)

"Efficacy of Coenzyme Q10 measured by change in intellectual function (the Mini-Mental State Examination [MMSE]) and Activities of Daily Living (ADL) scores.~MMSE: 30 point scale with 5 subsections (Total Score Range: minimum score = 0, maximum = 30): Orientation (max=10 pts, min=0 pts), Registration (max=3 pts, min=0 pts), Attention & Calculation (max=5pts, min=0 pts), Recall (max=3 pts, min= 0 pts), Language & Praxis (max=9 pts, min=0 pts). Lower scores indicate greater impairment. Scores <24 are considered abnormal.~Activities of Daily Living scores:~The UPDRS part II is used to assess subject's degree in which they can perform their Activities of Daily Living. Part II of the UPDRS rates subjects on a 0-4 scale, with 0 being Normal and 4 being Severe Impairment, for each respective item. For each item, the reported score is divided by the maximum total score for that item and multiplied by 100 to give a 0-100 scale range. Higher scores indicate greater impairment." (NCT00382824)
Timeframe: 12 months

,
Interventionunits on a scale (Mean)
Change in ADL scoresChange in MMSE scores
Coenzyme Q10 (2400mg/Day)-13.5-1.3
Placebo-18.4-1.3

[back to top]

Safety Profile of Coenzyme Q10

The safety Profile of Coenzyme Q10 as determined by the analysis of the frequency and severity of the adverse event data, changes in the vital signs, electrocardiograms and clinical laboratory values, recorded over the course of the trial. (NCT00382824)
Timeframe: 12 months

,
InterventionAdverse Events (Number)
Adverse EventsSerious Adverse Events
Coenzyme Q10 (2400mg/Day)275
Placebo388

[back to top]

Change in Stroop Interference Test - Word Reading From Baseline to Month 60

Stroop Interference Test - word reading score is the total number of correct words read in 45 seconds and reflects processing speed. (NCT00608881)
Timeframe: Baseline and Month 60

Interventionunits on a scale (Least Squares Mean)
A - Coenzyme Q10 2400 mg/Day-15.25
B - Placebo-19.13

[back to top]

Change in Stroop Interference Test - Color Naming From Baseline to Month 60

Stroop Interference Test - color naming score is the total number of correct colors identified in 45 seconds and reflects processing speed. (NCT00608881)
Timeframe: Baseline and Month 60

Interventionunits on a scale (Least Squares Mean)
A - Coenzyme Q10 2400 mg/Day-14.21
B - Placebo-14.51

[back to top]

Change in Behavioral Frequency Score From Baseline to Month 60

The Unified Huntington's Disease Rating Scale (UHDRS) behavioral subscale assesses frequency and severity of psychiatric-related symptoms, including depressed mood, apathy, low self-esteem/guilt, suicidal thoughts, anxiety, irritable behavior, aggressive behavior, obsessional thinking, compulsive behavior, delusions, and hallucinations. A total score was calculated by summing up all the individual behavioral frequency items (range 0-56) with higher scores representing more severe behavioral impairment. (NCT00608881)
Timeframe: Baseline and Month 60

Interventionunits on a scale (Least Squares Mean)
A - Coenzyme Q10 2400 mg/Day1.39
B - Placebo1.43

[back to top]

Change in Behavioral Frequency x Severity Score From Baseline to Month 60

The Unified Huntington's Disease Rating Scale (UHDRS) behavioral subscale assesses frequency and severity of psychiatric-related symptoms, including depressed mood, apathy, low self-esteem/guilt, suicidal thoughts, anxiety, irritable behavior, aggressive behavior, obsessional thinking, compulsive behavior, delusions, and hallucinations. The total score is the sum of the product of the individual behavioral frequency and severity items (range 0-176) with higher scores representing more severe behavioral impairment. (NCT00608881)
Timeframe: Baseline and Month 60

Interventionunits on a scale (Least Squares Mean)
A - Coenzyme Q10 2400 mg/Day4.29
B - Placebo5.06

[back to top]

Change in Functional Checklist Score From Baseline to Month 60

"The functional assessment checklist includes 25 questions about common daily tasks. A score of 1 is given for each yes reply and a score of 0 is given for each no reply (scale range is 0-25). Higher scores indicate better functioning." (NCT00608881)
Timeframe: Baseline and Month 60

Interventionunits on a scale (Mean)
A - Coenzyme Q10 2400 mg/Day-7.93
B - Placebo-8.02

[back to top]

Change in Independence Scale Score From Baseline to Month 60

The independence scale assesses independence on a 0 to 100 scale with higher scores indicating better functioning. (NCT00608881)
Timeframe: Baseline and Month 60

Interventionunits on a scale (Mean)
A - Coenzyme Q10 2400 mg/Day-26.30
B - Placebo-24.86

[back to top]

Change in Stroop Interference Test - Interference From Baseline to Month 60

Stroop Interference Test - interference score is the total number of correct items identified in 45 seconds and reflects an executive measure of inhibitory ability. (NCT00608881)
Timeframe: Baseline and Month 60

Interventionunits on a scale (Least Squares Mean)
A - Coenzyme Q10 2400 mg/Day-7.57
B - Placebo-8.61

[back to top]

Change in Symbol Digit Modalities Test (SDMT) From Baseline to Month 60

The SDMT assesses attention, visuoperceptual processing, working memory, and cognitive/psychomotor speed. The score is the number of correctly paired abstract symbols and specific numbers in 90 seconds with higher scores indicating better cognitive functioning. (NCT00608881)
Timeframe: Baseline and Month 60

Interventionunits on a scale (Least Squares Mean)
A - Coenzyme Q10 2400 mg/Day-10.95
B - Placebo-11.36

[back to top]

Change in Total Functional Capacity (TFC) Score From Baseline to Month 60

TFC consists of five ordinally scaled items assessing a person's capacity with: (1) occupation; (2) financial affairs; (3) domestic responsibilities; (4) activities of daily living; and (5) independent living. Total score ranges from zero (worst) to 13 (best). (NCT00608881)
Timeframe: Baseline and Month 60

Interventionunits on a scale (Least Squares Mean)
A - Coenzyme Q10 2400 mg/Day-4.53
B - Placebo-4.76

[back to top]

Change in Total Motor Score From Baseline to Month 60

The motor section of the Unified Huntington's Disease Rating Scale (UHDRS) assesses motor features of Huntington disease with standardized ratings of oculomotor function, dysarthria, chorea, dystonia, gait, and postural stability. The total motor score is the sum of all the individual motor ratings, with higher scores (124) indicating more severe motor impairment than lower scores. The score ranges from 0 to 124. (NCT00608881)
Timeframe: Baseline and Month 60

Interventionunits on a scale (Least Squares Mean)
A - Coenzyme Q10 2400 mg/Day18.06
B - Placebo19.18

[back to top]

Change in Verbal Fluency Test From Baseline to Month 60

The verbal fluency test is typically considered a measure of executive function. The score is the number of correct words produced across three 1-minute trials. (NCT00608881)
Timeframe: Baseline and Month 60

Interventionunits on a scale (Least Squares Mean)
A - Coenzyme Q10 2400 mg/Day-5.07
B - Placebo-4.47

[back to top]

Joint Rank (Combination of Time to Death (for Subjects Who Died) and Change in Total Functional Capacity Score (TFC) From Baseline to Month 60 (for Subjects Who Survived))

The primary outcome variable at the start of the trial was the change in TFC score from baseline to Month 60. The Data and Safety Monitoring Board recommended to the trial leadership that they reconsider how they accommodate missing data from subjects who die in their primary analysis of the change in TFC score. Based on these recommendations, the trial leadership changed the primary analysis to that of a joint rank approach. TFC consists of five ordinally scaled items assessing a person's capacity with: (1) occupation; (2) financial affairs; (3) domestic responsibilities; (4) activities of daily living; and (5) independent living. Total score ranges from zero (worst) to 13 (best). (NCT00608881)
Timeframe: 5 years

Interventionrank (Mean)
A - Coenzyme Q10 2400 mg/Day303.3
B - Placebo306.7

[back to top]

Number Completing Study at Assigned Dosage Level

(NCT00608881)
Timeframe: 5 years

Interventionparticipants completing study on drug (Number)
A - Coenzyme Q10 2400 mg/Day98
B - Placebo108

[back to top]

Time to a Three-Point Decline in TFC Score or Death

TFC consists of five ordinally scaled items assessing a person's capacity with: (1) occupation; (2) financial affairs; (3) domestic responsibilities; (4) activities of daily living; and (5) independent living. Total score ranges from zero (worst) to 13 (best). (NCT00608881)
Timeframe: 5 years

Interventiondays to event (Median)
A - Coenzyme Q10 2400 mg/Day917
B - Placebo911

[back to top]

Time to a Two-Point Decline in TFC Score or Death

TFC consists of five ordinally scaled items assessing a person's capacity with: (1) occupation; (2) financial affairs; (3) domestic responsibilities; (4) activities of daily living; and (5) independent living. Total score ranges from zero (worst) to 13 (best). (NCT00608881)
Timeframe: 5 years

Interventiondays to event (Median)
A - Coenzyme Q10 2400 mg/Day553
B - Placebo549

[back to top]

We Measured the Change in Rate Constant of Creatine Kinase in Individuals With Bipolar Depression Treated With CoQ 10 as Compared With Age and Gender Matched Controls. These Rate Constants Were Calculated Using Magnetic Resonance Imaging (MRI).

The rate constant for creatine kinase is a measurement of the reaction rate ADP+PCr <---> ATP + Cr, which is catalyzed by the enzyme creatine kinase. The rate constant shows the direction and magnitude of the reaction at equilibrium. A higher rate constant indicates a higher rate constant of the CK enzyme, meaning, more efficient/rapid conversion of PCr to ATP through the creatine kinase enzymatic reaction in tissues with high and fluctuating energy demands such as brain and muscle tissue. As the value is a reaction rate, there are no associated units. (NCT00720369)
Timeframe: 8 week trial

Interventionper second (Mean)
CoQ100.02
Healthy Controls0.03

[back to top]

We Measured Response to Treatment of Depression (Using the Montgomery Asberg Depression Rating Scale)in Older Adults With Bipolar Disorder After an 8 Week Trial of CoQ10.

"The Montgomery Asberg Depression Rating Scale (MADRS) is a 10 question questionnaire which assesses symptom severity of depression. The score is on a 0-60 scale with higher numbers indicating more severe depressive symptoms. The score is represented as a number of points.~Clinical improvement following treatment with CoQ10 supplement was only tested in the Bipolar subject cohort, not in healthy controls, therefore outcome data only apply to the bipolar group." (NCT00720369)
Timeframe: 8 week trial

Interventionunits on a scale (Mean)
Pre-Treatment (baseline)Post-Treatment (week 8)
CoQ1021.418.4

[back to top]

Change in Unified Parkinson's Disease Rating Scale (UPDRS) (Total Score (Sum of Parts I, II and III Ranges From 0 to 176))

Outcome is defined as change in total Unified Parkinson's Disease Rating Scale (UPDRS) between the baseline visit and month 16 or the time of sufficient disability to require dopaminergic therapy or study closure, whichever occurs first. The UPDRS score has three components, each consisting of questions answered on a 0-4 point scale. Part I assesses mentation, behavior and mood; Part II assesses activities of daily living in the week prior to the designated visit; and Part III assesses motor abilities at the time of the visit. A total of 31 items are included in Parts I, II and III. Each item will receive a score ranging from 0 to 4 where 0 represents the absence of impairment and 4 represents the highest degree of impairment. Total score ranges from 0-176. (NCT00740714)
Timeframe: Baseline to 16 months or the time of sufficient disability to require dopaminergic therapy or study closure, whichever occurs first

Interventionunits on a scale (Least Squares Mean)
A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day8.01
B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day7.50
C. Placebo With Vitamin E 1200 IU/Day6.92

[back to top]

CoQ10 Levels in Plasma

Based on samples analyzed to date (NCT00740714)
Timeframe: Baseline, 1, 8 and 16 months or the time of sufficient disability to require dopaminergic therapy or study closure, whichever occurs first

,,
Interventionug/ml (Mean)
1 month visit8 month visit16 month visit
A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day3.553.322.88
B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day2.572.672.17
C. Placebo With Vitamin E 1200 IU/Day.751.07.63

[back to top]

Adverse Experiences: Back Pain

Number of participants with back pain (NCT00740714)
Timeframe: Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)

Interventionparticipants (Number)
A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day9
B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day13
C. Placebo With Vitamin E 1200 IU/Day9

[back to top]

Adverse Experiences: Anxiety

Number of participants with anxiety (NCT00740714)
Timeframe: Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)

Interventionparticipants (Number)
A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day12
B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day13
C. Placebo With Vitamin E 1200 IU/Day14

[back to top]

Adverse Experiences: Anxiety: Moderate/Severe

Number of participants with moderate/severe anxiety (NCT00740714)
Timeframe: Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)

Interventionparticipants (Number)
A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day9
B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day9
C. Placebo With Vitamin E 1200 IU/Day7

[back to top]

Adverse Experiences: Back Pain: Moderate/Severe

Number of participants with moderate/severe back pain (NCT00740714)
Timeframe: Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)

Interventionparticipants (Number)
A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day7
B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day9
C. Placebo With Vitamin E 1200 IU/Day7

[back to top]

Adverse Experiences: Constipation

Number of participants with constipation (NCT00740714)
Timeframe: Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)

Interventionparticipants (Number)
A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day7
B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day13
C. Placebo With Vitamin E 1200 IU/Day7

[back to top]

Adverse Experiences: Constipation: Moderate/Severe

Number of participants with moderate/severe constipation (NCT00740714)
Timeframe: Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)

Interventionparticipants (Number)
A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day3
B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day10
C. Placebo With Vitamin E 1200 IU/Day3

[back to top]

Adverse Experiences: Depression

Number of participants with depression (NCT00740714)
Timeframe: Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)

Interventionparticipants (Number)
A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day9
B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day6
C. Placebo With Vitamin E 1200 IU/Day14

[back to top]

Adverse Experiences: Diarrhoea

Number of participants with diarrhoea (NCT00740714)
Timeframe: Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)

Interventionparticipants (Number)
A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day6
B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day9
C. Placebo With Vitamin E 1200 IU/Day11

[back to top]

Adverse Experiences: Headache

Number of participants with headache (NCT00740714)
Timeframe: Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)

Interventionparticipants (Number)
A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day9
B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day8
C. Placebo With Vitamin E 1200 IU/Day11

[back to top]

Adverse Experiences: Hypertension

Number of participants with hypertension (NCT00740714)
Timeframe: Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)

Interventionparticipants (Number)
A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day5
B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day7
C. Placebo With Vitamin E 1200 IU/Day0

[back to top]

Adverse Experiences: Insomnia

Number of participants with insomnia (NCT00740714)
Timeframe: Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)

Interventionparticipants (Number)
A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day6
B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day13
C. Placebo With Vitamin E 1200 IU/Day6

[back to top]

Adverse Experiences: Insomnia: Moderate/Severe

Number of participants with moderate/severe insomnia (NCT00740714)
Timeframe: Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)

Interventionparticipants (Number)
A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day2
B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day9
C. Placebo With Vitamin E 1200 IU/Day0

[back to top]

Adverse Experiences: Nasopharyngitis

Number of participants with nasopharyngitis (NCT00740714)
Timeframe: Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)

Interventionparticipants (Number)
A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day7
B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day9
C. Placebo With Vitamin E 1200 IU/Day3

[back to top]

Adverse Experiences: Nausea

Number of participants with nausea (NCT00740714)
Timeframe: Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)

Interventionparticipants (Number)
A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day7
B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day7
C. Placebo With Vitamin E 1200 IU/Day10

[back to top]

Adverse Experiences: Tremor

Number of participants with tremor (NCT00740714)
Timeframe: Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)

Interventionparticipants (Number)
A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day10
B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day13
C. Placebo With Vitamin E 1200 IU/Day8

[back to top]

Adverse Experiences: Urinary Tract Infection

Number of patients with urinary tract infections (NCT00740714)
Timeframe: Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)

Interventionparticipants (Number)
A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day6
B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day8
C. Placebo With Vitamin E 1200 IU/Day3

[back to top]

Change in Hoehn & Yahr Score From Baseline to 16 Months

The Modified Hoehn and Yahr Scale is an 8-level Parkinson disease staging instrument. The investigator will assess disease stage at each level. The disease stages range from the best outcome of 0 (no signs of disease) to the worst outcome of 5 (wheelchair bound or bedridden unless aided). (NCT00740714)
Timeframe: Baseline to 16 months or the time of sufficient disability to require dopaminergic therapy or study closure, whichever occurs first

Interventionunits on a scale (Least Squares Mean)
A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day.21
B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day.20
C. Placebo With Vitamin E 1200 IU/Day.16

[back to top]

Change in Modified Rankin Scale From Baseline to 16 Months

The Modified Rankin Scale is a global functional health index with a strong accent on physical disability. Subjects are scored on a scale of 0 (no symptoms at all) to 5 (severe disability: bedridden incontinent, and requiring constant nursing care and attention. (NCT00740714)
Timeframe: Baseline to 16 months or the time of sufficient disability to require dopaminergic therapy or study closure, whichever occurs first

Interventionunits on a scale (Least Squares Mean)
A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day.38
B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day.31
C. Placebo With Vitamin E 1200 IU/Day.40

[back to top]

Change in Modified Schwab & England Independence Scale From Baseline to 16 Months

This scale measures activities of daily living. This is an investigator and subject assessment of the subject's level of independence at all scheduled visits. The subject is scored on a percentage scale reflective of his/her ability to perform acts of daily living in relation to pre-Parkinson disease ability. Scores range in increments of 10%: 100% for normal (subject is completely independent; essentially normal) to 0% (vegetative functions such as swallowing, bladder and bowel functions are not functioning; bedridden). (NCT00740714)
Timeframe: Baseline to 16 months or the time of sufficient disability to require dopaminergic therapy or study closure, whichever occurs first

Interventionunits on a scale (Least Squares Mean)
A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day-4.94
B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day-4.29
C. Placebo With Vitamin E 1200 IU/Day-4.07

[back to top]

Change in PD Quality of Life Scale From Baseline to 16 Months

The subject will complete a questionnaire that will evaluate how Parkinson disease has affected their health and overall quality of life at each visit. The total quality of life scale measures a total of 33 aspects of quality of life. Each aspect is rated on scale of 0 (best outcome) to 4 (worst outcome). Total score range is 0-132. A higher score or increased score compared to a previous visit indicates a lowered quality of life. (NCT00740714)
Timeframe: Baseline to 16 months or the time of sufficient disability to require dopaminergic therapy or study closure, whichever occurs first

Interventionunits on a scale (Least Squares Mean)
A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day5.06
B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day6.12
C. Placebo With Vitamin E 1200 IU/Day5.57

[back to top]

Change in Symbol Digit Modalities Test From Baseline to 16 Months

The Symbol Digit Modalities Test screens cognitive impairment by using a simple substitution tasks that individuals with normal functioning can easily perform. The test score range is from 0(worst outcome) to 110 (best outcome). (NCT00740714)
Timeframe: Baseline to 16 months or the time of sufficient disability to require dopaminergic therapy or study closure, whichever occurs first

Interventionunits on a scale (Least Squares Mean)
A. Coenzyme Q10 2400 mg/Day With Vitamin E 1200 IU/Day-3.36
B. Coenzyme Q10 1200 mg/Day With Vitamin E 1200 IU/Day-0.49
C. Placebo With Vitamin E 1200 IU/Day-3.02

[back to top]

Rate of Change in Total Coronary Calcium Scores by Computed Tomography

progression of coronary artery calcium deposits as determined by computed tomography as measured by the Agatston score: The Agatston score was calculated by multiplying the lesion area (mm^2) by a density factor. The density was measured in Hounsfield units, and score of 1 for 130-199 HU, 2 for 200-299 HU, 3 for 300-399 HU, and 4 for 400 HU and greater The endpoint is the mean change (end of study value - baseline value) in each group. (NCT00860847)
Timeframe: 1 year

InterventionAgatston score change (Mean)
Aged Garlic Extract and Coenzyme Q1032
Placebo58

[back to top]

Tolerability as Assessed by Ability to Complete the Study on the Originally Randomized Treatment Assignment.

No dosage modifications, reported as a % (NCT00920699)
Timeframe: 20 weeks

Interventionpercentage of participants (Number)
600 mg Per Day of CoQ1090.0
1200 mg Per Day of CoQ1093.1
2400 mg Per Day of CoQ1081.3

[back to top]

CoQ10 Levels

ng/ml (NCT00920699)
Timeframe: change from baseline to 20 weeks

Interventionng/ml (Mean)
600 mg Per Day of CoQ101.82
1200 mg Per Day of CoQ101.92
2400 mg Per Day of CoQ102.33

[back to top]

8OHdG Levels

ng/ml. Negative value signifies an decrease in 8OHdG levels (NCT00920699)
Timeframe: change from baseline to 20 weeks

Interventionng/ml (Mean)
600 mg Per Day of CoQ100.15
1200 mg Per Day of CoQ10-1.56
2400 mg Per Day of CoQ100.55

[back to top]

Percentage of Participants With Adverse Effects

serious adverse effects and possible side effects were tracked through all phases of the study by participant interview and checklist at each visit, up to 4 weeks. (NCT01032993)
Timeframe: 4 weeks

,
Intervention% of participants reporting (Number)
Nausea/dyspepsiaFatigue
Coenzyme Q102110
Placebo1010

[back to top]

Continuation of Statin

Adherence of statin use was defined a priori as participant using Simvastatin 20 mg /day at the end of 4 weeks and having used >85% of statin doses. (NCT01032993)
Timeframe: 4 weeks

,
Interventionparticipants (Number)
Adherent with Statin at 4 wksNot Adherent with Statin at 4 wks
Coenzyme Q10172
Placebo182

[back to top] [back to top]

Percentage of Participants With Reduction in Muscle Pain Associated With Statin Use

Clinically significant pain reduction was defined, a priori, as a reduction > 1.5 points on the Brief Pain Inventory-Severity Scale (BPI-SS), range: 0 to 10 (NCT01032993)
Timeframe: 4 weeks

Intervention% of participants with pain reduction (Number)
Coenzyme Q1053
Placebo65

[back to top]

Red Blood Cells

(NCT01148836)
Timeframe: before and after three months of CoQ

,
Intervention10^6 cells/µl (Mean)
Before Co-QAfter Co-Q
Normal Controls4.54.3
Pulmonary Hypertension Subjects5.25.2

[back to top]

Right Ventricle Myocardial Performance

Tei Index=(IRT+ICT)/ET, where IRT is isovolumic (NCT01148836)
Timeframe: before and after three months of CoQ

Interventionratio (Mean)
Before Co-QAfter Co-Q
Pulmonary Hypertension Subjects0.90.7

[back to top]

Right Ventricular Outflow

Velocity time interval (NCT01148836)
Timeframe: before and after three months of CoQ

Interventioncm (Mean)
Before Co-QAfter Co-Q
Pulmonary Hypertension Subjects11.313.5

[back to top]

Tricuspid Regurgitation Grade

Tricuspid Regurgitation Grade ranges from 1 (normal) to 4 (severe regurgitation) (NCT01148836)
Timeframe: before and after three months of CoQ

Interventionunits on a scale (Mean)
Before Co-QAfter Co-Q
Pulmonary Hypertension Subjects1.41.2

[back to top]

Right Atrial Pressure

(NCT01148836)
Timeframe: before and after three months of CoQ

InterventionmmHg (Mean)
Before Co-QAfter Co-Q
Pulmonary Hypertension Subjects108

[back to top]

Hematocrit

(NCT01148836)
Timeframe: before and after three months of CoQ

,
Intervention% of red blood cell (Mean)
Before Co-QAfter Co-Q
Normal Controls39.938.6
Pulmonary Hypertension Subjects43.043.8

[back to top]

Hemoglobin

(NCT01148836)
Timeframe: before and after three months of CoQ

,
Interventiong/dl (Mean)
Before Co-QAfter Co-Q
Normal Controls13.312.9
Pulmonary Hypertension Subjects14.114.6

[back to top]

Left Ventricular End Diastolic Volume

Amount of blood in ventricle at end of diastole (NCT01148836)
Timeframe: before and after three months of CoQ

Interventionml (Mean)
Before Co-QAfter Co-Q
Pulmonary Hypertension Subjects8170

[back to top]

Mean Corpuscular Hemoglobin

(NCT01148836)
Timeframe: before and after three months of CoQ

,
Interventionpg (Mean)
Before Co-QAfter Co-Q
Normal Controls29.929.9
Pulmonary Hypertension Subjects26.827.8

[back to top]

Red Blood Cell Distribution Width

(NCT01148836)
Timeframe: before and after three months of CoQ

,
Interventionpercentage of sizes of red blood cells (Mean)
Before Co-QAfter Co-Q
Normal Controls12.912.9
Pulmonary Hypertension Subjects15.014.5

[back to top]

Prevalence of Low Serum CoQ10 Levels in Cardiac Arrest Patients

The primary outcome will be describing the prevalence of low serum CoQ10 levels compared to standard laboratory control values. (NCT01319110)
Timeframe: Baseline

Interventionug/mL (Mean)
CoenzymeQ100.706
Placebo0.66

[back to top]

Mean Concentrations of Cerebral Energetic Metabolites in Geriatric BPD and Older Controls at Baseline

Tissue-specific (gray or white matter) concentrations of of Phosphocreatine (PCr), Beta-Nucleoside Triphosphate (bNTP), and Inorganic Phosphate (Pi) in geriatric BPD compared with healthy controls at baseline. Concentrations were measured using CSI P MRS scan at 4T. The analysis of signal intensity is done through integration of the area under the curve and is expressed in arbitrary units. (NCT01390389)
Timeframe: Baseline

,
InterventionIntegration Expressed as Arbitrary Unit (Mean)
PCr in Gray MatterPCr in White MatterbNTP in Gray MatterbNTP in White MatterPi in Gray MatterPi in White Matter
Control4.353.232.632.431.171.37
CoQ103.943.062.302.381.391.23

[back to top]

To Determine Effects of CoQ 10 on Bioenergetics (PCr and Beta NTP) in Older Adults With Bipolar Depression.

Changes in Phosphocreatine and beta NTP (represented as adenosine triphosphate) in gray matter and white matter will be determined by measurements at Week 0 and Week 4 in Geri BD group challenged with CoQ10 and in healthy controls. (NCT01390389)
Timeframe: 4-week trial

,,,
InterventionIntegration Expressed as Arbitrary Unit (Least Squares Mean)
Gray Matter PhosphocreatineWhite Matter PhosphocreatineGray Matter Adenosine TriphosphateWhite Matter Adenosine Triphosphate
Control Baseline (Week 0)4.3503.2262.6202.417
Control Week 44.4253.4242.6492.148
CoQ10 Baseline (Week 0)3.9443.0632.2832.376
CoQ10 Week 44.4352.9972.0882.844

[back to top]

Phosphocreatine Recovery

Percentage change in phosphocreatine recovery from baseline to month as measured by 31PMRS is the primary outcome measure is a representative of mitochondrial oxidative capacity (NCT01702987)
Timeframe: 1 month

Interventionpercentage change from baseline (Mean)
Statin + Placebo-18.9
Statin + Ubiquinol7.7

[back to top]

Improvement in Left Ventricular Filling Abnormality

Doppler-derived transmitral blood flow and pulmonary venous blood flow data were used for grading of the severity of diastolic filling abnormality in patients before and after the intervention. Diastolic filling abnormality was categorized as: 1- normal 2- abnormal relaxation 3- pseudonormal 4- restricted pattern based on echo data. The proportion of patients who showed improvement in the diastolic function grading was compared between the study groups. (NCT02115581)
Timeframe: 6 months

InterventionPercentage (Number)
Conezyme Q1059
Placebo19

[back to top]

Improvement in Left Ventricular Ejection Fraction

Ejection Fraction of left ventricle (percentage of blood pumped out of left ventricle with each heart beat) calculated by echocardiography (NCT02115581)
Timeframe: 6 months

InterventionPercentage (Mean)
Conezyme Q1042.1
Placebo37.6

[back to top]

Adverse Events

Number of patients with evidence of adverse reaction to coenzyme Q10 including nausea, vomiting, changes in blood pressure, neurological signs or any abnormal behavior like disquiet in young children. (NCT02115581)
Timeframe: 6 months

InterventionParticipants (Number)
Conezyme Q100
Placebo0

[back to top]

Subject Reported Quality of Life Score

Subject quality of life as measured by a self-administered questionnaire (0 to 10 Likert scale with 0=No Effect to 10=Worst Effect) at each study visit. The symptoms or impact on activities scored included: Pain, Fatigue, Nausea, Sleep Disturbance, Distress, Shortness of Breath, Memory/Recall Problems, Appetite, Drowsiness, Dry Mouth, Sadness, Vomiting, Numbness, General Activities, Mood, Work, Relationships, Walking or Enjoyment. (NCT02486796)
Timeframe: Initial visit and study visits at 3-week intervals up to 4 months

Interventionunits on a scale (Mean)
Worst Pain (Visit 1)Worst pain (Visit 2)Worst Pain (Visit 3)Worst Pain (Visit 4)Worst Fatigue (Visit 1)Worst Fatigue (Visit 2)Worst Fatigue (Visit 3)Worst Fatigue (Visit 4)Worst Nausea (Visit 1)Worst Nausea (Visit 2)Worst Nausea (Visit 3)Worst Nausea (Visit 4)Worst Sleep Disturbance (Visit 1)Worst Sleep Disturbance (Visit 2)Worst Sleep Disturbance (Visit 3)Worst Sleep Disturbance (Visit 4)Worst Sleep Distress (Visit 1)Worst Sleep Distress (Visit 2)Worst Sleep Distress (Visit 3)Worst Sleep Distress (Visit 4)Worst Shortness of Breath (Visit 1)Worst Shortness of Breath (Visit 2)Worst Shortness of Breath (Visit 3)Worst Shortness of Breath (Visit 4)Worst Memory/Recall (Visit 1)Worst Memory/Recall (Visit 2)Worst Memory/Recall (Visit 3)Worst Memory/Recall (Visit 4)Worst Appetite (Visit 1)Worst Appetite (Visit 2)Worst Appetite (Visit 3)Worst Appetite (Visit 4)Worst Drowsiness (Visit 1)Worst Drowsiness (Visit 2)Worst Drowsiness (Visit 3)Worst Drowsiness (Visit 4)Worst Dry Mouth (Visit 1)Worst Dry Mouth (Visit 2)Worst Dry Mouth (Visit 3)Worst Dry Mouth (Visit 4)Worst Sadness (Visit 1)Worst Sadness (Visit 2)Worst Sadness (Visit 3)Worst Sadness (Visit 4)Worst Vomiting (Visit 1)Worst Vomiting (Visit 2)Worst Vomiting (Visit 3)Worst Vomiting (Visit 4)Worst Numbness (Visit 1)Worst Numbness (Visit 2)Worst Numbness (Visit 3)Worst Numbness (Visit 4)Worst Effect on General Activities (Visit 1)Worst Effect on General Activities (Visit 2)Worst Effect on General Activities (Visit 3)Worst Effect on General Activities (Visit 4)Worst Mood (Visit 1)Worst Mood (Visit 2)Worst Mood (Visit 3)Worst Mood (Visit 4)Worst Effect on Work (Visit 1)Worst Effect on Work (Visit 2)Worst Effect on Work (Visit 3)Worst Effect on Work (Visit 4)Worst Effect on Relationships (Visit 1)Worst Effect on Relationships (Visit 2)Worst Effect on Relationships (Visit 3)Worst Effect on Relationships (Visit 4)Worst Walking (Visit 1)Worst Walking (Visit 2)Worst Walking (Visit 3)Worst Walking (Visit 4)Worst Effect on Enjoyment (Visit 1)Worst Effect on Enjoyment (Visit 2)1Worst Effect on Enjoyment (Visit 3)Worst Effect on Enjoyment (Visit 4)
Delayed Dosing2.01.02.01.01.53.53.01.00.01.01.00.03.01.01.00.01.01.00.00.00.00.02.00.02.51.02.03.01.51.50.00.01.52.53.01.00.51.50.00.01.51.50.00.00.00.00.00.00.00.00.00.02.01.02.00.02.02.00.00.00.00.52.01.00.00.00.00.02.00.50.00.01.51.02.01.0

[back to top]

Concentration of C-reactive Protein in Serum (mg/L)

The serum concentration of C-reactive protein will be measured by approved methods. (NCT02486796)
Timeframe: Initial visit and study visits at 3-week intervals up to 4 months

,
Interventionmg/dl (Mean)
Visit 1Visit 2Visit 3Visit 4Visit 5
Delayed Dosing0.150.030.030.030.10
Immediate and Continuous Dosing0.200.500.300.400.30

[back to top]

Concentration of Circulating Tumor Cells in Blood (Cells Per Milliliter)

The serum concentration of circulating tumor cells will be measured by approved methods. (NCT02486796)
Timeframe: Initial visit and study visits at 3-week intervals up to 4 months

,
Interventioncells/ml (Mean)
Visit 1Visit 2Visit 3Visit 4Visit 5
Delayed Dosing0.00.00.00.00.0
Immediate and Continuous Dosing0.00.00.00.00.0

[back to top]

Sedimentation Rate of Erythrocytes in Blood (mm/hr)

The erythrocyte sedimentation rate will be measured by approved methods. (NCT02486796)
Timeframe: Initial visit and study visits at 3-week intervals up to 4 months

,
Interventionmm/hr (Mean)
Visit 1Visit 2Visit 3Visit 4Visit 5
Delayed Dosing17.011.013.016.018.0
Immediate and Continuous Dosing13.517.320.514.013.0

[back to top]

Subject Reported Quality of Life Score

Subject quality of life as measured by a self-administered questionnaire (0 to 10 Likert scale with 0=No Effect to 10=Worst Effect) at each study visit. The symptoms or impact on activities scored included: Pain, Fatigue, Nausea, Sleep Disturbance, Distress, Shortness of Breath, Memory/Recall Problems, Appetite, Drowsiness, Dry Mouth, Sadness, Vomiting, Numbness, General Activities, Mood, Work, Relationships, Walking or Enjoyment. (NCT02486796)
Timeframe: Initial visit and study visits at 3-week intervals up to 4 months

Interventionunits on a scale (Mean)
Worst Pain (Visit 1)Worst pain (Visit 2)Worst Pain (Visit 3)Worst Pain (Visit 4)Worst Pain (Visit 5)Worst Fatigue (Visit 1)Worst Fatigue (Visit 2)Worst Fatigue (Visit 3)Worst Fatigue (Visit 4)Worst Fatigue (Visit 5)Worst Nausea (Visit 1)Worst Nausea (Visit 2)Worst Nausea (Visit 3)Worst Nausea (Visit 4)Worst Nausea (Visit 5)Worst Sleep Disturbance (Visit 1)Worst Sleep Disturbance (Visit 2)Worst Sleep Disturbance (Visit 3)Worst Sleep Disturbance (Visit 4)Worst Sleep Disturbance (Visit 5)Worst Sleep Distress (Visit 1)Worst Sleep Distress (Visit 2)Worst Sleep Distress (Visit 3)Worst Sleep Distress (Visit 4)Worst Sleep Distress (Visit 5)Worst Shortness of Breath (Visit 1)Worst Shortness of Breath (Visit 2)Worst Shortness of Breath (Visit 3)Worst Shortness of Breath (Visit 4)Worst Shortness of Breath (Visit 5)Worst Memory/Recall (Visit 1)Worst Memory/Recall (Visit 2)Worst Memory/Recall (Visit 3)Worst Memory/Recall (Visit 4)Worst Memory/Recall (Visit 5)Worst Appetite (Visit 1)Worst Appetite (Visit 2)Worst Appetite (Visit 3)Worst Appetite (Visit 4)Worst Appetite (Visit 5)Worst Drowsiness (Visit 1)Worst Drowsiness (Visit 2)Worst Drowsiness (Visit 3)Worst Drowsiness (Visit 4)Worst Drowsiness (Visit 5)Worst Dry Mouth (Visit 1)Worst Dry Mouth (Visit 2)Worst Dry Mouth (Visit 3)Worst Dry Mouth (Visit 4)Worst Dry Mouth (Visit 15Worst Sadness (Visit 1)Worst Sadness (Visit 2)Worst Sadness (Visit 3)Worst Sadness (Visit 4)Worst Sadness (Visit 5)Worst Vomiting (Visit 1)Worst Vomiting (Visit 2)Worst Vomiting (Visit 3)Worst Vomiting (Visit 4)Worst Vomiting (Visit 5)Worst Numbness (Visit 1)Worst Numbness (Visit 2)Worst Numbness (Visit 3)Worst Numbness (Visit 4)Worst Numbness (Visit 5)Worst Effect on General Activities (Visit 1)Worst Effect on General Activities (Visit 2)Worst Effect on General Activities (Visit 3)Worst Effect on General Activities (Visit 4)Worst Effect on General Activities (Visit 5)Worst Mood (Visit 1)Worst Mood (Visit 2)Worst Mood (Visit 3)Worst Mood (Visit 4)Worst Mood (Visit 5)Worst Effect on Work (Visit 1)Worst Effect on Work (Visit 2)Worst Effect on Work (Visit 3)Worst Effect on Work (Visit 4)Worst Effect on Work (Visit 5)Worst Effect on Relationships (Visit 1)Worst Effect on Relationships (Visit 2)Worst Effect on Relationships (Visit 3)Worst Effect on Relationships (Visit 4)Worst Effect on Relationships (Visit 5)Worst Walking (Visit 1)Worst Walking (Visit 2)Worst Walking (Visit 3)Worst Walking (Visit 4)Worst Walking (Visit 5)Worst Effect on Enjoyment (Visit 1)Worst Effect on Enjoyment (Visit 2)1Worst Effect on Enjoyment (Visit 3)Worst Effect on Enjoyment (Visit 4)Worst Effect on Enjoyment (Visit 5)
Immediate and Continuous Dosing0.71.00.70.51.01.01.01.31.51.00.70.00.30.53.03.30.51.71.03.02.30.51.00.03.00.00.00.00.00.00.70.51.00.52.00.71.02.0.052.01.01.01.01.01.00.00.50.70.51.01.30.00.30.02.00.00.00.00.00.00.00.50.71.02.00.01.51.00.51.01.70.50.70.52.01.71.00.71.01.01.00.00.70.51.00.71.00.70.52.00.70.50.70.51.0

[back to top]

Response to Therapy on Hypothalamic-Pituitary-Gonadal (HPG) Axis: Progesterone

HPG will measure progesterone. Average values fell within the normal range for this type of assay. (NCT02865460)
Timeframe: Baseline, Weeks 8, 16, and 24

,
Interventionng/mL (Mean)
Change from Baseline to Week 8Change from Baseline to Week 16Change from Baseline to Week 24
Placebo0.00-0.03-0.05
Ubiquinol0.01-0.00-0.02

[back to top]

Response to Therapy on Hypothalamic-Pituitary-Gonadal (HPG) Axis: Testosterone

HPG will measure testosterone. Average values fell within the normal range for this type of assay. (NCT02865460)
Timeframe: Baseline, Weeks 8, 16, and 24

,
Interventionng/mL (Mean)
Change from Baseline to Week 8Change from Baseline to Week 16Change from Baseline to Week 24
Placebo-0.14-0.39-0.53
Ubiquinol-0.12-0.19-0.13

[back to top]

Response to Therapy on Hypothalamic-Pituitary-Thyroid (HPT) Axis: FT3

Thyroid status is assessed using a chemiluminescent method: Free triiodothyronine (FT3). Average values fell within the normal range for this type of assay. (NCT02865460)
Timeframe: Baseline, Weeks 8, 16, and 24

,
Interventionpg/mL (Mean)
Change from Baseline to Week 8Change from Baseline to Week 16Change from Baseline to Week 24
Placebo-0.04-0.10-0.17
Ubiquinol-0.06-0.13-0.05

[back to top]

Response to Therapy on Hypothalamic-Pituitary-Thyroid (HPT) Axis: TSH

Thyroid status is assessed using a chemiluminescent method: thyroid stimulating hormone (TSH). Average values fell within the normal range for this type of assay. (NCT02865460)
Timeframe: Baseline, Weeks 8, 16, and 24

,
InterventionmIU/L (Mean)
Change from Baseline to Week 8Change from Baseline to Week 16Change from Baseline to Week 24
Placebo0.09-0.06-0.04
Ubiquinol0.3440.15-0.10

[back to top]

Veterans Short Form 36-Item Health Survey Physical Component Summary

Veterans Health Survey contains 36 items to measure health functioning from the patient's point of view. The scale is 0-100. The higher value indicates better physical health. (NCT02865460)
Timeframe: Baseline, Weeks 4, 8, 12, 16, 20, and 24

,
Interventionunits on a scale (Mean)
Change Baseline to 4 WeeksChange Baseline to 8 WeeksChange Baseline to 12 WeeksChange Baseline to 16 WeeksChange Baseline to 20 WeeksChange Baseline to 24 Weeks
Placebo-1.11.1-1.81.80.70.3
Ubiquinol1.61.41.52.11.60.7

[back to top]

Veterans Short Form 36-Item Health Survey: Mental Component Score (MCS)

Veterans Health Survey contains 36 items to measure health functioning from the patient's point of view. The Veterans Short Form 36-item Health Survey Mental Component Score scale is 0-100. The higher value indicates more favorable mental health. (NCT02865460)
Timeframe: Baseline, Weeks 4, 8, 12, 16, 20, and 24

,
Interventionscore on a scale (Mean)
Change from baseline to 4 weeksChange from baseline to 8 weeksChange from baseline to 12 weeksChange from baseline to 16 weeksChange from baseline to 20 weeksChange from baseline to 24 weeks
Placebo0.43.62.84.93.11.1
Ubiquinol4.54.24.03.8-3.72.6

[back to top]

Connors Continuous Performance Test (CPT-3):Omissions T-score

CPT-3 asks questions about cognitive symptoms related to attention and reaction time. The Connors Continuous Performance Test Omissions score is 0-100. 50 indicates the population mean with a standard deviation of 10. The higher T-score indicates poorer outcomes. (NCT02865460)
Timeframe: Baseline, Weeks 8, 16, and 24

,
InterventionT-score (Mean)
Change from baseline to 8 weeksChange from baseline to 16 weeksChange from baseline to 24 weeks
Placebo-1.2-1.6-1.6
Ubiquinol-2.00.2-0.4

[back to top]

Connors Continuous Performance Test (CPT-3):Commissions T-score

CPT-3 asks questions about cognitive symptoms related to attention and reaction time. The Connors Continuous Performance Test Commissions T-score scale is 0-100. 50 indicates the population mean with a standard deviation of 10. The higher score indicates poorer outcomes. (NCT02865460)
Timeframe: Baseline, Weeks 8, 16, and 24

,
InterventionT-score (Mean)
Change from baseline to 8 weeksChange from baseline to 16 weeksChange from baseline to 24 weeks
Placebo-2.0-3.0-4.5
Ubiquinol-3.2-3.2-3.5

[back to top]

Connors Continuous Performance Test (CPT-3): Hit Reaction Time

CPT-3 asks questions about cognitive symptoms related to attention and reaction time. The Connors Continuous Performance Test Hit Reaction Time scale is 0-No limit. The higher score indicates poorer outcomes. (NCT02865460)
Timeframe: Baseline, Weeks 8, 16, and 24

,
Interventionscore on a scale (Mean)
Change from baseline to 8 weeksChange from baseline to 16 weeksChange from baseline to 24 weeks
Placebo-1.6-3.012.8
Ubiquinol10.717.224.0

[back to top]

California Verbal Learning Test (CVLT-II): Short Delay

CVLT-II asks questions about cognitive symptoms related to recall and memory. The California Verbal Learning Test (CVLT-II) Short Delay Test scale is 0-16. The higher score indicates better performance. (NCT02865460)
Timeframe: Baseline, Weeks 8, 16, and 24

,
Interventionunits on a scale (Mean)
Change from baseline to 8 weeksChange from baseline to 16 weeksChange from baseline to 24 weeks
Placebo0.51.51.5
Ubiquinol0.21.11.1

[back to top]

California Verbal Learning Test (CVLT-II): Correct Trials # 1-5

CVLT-II asks questions about cognitive symptoms related to recall and memory. The California Verbal Learning Test (CVLT-II) Correct Trials #1-5 score is 0-80. The higher score indicates better performance. (NCT02865460)
Timeframe: Baseline, Weeks 8, 16, and 24

,
Interventionscore on a scale (Mean)
Change from baseline to 8 weeksChange from baseline to 16 weeksChange from baseline to 24 weeks
Placebo0.96.76.9
Ubiquinol0.44.05.8

[back to top]

Brief Visual Memory Test (BVMT): Percent Retained

BVMT asks questions about cognitive symptoms related to visual memory. The Brief Visual Memory Test Percent Retained score is 0-100. The higher value indicates better performance. (NCT02865460)
Timeframe: Baseline, Weeks 8, 16, and 24

,
Interventionscore on a scale (Mean)
Change from baseline to 8 weeksChange from baseline to 16 weeksChange from baseline to 24 weeks
Placebo13.71.10.4
Ubiquinol-4.1-5.6-0.4

[back to top]

Brief Visual Memory Test (BVMT): Delayed Recall

BVMT asks questions about cognitive symptoms related to visual memory. The Brief Visual Memory Test Delayed Recall scale is 0-12. The higher value indicates better performance. (NCT02865460)
Timeframe: Baseline, Weeks 8, 16, and 24

,
Interventionscore on a scale (Mean)
Change from baseline to8 weeksChange from baseline to 16 weeksChange from baseline to 24 weeks
Placebo0.30.90.4
Ubiquinol0.30.30.4

[back to top]

Brief Pain Inventory

The Brief Pain Inventory is a linear scale of pain. The scale is 0-10. The higher value indicates more pain. (NCT02865460)
Timeframe: Baseline, Weeks 4, 8, 12, 16, 20, and 24

,
Interventionunits on a scale (Mean)
Change from baseline to 4 weeksChange from baseline to 8 weeksChange from baseline to 12 weeksChange from baseline to 16 weeksChange from baseline to 20 weeksChange from baseline to 24 weeks
Placebo00.30.30.10.6-0.3
Ubiquinol0-0.10.3-0.10.2-0.3

[back to top]

California Verbal Learning Test (CVLT-II): Long Delay Test

CVLT-II asks questions about cognitive symptoms related to recall and memory. The California Verbal Learning Test (CVLT-II) Long Delay Test scale is 0-16. The higher score indicates better performance. (NCT02865460)
Timeframe: Baseline, Weeks 8, 16, and 24

,
Interventionscore on a scale (Mean)
Change from baseline to 8 weeksChange from baseline to 16 weeksChange from baseline to 24 weeks
Placebo0.61.61.4
Ubiquinol-0.40.30.9

[back to top]

FitBit Sleep Measurement - Total Sleep

FitBit measures the duration of sleep daily via a bracelet-type instrument worn on the participant's wrist throughout the study. No normative data for FitBit Sleep was available. (NCT02865460)
Timeframe: Baseline to 8 weeks, 8 weeks to 16 weeks, 16 weeks to 24 weeks

,
Interventionminutes (Mean)
Average Total Sleep, Baseline to Week 8Average Total Sleep, Week 8 to Week 16Average Total Sleep, Week 16 to Week 24
Placebo343.4348.15334.22
Ubiquinol344.14346.31350.98

[back to top]

FitBit Sleep Measurement - Types of Sleep

FitBit measures the time spent in each type of sleep (Light, Deep, Rapid Eye Movement (REM)) daily via a bracelet-type instrument worn on the participant's wrist throughout the study. No normative data for FitBit Sleep was available. (NCT02865460)
Timeframe: Baseline to 8 weeks, 8 weeks to 16 weeks, 16 weeks to 24 weeks

,
Interventionaverage percentage of total time in bed (Mean)
Asleep, Baseline to Week 8Asleep, Week 8 to Week 16Asleep, Week 16 to Week 24Awake, Baseline to Week 8Awake, Week 8 to Week 16Awake, Week 16 to Week 24Light Sleep, Baseline to Week 8Light Sleep, Week 8 to Week 16Light Sleep, Week 16 to Week 24Deep Sleep, Baseline to Week 8Deep Sleep, Week 8 to Week 16Deep Sleep, Week 16 to Week 24REM Sleep, Baseline to Week 8REM Sleep, Week 8 to Week 16REM Sleep, Week 16 to Week 24
Placebo88.5788.588.8511.3411.4311.0964.6865.8965.2814.713.8215.236.4120.2118.75
Ubiquinol89.0689.188.8110.6810.6410.9265.3767.3164.4915.2914.0415.7819.3318.6519.74

[back to top]

Gulf War Illness Health Symptom Checklist

The Gulf War Illness Health Symptoms Checklist asks questions about symptoms related to Gulf War Illness. The linear scale is 0-42. The higher value indicates more symptoms. (NCT02865460)
Timeframe: Baseline, Weeks 4, 8, 12, 16, 20, 24, and 28

,
Interventionunits on a scale (Mean)
Change from baseline to 4 weeksChange from baseline to 8 weeksChange from baseline to 12 weeksChange from baseline to 16 weeksChange from baseline to 20 weeksChange from baseline to 24 weeksChange from baseline to 28 weeks
Placebo-2.0-2.6-2.7-1.6-3.7-3.1-9.4
Ubiquinol-3.7-3.7-5.8-4.6-6.1-3.8-8.7

[back to top]

Hamilton Anxiety Scale (HAM-A)

This measure allows the participant to rate levels of anxiety. The Hamilton Anxiety Scale is 0-56. The higher value indicates more anxiety. (NCT02865460)
Timeframe: Baseline, Weeks 8, 16, and 24

,
Interventionunits on a scale (Mean)
Change from baseline to 8 weeksChange from baseline to 16 weeksChange from baseline to 24 weeks
Placebo1.7-1.70.1
Ubiquinol-0.9-0.7-1.5

[back to top]

Hamilton Depression Scale (HAM-D)

This measure allows the participant to rate level of depression. The Hamilton Depression Scale is a linear scale 0-62. The higher value indicates more depression. (NCT02865460)
Timeframe: Baseline, Weeks 8, 16, and 24

,
Interventionunits on a scale (Mean)
Change from baseline to 8 weeksChange from baseline to 16 weeksChange from baseline to 24 weeks
Placebo-1.3-3.6-2.8
Ubiquinol-2.4-2.8-2.5

[back to top]

Multidimensional Fatigue Inventory (MFI)

MFI asks questions about general fatigue, physical fatigue, reduced activity, reduced motivation, and mental fatigue. The Multidimensional Fatigue Inventory score is 0-100. The higher value indicates more fatigue. (NCT02865460)
Timeframe: Baseline, Weeks 4, 8, 12, 16, 20, and 24

,
Interventionscore on a scale (Mean)
Change Baseline to 4 WeeksChange Baseline to 8 WeeksChange Baseline to 12 WeeksChange Baseline to 16 WeeksChange Baseline to 20 WeeksChange Baseline to 24 Weeks
Placebo0.20.53.60.32.50.8
Ubiquinol-0.6-1.8-1.4-3.2-0.5-2.3

[back to top]

Davidson Trauma Scale

Davidson Trauma Scale asks questions about stress, arousal, and avoidance. The scale is 0 - 136. The higher value indicates worse outcome. (NCT02865460)
Timeframe: Baseline, Weeks 8, 16, and 24

,
Interventionscore on a scale (Mean)
Change from baseline to 8 weeksChange from baseline to 16 weeksChange from baseline to 24 weeks
Placebo-6.7-12.1-9.4
Ubiquinol-7.6-5.4-13.3

[back to top]

Pittsburgh Sleep Quality Index

The PSQI measures quality and patterns of sleep and wake cycles and is completed by the participant. The Pittsburgh Sleep Quality Index scale is 0-21. The higher value indicates more sleep disturbance. (NCT02865460)
Timeframe: Baseline, Weeks 4, 8, 12, 16, 20, and 24

,
Interventionunits on a scale (Mean)
Change from baseline to 4 weeksChange from baseline to 8 weeksChange from baseline to 12 weeksChange from baseline to 16 weeksChange from baseline to 20 weeksChange from baseline to 24 weeks
Placebo0.0-0.40.1-1.00.3-0.4
Ubiquinol-1.0-1.2-1.7-1.6-0.3-1.4

[back to top]

Response to Therapy of Gulf War Illness-associated Peripheral Blood Biomarkers - Complete Blood Count (CBC) Hemoglobin

Peripheral blood biomarker levels are quantified by complete blood count (CBC) analyses: hemoglobin. Average values fell within the normal range for this type of assay. (NCT02865460)
Timeframe: Baseline, Weeks 8, 16, and 24

,
Interventiongrams per deciliter (Mean)
Change from baseline to 8 weeksChange from baseline to 16 weeksChange from baseline to 24 weeks
Placebo0.05-0.25-0.28
Ubiquinol0.180.170.10

[back to top]

Response to Therapy of Gulf War Illness-associated Peripheral Blood Biomarkers - Complete Blood Count (CBC) White Blood Cell Percentages

Peripheral blood biomarker levels are quantified by complete blood count (CBC) analyses: percentages of white blood cells. Average values fell within the normal range for this type of assay. (NCT02865460)
Timeframe: Baseline, Weeks 8, 16, and 24

,
Interventionpercentage of white blood cells (Mean)
Neutrophils, Change from baseline to 8 weeksNeutrophils, Change from baseline to 16 weeksNeutrophils, Change from baseline to 24 weeksLymphocytes, Change from baseline to 8 weeksLymphocytes, Change from baseline to 16 weeksLymphocytes, Change from baseline to 24 weeksMonocytes, Change from baseline to 8 weeksMonocytes, Change from baseline to 16 weeksMonocytes, Change from baseline to 24 weeksEosinophils, Change from baseline to 8 weeksEosinophils, Change from baseline to 16 weeksEosinophils, Change from baseline to 24 weeksBasophils, Change from baseline to 8 weeksBasophils, Change from baseline to 16 weeksBasophils, Change from baseline to 24 weeks
Placebo1.130.742.04-0.390.10-1.01-0.37-0.12-0.39-0.30-0.82-0.67-0.060.140.07
Ubiquinol2.080.263.33-1.64-0.18-3.01-0.19-0.43-0.23-0.250.07-0.16-0.020.230.00

[back to top]

Response to Therapy of Gulf War Illness-associated Peripheral Blood Biomarkers - Complete Blood Count (CBC) Red Blood Cell (RBC) Counts

Peripheral blood biomarker levels are quantified by complete blood count (CBC) analyses: red blood cell counts. Average values fell within the normal range for this type of assay. (NCT02865460)
Timeframe: Baseline, Weeks 8, 16, and 24

,
Intervention1000000 cells per microliter (Mean)
RBC, Change from baseline to 8 weeksRBC, Change from baseline to 16 weeksRBC, Change from baseline to 24 weeks
Placebo0.01-0.03-0.02
Ubiquinol0.100.120.08

[back to top]

Response to Therapy of Gulf War Illness-associated Peripheral Blood Biomarkers - Complete Blood Count (CBC) White Blood Cell Counts and Platelets

Peripheral blood biomarker levels are quantified by complete blood count (CBC) analyses: white blood cell (WBC) counts and platelets. Average values fell within the normal range for this type of assay. (NCT02865460)
Timeframe: Baseline, Weeks 8, 16, and 24

,
Intervention1000 cells per microliter (Mean)
WBC, Change from baseline to 8 weeksWBC, Change from baseline to 16 weeksWBC, Change from baseline to 24 weeksPlatelets, Change from baseline to 8 weeksPlatelets, Change from baseline to 16 weeksPlatelets, Change from baseline to 24 weeks
Placebo0.340.140.44-2.003.7414.48
Ubiquinol0.410.220.22-0.94-5.88-6.00

[back to top]

Response to Therapy of Gulf War Illness-associated Peripheral Blood Biomarkers - Complete Blood Count (CBC) Hematocrit

Peripheral blood biomarker levels are quantified by complete blood count (CBC) analyses: percentages of hematocrit in blood. Average values fell within the normal range for this type of assay. (NCT02865460)
Timeframe: Baseline, Weeks 8, 16, and 24

,
Interventionpercentage of red blood cells in blood (Mean)
Change from baseline to 8 weeksChange from baseline to 16 weeksChange from baseline to 24 weeks
Placebo0.11-0.27-0.25
Ubiquinol0.730.630.53

[back to top]

Response to Therapy on Hypothalamic-Pituitary-Thyroid (HPT) Axis: FT4

Thyroid status is assessed using a chemiluminescent method: Free thyroxine (FT4). Average values fell within the normal range for this type of assay. (NCT02865460)
Timeframe: Baseline, Weeks 8, 16, and 24

,
Interventionng/dL (Mean)
Change from Baseline to Week 8Change from Baseline to Week 16Change from Baseline to Week 24
Placebo-0.03-0.02-0.06
Ubiquinol-0.00-0.01-0.02

[back to top]

Response to Therapy on Cortisol Levels

Cortisol will be measured using a 24-hour salivary collection to assess circadian rhythm. (NCT02865460)
Timeframe: Baseline, Weeks 8, 16, and 24 upon waking, mid-morning, evening, and sleep for each.

,
Interventionmicrograms/dL (Mean)
Waking, Change from Baseline to Week 8Morning, Change from Baseline to Week 8Evening, Change from Baseline to Week 8Sleep, Change from Baseline to Week 8Waking, Change from Baseline to Week 16Morning, Change from Baseline to Week 16Evening, Change from Baseline to Week 16Sleep, Change from Baseline to Week 16Waking, Change from Baseline to Week 24Morning, Change from Baseline to Week 24Evening, Change from Baseline to Week 24Sleep, Change from Baseline to Week 24
Placebo-0.040.100.050.050.02-0.020.050.010.030.030.00-0.02
Ubiquinol-0.040.04-0.020.030.080.120.030.110.060.02-0.010.01

[back to top]

Response to Therapy on Hypothalamic-Pituitary-Gonadal (HPG) Axis: Estradiol

HPG will measure estradiol. Average values fell within the normal range for this type of assay. (NCT02865460)
Timeframe: Baseline, Weeks 8, 16, and 24

,
Interventionpg/mL (Mean)
Change from Baseline to Week 8Change from Baseline to Week 16Change from Baseline to Week 24
Placebo1.77-1.37-2.19
Ubiquinol6.06-0.976.21

[back to top]

Change in Lactate

Change was measured for lactate. Lactate is produced by anaerobic metabolism and may reflect inadequate tissue perfusion in conditions such heart failure with preserved ejection fraction. (NCT03133793)
Timeframe: Change from Baseline to Week 12

Interventionmmol/L (Mean)
Placebo Only0.33
CoQ10 Only0
D-ribose Only-0.35
CoQ10 + D-ribose-0.24

[back to top]

Change in 6 Minute Walk Test (6MWT)

Change was measured using the 6-minute walking test. The 6-minute walking test (6MWT) is a simple test. Test measures the total distance in meters a person can walk in 6 minutes. (NCT03133793)
Timeframe: Change from Baseline to Week 12

Interventionmeters (Mean)
Placebo Only19.62
CoQ10 Only21.21
D-ribose Only29.42
CoQ10 + D-ribose36.21

[back to top]

Change in Adenosine Triphosphate (ATP)

All cellular processes require ATP as a primary energy source. The heart requires ATP for the function of membrane transport systems (e.g., Na+/K+-ATPase) as well as for sarcomere contraction and relaxation. (NCT03133793)
Timeframe: Change from Baseline to Week 12

Interventionrelative light units (RLU) (Mean)
Placebo Only-189.08
CoQ10 (Ubiquinol) Only1133.5
D-ribose Only907.44
CoQ10 (Ubiquinol) + D-ribose686.19

[back to top]

Change in Vigor

Change were measured using the the Vigor subscale from the Profile of Mood States (POMS) questionnaire. Patients rated themselves on eight adjectives (lively, active, energetic, cheerful, alert, full of pep, carefree, and vigorous) on a five-point scale (0 = not at all, 1 = a little, 2 = moderately, 3 = quite a bit, and 4 = extremely). Scores for the subscale range from 0-32, in which higher scores of 32 reflected more vigor and a score of 0 reflected no vigor. (NCT03133793)
Timeframe: Change from Baseline to Week 12

InterventionScores on a scale (Mean)
Placebo Only-0.54
CoQ10 Only7.11
D-ribose Only7.3
CoQ10 + D-ribose7.61

[back to top]

Change in Health Status of Patients With HFpEF

Patients' perceptions of their symptoms were measured using the Kansas City Cardiomyopathy Questionnaire (KCCQ), a self-administered questionnaire that measures patients' perceptions of five domains of their health status relevant to HFpEF. The KCCQ is a 24 item questionnaire. Scores are transformed to a range of 0-100, in which higher scores reflect better health status. All scores are represented on a 0-to-100-point scale, where lower scores represent more severe symptoms and/or limitations and scores of 100 indicate no symptoms, no limitations, and excellent quality of life. (NCT03133793)
Timeframe: Change from Baseline to Week 12

InterventionScores on a scale (Mean)
Placebo Only4.15
CoQ10 Only26.56
D-ribose Only29.97
CoQ10 + D-ribose33

[back to top]

Change in Venous Blood B-type Natriuretic Peptide (BNP) Levels

Change was measured for brain natriuretic peptide. Brain natriuretic peptide (BNP) levels are objective measures of cardiac function. BNP testing is a useful tool in predicting prognoses in patients with heart failure (NCT03133793)
Timeframe: Change from Baseline to Week 12

Interventionpg/mL (Mean)
Placebo Only-18.43
CoQ10 Only-29.56
D-ribose Only-42.94
CoQ10 + D-ribose29.08

[back to top]

Change in Ejection Fraction (EF)

Change was measured using the the ejection fraction using echocardiographic imaging. Ejection fraction (EF) is the percentage of blood volume ejected in each cardiac cycle and is a representation of left ventricular systolic performance. (NCT03133793)
Timeframe: Change from Baseline to Week 12

Interventionpercentage of ejection fraction (Mean)
Placebo Only-2.39
CoQ10 Only4.69
D-ribose Only5.64
CoQ10 + D-ribose5.07

[back to top]

Change in Septal E/e'

Change was measured using the the Septal E/e' using advanced echocardiographic imaging. Septal E/e' is the early diastolic mitral annulus velocity (e') estimated by tissue Doppler using an echocardiogram and the ratio of the transmitral early peak velocity (E) by pulsed wave Doppler over e' (E/e'). These are the two key parameters for grading a diastolic dysfunction as they represent a reliable noninvasive surrogate for left ventricular diastolic pressures. (NCT03133793)
Timeframe: Change from Baseline to Week 12

Interventionratio (Mean)
Placebo Only1.39
CoQ10 (Ubiquinol) Only-1.27
D-ribose Only-0.65
CoQ10 (Ubiquinol) + D-ribose-0.47

[back to top]

Maximal Aerobic Capacity- CoQ10

The maximal aerobic capacity (oxygen uptake mL/min/kg body weight) during cycle ergometry at the end of each treatment period. (NCT03579693)
Timeframe: 6 weeks

InterventionmL/min/kg (Mean)
CoQ1021.4
Nicotinamide Riboside20.7
Placebo20.7

[back to top]

Work Efficiency

The work efficiency (oxygen uptake mL/min/kg body weight at a specified constant of 60 watts work rate for 3 minutes) during cycle ergometry at the end of each treatment period. This is reported as the work performed at 60 watts divided by the energy expended at 0 watts times 100, and reported on the percent scale.. (NCT03579693)
Timeframe: 6 weeks

InterventionPercent difference (Mean)
CoQ1033.3
Nicotinamide Riboside32.5
Placebo33.1

[back to top]